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ABSTRACT
CYP3A4 is the predominant isoform of CYP3A in humans and is responsible for the 
metabolism of a wide range of drugs and endogenous compounds (Dresser et al., 
2000 & Guengerich et al., 1998). CYP3A4 has a very broad substrate specificity and 
accounts for up to 60% of the cytochrome P450 enzyme content in human liver and 
70% of P450s in enterocytes (Slaughter and Edwards, 1995 & Westlind et al., 1999).
Expression of the CYP3A4 gene is markedly induced both in vivo and in primary 
hepatocytes in response to treatment with a variety of compounds; many of the most 
efficacious inducers of CYP3A4 expression are commonly used drugs such as the 
glucocorticoid dexamethasone, the antibiotic rifampicin, and the antimycotic 
clotrimazole (Lehmann et al., 1998). The inducibility of CYP3A4 expression levels 
coupled with the broad substrate specificity of the CYP3 A4 protein represents a basis 
for drug interactions in patients undergoing combination drug therapy or through 
environmental exposures.
Although a wide interindividual variation exists in levels of expression of CYP3A4, 
as assessed by direct analysis of liver microsomes (Shimada and Guengerich 1989) 
and through the use of in vivo probe drugs (Lown et al., 1995), there is limited 
evidence for a functional polymorphism that involves this P450.
The initial aim of my research was to study the molecular mechanisms of induction of 
CYP3A4 gene by a number of steroids and xenobiotics. Specifically, the role of the 
antiglucocorticoid RU-486, the human glucocorticoid receptor and the human 
pregnane X receptor in the steroid and xenobiotic induction of CYP3A4 was 
established by the use of an in vitro CYP3A4 promoter-reporter gene system in 
HepG2 cells.
Approximately Ikb of the regulatory region of the CYP3A4 gene (-1087 to -57bp) 
was previously isolated by PCR and engineered into a reporter plasmid pCMV- 
cSPAP to create a construct in which expression of the reporter protein Secretory 
Placental Alkaline Phosphatase (SPAP) was regulated by the CYP3A4 region. This
plasmid was transiently transfected into human liver hepatoma cell line, HepG2, in 
order to study the effects of xenobiotics and steroids on the regulation of the CYP3 A4 
gene.
The second aim of my project was to isolate approximately 308 bp of the 5' upstream 
regulatory region of the CYP3 A4 gene which was previously shown to have base pair 
changes in either the HNF-5 or the estrogen response elements. Sequence 
confirmation of the isolated regions followed by cloning into a secretory placental 
alkaline phosphatase (SEAP) expression vector. The functional effect of these 
mutations on the transactivation of CYP3A4 gene by steroids and xenobiotics has 
been accomplished.
The results presented in this work show that regulation of CYP3 A4 gene is a complex 
process and that hGR and hPXR are both involved in the transcriptional regulation of 
CYP3A4 gene by steroids and xenobiotics, which was proved by changes in the rank 
order inducer potencies of compounds from the basal to the receptor augmented 
system. Hence, the likelihood exists that there is mutual competition for these two 
receptors between endobiotics and xenobiotics, which may decrease the therapeutic 
effects of many administered xenobiotics.
RU-486 (IpM) induced the CYP3A4 reporter gene expression and blocked the hGR- 
médiated induction of CYP3A4 gene by steroids including DEX.
The functional HNF-5 RE and ERE mutations identified within the CYP3A4 
promoter provide an insight into the possible interindividual variation in CYP3A 
activity seen in the human population and their mixed response to xenobiotic 
treatment. They also provide useful tools in our understanding of the molecular 
mechanism of CYP3A4 transcriptional gene activation.
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CHAPTER 1 - INTRODUCTION
1.1 Background
Maturation of organ systems during fetal life and in the neonatal and childhood periods 
exerts a profound effect on drug disposition. From fetal life through to adolescence, 
dramatic changes in pharmacokinetics occur (de Wildt et ah, 1999). Accordingly, 
effective and safe drug therapy in neonates, infants and children requires a thorough 
understanding of human developmental biology and the dynamic ontogeny of drug 
absorption, distribution, metabolism and excretion (Morselli et ah, 1980). These four 
factors, absorption, distribution, metabolism and excretion (ADME), affect the overall 
disposition of a xenobiotic in the body (Rang et ah, 1999).
The term "xenobiotics" (chemicals normally foreign to the body) includes not only drugs 
but also pollutants and potential toxicants that are transformed in similar ways and for 
which many of the same issues exist. The enzymes involved in the metabolism of these 
xenobiotics are of considerable current interest in pharmaceutical discovery and 
development and in environmental health research (Guengerich, 2000). It should be noted 
that the words "toxicant", "drug", "xenobiotic" or "chemical" are used interchangeably in 
this study, since all chemical entities, whether endogenous or exogenous in origin, can 
cause toxicity at some dose (Rozman and Klassen, 1996).
The absorption of a chemical (its ability to enter the systemic circulation) depends on the 
physicochemical properties of the chemical, its initial dose and formulation, and the route 
of administration (Rang et ah, 1999). A toxicant may pass through the cell membrane by 
one of two general processes: first, passive transport (diffusion), in which the cell 
expends no energy, and second, specialized transport, in which the cell provides energy 
to translocate the toxicant across its membrane (Rozman and Klassen, 1996).
The distribution (translocation) of a toxicant throughout the body to organs or tissues is 
determined primarily by the blood flow to the organ or tissue, plasma protein binding of 
the xenobiotic, and the affinity of a xenobiotic for various tissues (Rang et ah, 1999). A 
well-perfused organ such as the liver may attain high initial concentration of a xenobiotic.
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Chemicals can have affinity for a binding site (intracellular protein or bone matrix) or to 
a cellular constituent (fat). The metabolism of xenobiotics will be discussed later.
Toxicants are eliminated from the body by several routes with the kidney being the most 
important organ for the excretion of xenobiotics. However, many xenobiotics have to be 
biotransformed to more water-soluble products before they can be excreted into the urine. 
The second important route of elimination is biliary excretion, followed by the lung, 
primarily for gases and compounds with low vapour pressure. Other routes are sweat, 
saliva, tears and milk (Rang et al., 1999).
1.2 Drug metabolizing enzymes
During species evolution, a great number of gene encoding enzyme systems involved in 
metabolism of xenobiotics have been selected for their capacity to protect organisms 
from the chemical threat represented by those compounds (Gonzalez, 1989). Drug 
metabolism is one of the major determinants of drug clearance in a given individual. 
Although the relative size of the liver and the hepatic blood flow may affect the rate of 
drug metabolism during development, the maturation of the drug-metabolizing enzymes 
is probably the predominant factor accounting for age-associated changes in non-renal 
drug clearance (de Wildt et al., 1999).
Drug metabolism is an important process for several reasons. First, the metabolism of a 
drug controls its blood level and therefore influences its therapeutic and/or possible toxic 
effects. Second, some drugs (often termed prodrugs) require biotransformation into 
metabolites which are the actual pharmacologically active species (Maurel, 1996).
Third, the metabolism of a drug may generate highly reactive metabolite(s) which, after 
covalent binding to either protein or nucleic acids, may generate serious side effects and 
pathologies such as hepatitis, DNA mutations and carcinogenesis. Fourth, drugs may 
increase or decrease the expression and activity of drug metabolizing enzymes, thus 
modifying the response of the organism to other compounds which are biotranformed by 
these enzyme systems (drug interaction) (Maurel, 1996).
The major organ of drug metabolism is the liver (Watkins, 1992). In some cases 
extrahepatic tissues, frequently the site of absorption or excretion (e.g. the lung, kidney or
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gastrointestinal mucosa), may also play an important role in the metabolism of a 
compound (Rang et al., 1999). Basically, the drug metabolizing enzymes convert 
xenobiotics, which are generally lipophilic, into metabolites which are more water- 
soluble, thus allowing their elimination from the body. The numerous enzyme systems 
involved in the metabolism of xenobiotics, have been classified as either phase I 
(oxidases, reductases, hydrolases) or phase II (conjugation enzymes) (Iyer and Sinz, 1999 
& Maurel, 1996).
Phase I (functionalisation) reactions either introduce or uncover a polar functional group 
in the molecule (e.g. -OH, -NH2, -SH, -COOH), activating it for subsequent phase II 
(conjugation) reactions, which render the compound more water soluble, thereby 
facilitating its excretion (Gibson and Skett, 1994 & Iyer and Sinz, 1999). Some workers 
have proposed the existence of a third phase, phase IE, which involves the further 
processing of glutathione conjugates (Gibson and Skett, 1994). Table 1.1 shows the 
phases of drug metabolism.
The variety of transformations presents a unique challenge in identifying which of the 
various possible metabolites are actually formed in vitro or in vivo and the enzymes 
responsible for the formation of the metabolites (i.e. reaction phenotyping) (Iyer and 
Sinz, 1999). This knowledge is crucial for determination of the fate of the xenobiotic as 
well as anticipated effects of age, gender, genetics, disease state, species differences, and 
environmental factors (including dmg-drug interactions) on the disposition of a 
xenobiotic (Gonzalez and Idle, 1996 & Sharer et al., 1995 & Shimada et al., 1994 and
1996).
Table 1.1 The phases of drug metabolism
Phase I Phase n Phase m
Oxidation Glucoronidation/Glucosidation Processing of glutathione
Reduction Sulfation conjugates
Hydrolysis Méthylation
Hydration Acétylation
Dethioacetylation Amino acid conjugation
Isomérisation Glutathione conjugation 
Fatty acid conjugation 
Condensation
1.2.1 Phase I metabolism
The mixed-function oxidase system (cytochrome P450-dependent) is capable of many 
diverse functionalisation reactions and will be considered later. Other oxidative enzymes 
include alcohol dehydrogenase, aldehyde dehydrogenase, alkylhydrazine oxidase, amine 
oxidases, aromatases and xanthine oxidase (Gibson and Skett, 1994).
Hepatic microsomes can catalyse a number of reductive reactions. These generally 
require NADPH, but are inhibited by oxygen. Azo- and nitro-reduction can be catalysed 
by cytochrome P450 and NADPH-cytochrome c (P450) reductase, some heterocyclics 
are ring cleaved by reduction, and fluorocarbons of the halothane type are defluorinated 
under anaerobic conditions (Gibson and Skett, 1994).
The hydrolysis of esters, amides, hydrazides and carbamates is carried out by a variety of 
enzymes present both in the plasma and the liver (e.g. plasma esterases). Epoxide 
hydratase carries out the hydration of epoxides to form dihydrodiols.
Other less common phase I reactions include ring cyclisation, N-carboxylation, 
dimérisation, transamidation, isomérisation, decarboxylation and dithioacetylation 
(Gibson and Skett, 1994).
1.2.2 Phase H metabolism
Phase n  reactions are carried out by a diverse range of enzymes as illustrated in Table 
1.2. These reactions involve the conjugation of endogenous compounds to the chemically 
active metabolites of the phase I reactions and generally lead to water-soluble products 
that may be excreted in the urine or bile (Gibson and Skett, 1994).
1.2.3 Phase HI metabolism
A large number of phase I metabolites are detoxified by conjugation with the tripeptide 
glutathione (glutamyl-cysteinyl-glycine). Further processing of these conjugates can then 
occur, and this is considered by some workers to constitute a third phase of xenobiotic 
metabolism (Gibson and Skett, 1994).
Subsequent to glutathione conjugation, a glutamyltranspeptidase, and a peptidase can 
further metabolise the conjugate, yielding the cysteine conjugate of the xenobiotic, which 
can then be N-acetylated to yield the N-acetylcysteine conjugate or mercapturic acid 
(Gibson and Skett, 1994). Depending on the substrate and species involved the 
glycylcysteine and cysteine conjugates and the mercapturic acid may occur as excretion 
products.
Sulphur-containing conjugates excreted in bile can also be further metabolised by an 
enzyme in the gut and kidney called C-S lyase (or cysteine conjugate P-lyase).
Table 1.2 Conjugation reactions
Reaction Enzyme Functional group 
conjugated
Glucuronidation UDP-Glucuronyltransferase -OH
-COOH
-NH2
-SH
Glycosidation UDP-Glycosyltransferase -OH
-COOH
-SH
Sulfation Sulfotransferase -NH2
-SO2NH2
-OH
Méthylation Methyltransferase -OH
-NH2
Acétylation Acetyltransferase -NH2
-SO2 NH2
-OH
Amino acid conjugation Acetyltransferase -COOH
Glutathione conjugation Glutathione-S-transferase Epoxide 
Organic halide
Fatty acid conjugation Microsomal fraction from liver -OH
Condensation Purely chemical Various
Adapted from Gibson and Skett, 1994.
1.3 The cytochrome P450 superfamily
1.3.1 Historical background
Cytochrome P450 was first discovered about 45 years ago with the work of Axelrod 
(1955) and Brodie et al. (1955) who reported that an enzyme system in the liver 
endoplasmic reticulum was able to oxidatively metabolize certain xenobiotic compounds. 
Later that year, Hayaishi and co-workers (1955) reported that dioxygenase reactions were 
possible in the liver microsomal preparations. Mason et al. (1955) demonstrated that 
monooxygenase activity was present in the same system and used NADPH as a source of 
reducing equivalents.
The detection of a carbon monoxide (CO) binding pigment in liver microsomes, 
characterised by an absorption maximum at 450nm, was made independently by 
Garfinkel (1958) and Klingenberg (1958), who are generally credited with the discovery 
of P450. Omura and Sato (1964a and b) were later able to demonstrate that this pigment 
was, in fact, a haemoprotein of the b-type cytochrome class and they first coined the term 
cytochrome P450, after the wavelength of the UV absorption maximum in the optical 
spectrum for the CO complex of the reduced cytochrome pigment (Omura and Sato, 
1962). These latter workers and others subsequently reported that the position of the 
characteristic Soret band could be shifted by binding of substrates to the enzyme 
(Schenkman et al., 1967a and b & Schenkman, 1970) or by treatment with detergent 
(Omura and Sato, 1962).
The effect of substrate binding on the UV absorption characteristics of cytochrome P450 
was of particular importance, as it appeared that different types of substrate elicited 
differing varieties of spectral change; namely, types I, II and modified type II 
(Schenkman et al., 1967a and b & Schenkman, 1970 & Schenkman et al., 1972). The 
type I change brought about by apolar substrates involved a blue shift (hypochromic) in 
the Soret band, whereas type II substrates give rise to a red shift (bathochromic) thought 
to be associated with ligation of the haem iron. Modified type II (or reverse type II) 
binding gives rise to a UV spectrum which has the appearance of a "mirror image" of the 
type I spectral change.
1.3.2 Overview of the cytochrome P450 (CYP) superfamily
The cytochrome P450s constitute a superfamily of haem-thiolate proteins present in both 
prokaryotes and eukaryotes (Nelson et ah, 1996). They act as mono-oxygenases, with 
functions ranging from the synthesis and degradation of endogenous steroid hormones, 
vitamins and fatty acid derivatives ("endobiotics") to the metabolism of foreign 
compounds such as drugs, environmental pollutants, and carcinogens ("xenobiotics") 
(Nelson a/., 1996).
The P450 mono-oxygenases range in size from 45 to 60 kDa (Gonzalez and Gelboin, 
1991 and 1992). All the P450s contain iron protoporphyrin IX as the prothetic group and 
thus contain a haem-binding domain (including a cystein residue), located near the 
carboxyl terminus of the polypeptide chain, which is conserved in all cytochrome P450s 
studied, from bacterial to mammalian forms (Gibson and Skett, 1994).
At present, 17 mammalian cytochrome P450 gene families collectively encode 
approximately 60 distinct P450 forms in any given species, a number expected to rise by 
the completion of genome-wide sequencing projects (Nelson, 1999). On the basis of 
crystal structures of bacterial P450s, molecular modelling and site-directed mutagenesis, 
the overall structure of mammalian membrane-bound P450 has been deduced and 
residues required for substrate binding, electron transfer and haem binding have been 
identified (Negishi et ah, 1996 & Peterson and Graham, 1998).
Cytochrome P450s in gene families 1-4 exhibit broad, but overlapping, substrate and 
product specificities that may vary between corresponding forms from different species 
(Guengerich, 1997 & Nelson, 1999). Their ability to metabolize a wide array of 
xenobiotics (Rendic and DiCarlo, 1997), the inducibility of many P450 forms by 
xenobiotics (Waxman, 1999), and documented gene polymorphisms (Meyer and Zanger, 
1997) have all contributed to an explosion of literature on P450-dependent drug 
metabolism. To name just a few examples, differences in the amount and intrinsic 
capacities of cytochrome P450 forms to metabolize a particular drug or chemical may 
contribute to drug-drug interactions, drug or carcinogen activation and detoxification, or 
species differences in cytochrome P450 catalysed reactions of toxic chemicals 
(Honkakoski and Negishi, 2000).
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The cytochrome P450s in families 1-4 also metabolize endogenous compounds, including 
steroids and bile acids, fatty acids, prostaglandins and other eicosanoids, and retinoids 
(Nelson et al., 1996), which are structurally diverse substrates related only by their 
apparent lipophilicity. They also display complex sex-, tissue- and developmental- 
specific expression patterns which are controlled by hormones or growth factors 
(Waxman and Chang, 1995), suggesting that these P450s may have critical role, not only 
in elimination of endobiotic signalling molecules, but also in their synthesis (Nebert, 
1991).
Other mammalian P450s have prominent roles in biosynthetic pathways. Cytochrome 
P450s belonging to gene families 5 and 8A are involved in thromboxane and prostacyclin 
synthesis, P450s from families 11, 17, 19, and 21 are required for steroid hormone 
biosynthesis, P450s from families 7, 8B, 24, 27, 46, and 51 catalyse reactions in the 
pathways leading to the biosynthesis of bile acids, vitamin Ds and cholesterol and CYP26 
is involved in retinoid metabolism (Nelson et al., 1996 & Nelson, 1999). These P450s 
usually have relatively selective substrate specificities and are subject to tight tissue- 
specific and hormone-dependent regulation.
In addition, mutations in the structural genes for these P450s underlie some common and 
severe inherited diseases such as progressive cholestatic liver disease, neurological 
disease and fat-soluble vitamin malabsorption (Setchell, 1996 & Setchell and O'Connell, 
1994).
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1.3.3 Nomenclature and distribution of cytochrome P450s
When the cytochrome P450s were discovered in the 1950s and 1960s, the enzymes were 
generically named "cytochromes P450" although the enzymes are not cytochromes as 
classically defined (Rendic and Di Carlo, 1997). In mammals, the enzymes are expressed 
in nearly every tissue, being most abundantly present in the liver (Gonzalez, 1989). 
Human cytochrome P450 enzymes involved in the metabolism of xenobiotics located in 
the liver and in the extrahepatic tissues are presented in Tables 1.3 & 1.4, respectively.
The cytochrome P450 enzymes comprise a large superfamily of proteins whose 
biosynthesis is controlled by a superfamily of genes (Nelson et al., 1993 & 1996). The 
superfamily of the cytochrome P450 enzymes is, for convenience, abbreviated as CYP 
enzymes and has been classified in different families in accordance to the degree of 
sequence similarity of amino acids in their protein structures (Nelson et al., 1993). CYP 
enzymes having < 40% homology in their amino acid sequence are classified in different 
families which are designated by Arabic numbers, for example, CYPl. Each family is 
further divided into subfamilies of enzymes which have > 55% sequence homology and 
are designated by capital letters, for example, CYPl A. An Arabic number is used for 
designating individual enzymes within a subfamily, for example, enzymes CYPlAl and 
CYP1A2 (Nebert etal., 1989 and 1991 & Nelson et ah, 1993).
Each of the cytochrome P450 genes almost always produces a single protein, there being 
only a few exceptions to this rule where functional alternative splicing produces an 
enzyme with new catalytic activity (Nelson et ah, 1993). The gene for an individual 
isoform may display more than one type of regulation if the gene is expressed at both 
basal and induced levels, or if both endogenous and exogenous substrates can be 
metabolized (Goldfarb, 1990).
To date, genes within a defined subfamily have been found to lie within the same "gene 
cluster" and are referred to as non-segregating. It is possible that such clusters have arisen 
via gene duplication events, mostly during the last 400 million years and it is thus 
expected that each subfamily might be a genetically segregating distinct entity (Nelson et 
ah, 1993).
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Table 1.3 Human CYP enzymes involved in the metabolism of
xenobiotics located in the liver‘s
CYP enzyme Level of the enzyme 
(% of liver)
Extent of variability 
in level
1A2 13 40-fold
IBl <1
2A6 4 30- > 100-fold
2B6 < 1 50-fold
2C 18 25- to 100-fold
(depending on the enzyme)
2D6 up to 2.5 >1000-fold
2E1 up to 7 20-fold
2F1’’
2J2'’
3A4 up to 28 20-fold
4A"
4F'*
Adapted from Rendic and Di Carlo, (1997).
 ^Bold type indicates enzymes involved in the metabolism of numerous drugs. 
Underlining indicates enzymes involved in the metabolism of major chemicals with 
possible toxicological consequences.
 ^No data available.
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Table 1.4 Human CYP enzymes involved in the metabolism of
xenobiotics located in extrahepatic tissues^
CYP enzyme Tissue
lA l Lung, kidney, GI tract, skin, placenta, lymphocytes, and others
IBl Skin, kidney, mammary, prostate, uterus, fetus
2A6 Lung, nasal membrane, and others
2B6 GI tract, lung
GI tract (small intestine mucosa), larynx, lung
2D6 GI tract
2E1 Lung, placenta, and others
2F1 Lung, placenta
2J2 Heart
GI tract, placenta, fetus, uterus, kidney, lung
4B1 Lung, placenta
4A11 Kidney
Adapted from Rendic and Di Carlo, (1997).
 ^Bold type indicates enzymes involved in the metabolism of numerous drugs. 
Underlining indicates enzymes involved in the metabolism of major chemicals 
with possible toxicological consequences.
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More than 500 CYP enzymes have now been identified and characterized, and 481 
cytochrome P450 genes have been described in living organisms (Rendic and Di Carlo,
1997). They are classified into 74 families, 14 of which exist in all mammals. These 14 
families comprise 26 mammalian subfamilies of genes, of which 20 have been mapped in 
the human genome. The use of recombinant DNA technology can now provide an 
unlimited source of CYP enzymes for studying their structure and function (Rendic and 
Di Carlo, 1997). A number of members of the P450 superfamily have been successfully 
expressed in bacteria, yeast, insect and mammalian cells (Rendic and Di Carlo, 1997).
Moreover, 17 families and 39 subfamilies of cytochrome P450 genes have been found in 
humans (http://dmelson.utmem.edu/P4501ect.html) (Table 1.5)
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Table 1.5 Human cytochrome P450 families
CYP Family Function Subfamilies Genes Pseudo­
genes
CYPl Drug metabolism 2 3
CYP2 Drug and steroid metabolism 12 17 11
CYP3 Drug metabolism 1 4 2
CYP4 Arachidonic acid or fatty acid metabolism 5 11 7
CYP5 Thromboxane A2 synthase 1 1
CYP7A Bile acid biosynthesis 7-alpha hydroxylase 
of steroid nucleus
1
CYP7B Brain specific form of 7-alpha 
hydroxylase
1
CYP8A Prostacyclin synthase 1
CYP8B Bile acid biosynthesis 1
CYPll Steroid biosynthesis 3
CYP17 Steroid biosynthesis 1 1
CYP19 Steroid biosynthesis 1 1
CYP21 Steroid biosynthesis 1 1 1
CYP24 Vitamin D degradation 1
CYP26A Retinoic acid hydroxylation 1
CYP26B Probable retinoic acid hydroxylation 1
CYP27A Bile acid biosynthesis 1
CYP27B Vitamin D3 1-alpha hydroxylase activates 
vitamin D3
1
CYP39 Unknown function 1
CYP46 Cholesterol 24-hydroxylase 1
CYP51 Cholesterol biosynthesis 1 1 2
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The expression and function of cytochrome P450s may be affected by a number of 
factors, including, physiological (hormones, growth factors, cytokines, etc.), pathological 
(infections, inflammation, hepatectomy, etc.), genetic (polymorphism of expression or 
function) and environmental (drugs, diet compounds, pollutants) factors (Gonzalez, 
1989). These various possibilities of modulation account for the wide interindividual 
variability exhibited by human populations in response to drugs and environmental 
pollutants in terms of metabolism and toxicity (Cholerton et al., 1992 & Gonzalez, 1992 
Kalow, 1991 & Meyer, 1991 & Westlind etal., 1999).
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1.3.3.1 The cytochrome P450 clans
The nomenclature of the cytochrome P450s was devised to reflect the evolutionary 
relationships of their sequences (Nelson et al., 1996). Phylogenetic trees have been 
constructed that include P450s from plant, animal, and fungal origin (Nelson, 1999). 
These trees have reproducible groupings of P450s to a point, but the more distant 
associations tend to be volatile. Shifting of an alignment or the addition of a new 
sequence can alter the position of deeper branches. Fungal sequences do not all cluster 
together nor do the plant or animal sequences. These branches seem to be interleaved. 
However, there is consistent assortment of these groups into a small number of kingdom- 
specific clusters (Nelson, 1999), which reflect a good approximation to the true tree.
Because these clusters include multiple families, a new nomenclature level has been 
created to name them and are now designated as clans (Figure 1.1) (Nelson, 1999). The 
resemblance to clade is intentional. These clusters of P450 families are not organisms that 
share a single common ancestor, as in the classical definition of a clade, but they 
probably represent genes that diverged from a single common ancestor (Nelson, 1999).
Animals currently are assigned 43 families which cluster into several well-behaved 
groups. The clans are named for a representative family as in the 2, 3, 4, and 7 clans, a 
unique location as in the mitochondrial clan, or for a specific organism, as in the C. 
elegans clan, which does not contain sequences from any other organism. The C. elegans 
clan seems to have driven from a common ancestor with the clan 2, so these two groups 
might be considered a superclan with more than half of the C. elegans P450s in this clan 
(Nelson, 1999). The 3 clan has the mammalian 3 and 5 families, the insect 6 and 9 
families, as well as the C. elegans 13 and 25 families. The 28 family from insects 
(Danielson et al., 1998), the 30 family from clams (Brown et ah, 1998), and the 45 family 
from lobster (Snyder, 1998) are also included here. The vertebrate and invertebrate 
members of the 2, 3, and 4 and mitochondrial clans necessarily diverged when these 
major groups split 600 million years ago. Therefore, the most distant branches within the 
animal clans may represent the protostome-deuterostome divergence (Nelson, 1999).
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Figure 1.1 The cytochrome P450 clans (Adapted from Nelson, 1999)
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1.3.4 The cytochrome P450s catalytic cycle
The mixed function oxidase (MFO) system consists of cytochrome P450 (the terminal 
oxidase), NADPH-cytochrome P450 reductase (a flavoprotein, sometimes termed 
NADPH-cytochrome c reductase) and a lipid component (White and Coon, 1980 & 
Guengerich, 1991). The central features of the cytochrome P450 catalytic cycle are the 
ability of the haem iron to undergo cyclic oxidation/reduction reactions in conjunction 
with substrate binding and oxygen activation (Figure 1.2). The precise molecular details 
of this catalytic cycle have not all been fully elucidated (Gibson and Skett, 1994).
The overall reaction of the cytochrome P450-catalysed mixed function oxidation 
conforms to the following stoichiometry:
NADPH + IT  + 02 + RH Cytochrome P450^ NADP"  ^+ H2O + ROH
Where RH represents the substrate and ROH represents the oxidised metabolite; 
subsequent decomposition or arrangement of the metabolite may occur. The reaction 
requires the presence of both NADPH and molecular oxygen, in addition to the 
components of the mixed function oxidase system (Gibson and Skett, 1994).
The NADPH-cytochrome P450 reductase is a vital component of the MFO system due to 
the ability of the flavoprotein to transfer reducing equivalents from NADPH + H^ to 
cytochrome P450 (Gibson and Skett, 1994). The precise role of the lipid component is 
unclear; however it may facilitate electron transfer, provide a template for the interaction 
of the cytochrome P450 and NADPH-cytochrome P450 reductase molecules, or may be 
required for substrate binding (Gibson and Skett, 1994).
The catalytic cycle begins with the binding of the substrate to the oxidised P450 enzyme, 
followed by haem reduction and biding of molecular oxygen; this is followed by electron 
rearrangement, oxygen insertion and product release (Gibson and Skett, 1994 & 
Guengerich, 1991).
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Goeptar et al. (1995) referred to the P450 one-electron reduction of oxygen (which 
occurs under aerobic conditions) as "oxygen reductase activity" of P450 instead of the 
usual "oxidase" or "uncoupling" activity. The formation of O2 (reactive oxygen species) 
during the oxygen reductase activity of P450 is attributed to autooxidation of the [Fe^ -^ 
P450] [O2 ] complex either spontaneously or in the presence of xenobiotics. When the 
rate of P450 reduction is greater than the turnover of xenobiotic oxidation, the [Fe^ -^ 
P450] [O2 ] complex will accumulate during steady-state metabolism and consequently 
lead to O2 formation (Goeptar et al., 1995) that can cause irreversible cell damage 
unless effective means of detoxication are present.
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Figure 1. 2 The catalytic cycle of the cytochrome P450 enzyme 
(Adapted from Guengerich, 1999)
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1.4 The human CYP3A subfamily
The CYP isoforms belonging to the 3A subfamily account for the majority of drug- 
metabolizing enzymes present in the human liver and intestine (de Wildt et al., 1999 & 
McKinnon et al., 1995 & Watkins et al., 1985). The CYP3A subfamily consists of at 
least three functional genes: CYP3A4, CYP3A5 and CYP3A7 (Nelson et al., 1996), 
which are located on chromosome 7, at position 7q22.1 (Inoue etal., 1992). The enzymes 
comprising the CYP3A family share at least 85% amino acid sequence homology, 
however, they have been shown to differ substantially in substrate specificity and 
expression (Wiighton and Stevens, 1992).
CYP3A7 is the main form of CYP expressed in fetal liver (Yang et al., 1994). This gene 
is also expressed in the endometrium and placenta (Schuetz et ah, 1993b). During the 
perinatal period, the level of CYP3A7 mRNA decreases gradually to become either low 
or undetectable in the newborn and in the adult liver (Pascussi et al., 1999). In contrast, 
the pattern of CYP3A4 expression exhibits a mirror image of that of the CYP3A7, the 
levels of mRNA and protein rising sharply in the newborn, so that CYP3A4 is the major 
form of CYP expressed in the adult liver (Greuet et ah, 1996 & Pascussi et ah, 1999).
CYP3A5 is expressed in a greater percentage of children, as compared with adults 
(Wiighton et al., 1990). Immunochemical and molecular studies have demonstrated that 
CYP3A5 is polymorphically expressed (Aoyama et al., 1989 & Wrighton et al., 1989). 
Specifically, only 25 to 30% of the human liver specimens examined have been found to 
contain detectable levels of CYP3A5 (Aoyama etal., 1989 & Wrighton etal., 1989). The 
metabolic capabilities of CYP3A5 appear to overlap somewhat with those of CYP3A4, 
although CYP3A5 appears to have slower turnover rates than CYP3A4 in some cases 
(Aoyama û r / . ,  1989).
The sequence reported as CYP3A3 (Molowa et ah, 1986) differs from CYP3A4 in 14 
coding positions. It is currently unclear whether CYP3A3 and CYP3A4 represent the 
product of distinct genes at different genetic loci, or whether they represent alleles 
corresponding to an identical genetic locus (Watkins, 1994). These genes are so highly 
related (98% sequence homology) (Watkins, 1994) that their relative expression at the
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mRNA level, as determined by oligonucleotide hybridisation, is in dispute (Bork et al., 
1989 & Schuetz et al., 1989) and at the protein level is unknown (Wrighton et al., 1989).
CYP3A enzymes are very active in steroid and bile acid 6(3-hydroxylation and oxidation 
of many of xenobiotics (Chang et al., 1993 & Guengerich, 1997 & Rendic and Di Carlo, 
1997). Because of their wide substrate specificity and prominent expression in the liver 
and gut, the CYP3As are the most important group of enzymes involved in drug 
metabolism (Thummel and Wilkinson, 1998).
Some CYP3 A forms display sex- and development-specific expression (Quattrochi et ah, 
1995 & Waxman and Chang, 1995) and inducibility (Honkakoski and Negishi, 2000). 
For example, rat CYP3A23, rabbit CYP3A6, and human CYP3A4 genes are activated by 
a wide variety of antibiotics, barbiturates and other drugs, glucocorticoids and 
antiglucocorticoids, and pesticides in a species-specific manner (Barwick et ah, 1996 & 
Schuetz e/a/., 1998).
The DNA elements responsible for induction of CYP3A genes by dexamethasone have 
been located in the proximal promoters, upstream of the HNF-4 binding site (Barwick et 
ah, 1996 & Huss and Kasper, 1998 & Huss et ah, 1996 & Quattrochi et ah, 1995 & 
Pascussi et ah, 1999). The rat CYP3A genes contain a DR3 (direct repeat with 3 bp 
spacing) motif (5' AGTTCANNNAGTTCA) at -130 bp and an BR6 (everted repeat with 
6 bp spacing) motif (5' TGAACTNNNNNNAGGTCA) at -160 bp. The rabbit CYP3A6 
and the human CYP3 A genes contain only the ER6 motif in the proximal promoter, while 
both DR3 and ER6 are present in a strong distal enhancer in the CYP3A4 gene at -7.7 
kbp (Goodwin et ah, 1999).
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1.4.1 The CYP3A4 gene
CYP3A4 is the predominant isoform of CYP3A in adult humans and is responsible for 
the metabolism of a wide range of drugs and endogenous compounds in humans (~50%) 
(Dresser et al., 2000 & Guengerich et al., 1998 & Harvey et al., 2000 & Michalets, 1998 
& Tsunoda et al., 1998). CYP3A4 has a very broad substrate specificity and accounts for 
60% of cytochrome P450 enzymes in human liver and 70% of those in enterocytes found 
in the gut wall responsible for first-pass metabolism (Slaughter and Edwards, 1995 & 
Westlind et al., 1999). Hepatic and enteric CYP3A4 content appear to be independently 
regulated (Dresser et al., 2000).
The cytochrome P450 3A4 gene has been isolated and sequenced (Hashimoto et ah, 1993 
& Jounidi et al., 1994), and is 27 kb long, with 13 exons and 12 introns. The promoter 
motif contains a basal transcription element (-35 to -50bp). Also present in the 5'- 
untranslated region are putative AP-3, P53, hepatocyte nuclear factor-4 and -5 elements, 
a glucocorticoid response element (GRE), estrogen receptor element sequence 
(Hashimoto et al., 1993 & Itoh et al., 1992) and an ER6 motif (Barwick et ah, 1996). It 
should be emphasized that these are considered putative elements and have not all been 
further characterized by gel mobility shift and transfection experiments (Guengerich, 
1999).
1.4.1.1 Substrates, inducers and inhibitors of CYP3A4
The catalytic activity of CYP3A4 has been studied extensively using expressed enzyme, 
immunoinhibition experiments and the correlation of metabolic activity with 
immunoreactive CYP3A4 content in microsomal samples (Wrighton and Stevens, 1992). 
CYP3A4 catalyses a remarkable number of metabolic processes including aliphatic 
oxidation, aromatic hydroxylation, iV-dealkylation, 0-demethylation, ^-déméthylation, 
oxidative deamination, sulfoxide formation, A^oxidation and iV^hydroxylation, to mention 
a few (Dresser et al., 2000). This produces inactivation and elimination of most 
pharmaceuticals. However, CYP3A4 can also activate carcinogenic substances such as 
the aflatoxins and polycyclic aromatic hydrocarbons (Dresser et ah, 2000).
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Due to the predicted large active site of CYP3A4 (Yamazaki and Shimada, 1998), the 
enzyme is able to metabolise high molecular weight substrates, such as cyclosporin A 
(Combalbert et ah, 1989 & Herbert, 1997). Molecular modelling and metabolism studies 
suggest that more than one substrate can bind to the active site simultaneously, and that 
one substrate, when bound, can enhance the metabolism of a second substrate e.g. 
phenanthrene metabolism is activated by 7,8 benzoflavone (Lewis et al., 1996 & Shou et 
al., 1994). CYP3A4 can exist in different conformations with different substrate 
specificities, and binding of the activator substrate changes the conformation of the 
enzyme (Gillam et al., 1993).
A number of drugs from a broad range of therapeutic categories are CYP3A4 substrates 
and the list is growing very fast (Table 1.6). They include erythromycin, midazolam, 
triazolam, cyclosporin, lidocaine (lignocaine) and nifedipine amongst many others 
(Leeder and Kearns, 1997). Endogenous substrates for CYP3A4 include steroids such as 
testosterone, cortisol, progesterone, androstenedione, dehydroepiandrosterone 3-sulfate 
(DHEA-S) and estradiol (Wrighton and Stevens, 1992). Cytochrome P450 3A4 is known 
to catalyze the oxidation of a number of substrates in a co-operative manner (Szklarz and 
Halpert, 1998).
Although CYP3A4 drug metabolizing activity varies substantially between individuals, it 
has an apparent unimodal population distribution and does not appear to be subject to 
genetic polymorphism as seen with other CYP isoforms (2D6, 2C9 and 2C19) (Dresser et 
al., 2000). However, it should be noted that sufficiently large population samples have 
not been studied to date to confirm a unimodal distribution. Other workers reported 
variability in the CYP3A4 activity with at least ten-fold difference in activity observed in 
the general population (Guengerich, 1989 & Watkins, 1990), this variability is thought to 
be due to both genetic and nongenetic factors (Tsunoda et ah, 1998). There is evidence 
that differences in steroid hormone levels may be responsible for some of the variability 
of CYP3A4 activity (Tsunoda etal., 1998).
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Table 1.6 Drug substrates of cytochrome P4503A4 (including steroids)
(Guengerich, 1999)
Acetaminophen (quinoneimine fonnation) 
Alfentanil (noralfentanil formation) 
A^idem (propyl oc&p)
Alprazolam
Amiodarone (N-deethylation) 
Amitriptyline (N-demethylaUon)
Artelinic acid (débenzylation)
Astemizole
Atorvastatm
Bayer R4407 (+) (pyridine formation) 
Bayer R5417 (-) (pyridine formation) 
Benzphetamine (N-demethylation) 
Budesonide (6p)
Carbamazepine (10,11 epoxidation)
Citalopram (N-demethylation)
Clarithromycin
Clopidogrel
Cloz^ine
Codeine (N-demethylation)
Colchidne (2,3)
Cortisol (6p)
Cyclobenz^rine 
cyclophosphamide 
cyclosporin A 
cyclosporin G 
D^sone (N)
Dehydroq)iandrosterone 3-sulfate (16a)
Delaviridine (6', N-dealkylation)
Dextromethoiphan (N-demethylation)
Diazepam
Digitoxin
Diltiazem
Docetaxel (taxoterc)
Ebastine (alcohol oxidation) 
l?p-estradiol
Erythromycin (O-demethylation) 
Ethylmoiphine (N-demethylation) 
17p-Ethynylestradiol 
Etoposide
Felodipine (pyridine formation) 
Finasteride (i-butyl)
Flutamide
Germander
Gestodene
Granisetrone
Halopridol (alcohol oxidation) 
Ifosphamide
Imq)ramine (N-demethylation)
Indivanir
hinotecan (piperidine a )
Ivermectin 
Lansoprazole 
Lepetit MDL
Lidocaine (N-deethylation)
Lisuride (N-deethylation)
Loratidine
Losartan (alcohol, aldehyde oxidation)
Lovastatin
Meloxicam
Merck KgaA EMD
Methadone (N-demethylation)
Midazolam
Mifepristone (RU-486) (N-demethylation)
N-Hydroxyarginine
Nevarq)ine
Nicardipine (pyridine formation) 
Nifedipine (pyridine formation) 
Niludipine (pyridine formation) 
Nimodipine (pyridine formation) 
Nisoldipine (pyridine formation) 
Nitrendipine (pyridine formation)
Novartis PSC 833 
Novartis SDZ NKT 343 
Omeprazole 
Oxodipine 
Paclitaxel (taxol)
Progesterone (6p, some 16a)
Propafenone 
Proquanil (cyclization)
Queti^ine (S,N,0-dealkylation)
C^uinidine
P^amydn
Retinoic acid
Ritonavir
Sameterol (a)
Schering AG ergot CQA 206-291 
Sequenavir
Sertindole (N-dealkylation) 
Sulfamethoxazole 
Sulfentanil 
Tacrolimus (FK 506)
Tamoxifen (N-deme&ylation)
Tasosartan
Teniposide
Terfenadine (/-butyl, N-dealIg?'lation) 
Terguride
Testosterone (6p, trace 15p,2p)
T etrahydrocannabinol 
Theophylline
Toremifine (N-demethylation)
Trizolam
Trimethadone (N-demethylation)
Troleandomycin
Ver^amil
Warfarin (R-10,5'-dehydro)
Zatosetron
Zonisamide
26
With regard to orally administered drugs, knowledge of the extent of, and factors 
determining, the bioavailability of these substrates allows for prediction of the changes in 
pharmacokinetics with administration of a CYP3A4 inducer (Michalets, 1998) or 
inhibitor (Dresser et ah, 2000). The effect of a single substrate on the metabolism of a 
second is dependent on the identity of the latter. Apparently, there is no hierarchical 
relationship where in the presence of a specific drug has a consistent effect on the 
metabolism of all others, i.e., the interaction patterns between compounds with CYP3 A4 
were found to be substrate-dependent (Wang et al., 2000).
Enzyme induction, first recognized in the 1940s, occurs when hepatic blood flow is 
increased or the synthesis of more CYP-450 enzymes is stimulated (Michalets, 1998). In 
animal models, phénobarbital increases liver weight in a dose-dependent manner and in 
humans, liver biopsies in patients taking anticonvulsants resulted in up to 52% larger 
absolute liver size (Pirttiaho et al., 1982). Inducers tend to be lipophilic, and the time 
course of the interaction is dependent on the half-life of the inducer. For example, 
rifampicin's short half-life results in enzyme induction (CYP3A4, CYP2C) apparent 
within 24 hours, whereas phenobarbital's longer half-life of 3-5 days requires 
approximately 1 week for induction (CYP3A4, CYP2B1/2, CYP2C) to become apparent 
(Michalets, 1998).
A complicating factor is that the time course of induction is also dependent on the time 
required for enzyme degradation and new enzyme production. In other words, the rate- 
limiting factor may be the half-life of CYP-450 enzyme turnover, which ranges from 1- 6 
days (Cupp and Tracy, 1997). Since rifampicin is eliminated more rapidly than the excess 
cytochrome enzymes, the rate-limiting factor in the duration of the interaction would be 
enzyme turnover. With phénobarbital, accumulation and elimination would be the rate- 
limiting factor in the onset and loss of induction (Cupp and Tracy, 1997).
Although the expression of the CYP3A4 gene is known to be induced in response to a 
variety of compounds (Table 1.7), the specific molecular mechanisms underlying this 
induction, which represents a basis for drug interactions in patients, has remained unclear 
(Lehmarm et al., 1998).
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Enzyme inhibition most often occurs as a result of competitive binding at the enzyme's 
binding site. Competitive inhibition depends on the affinity of the substrate for the 
enzyme being inhibited, the concentration of the substrate required for inhibition, and the 
half-life of the inhibitor drug (Michalets, 1998). The onset and loss of enzyme inhibition 
are dependent on the half-life and time to steady state of the inhibitor drug. A second and 
less common mechanism of inhibition is non-competitive, which can occur as a result of 
inhibitor inactivation of the enzyme with normal substrate binding. The duration of this 
type of inhibition may be longer if new enzymes are synthesized after the inhibitor drug 
is discontinued (Brouwer etal., 1993).
A list of CYP3A4 inhibitors is shown in Table 1.8.
28
Table 1.7 Inducers of the CYP3A4 gene
Drug class Inducer
Analgesics Phenylbutazone
Antibiotics Sulfadimidine, Erythromycin
Triacetyloleandomycin, Rifampicin
Antiepileptics Carbamazepine, Phénobarbital, Phenytoin
Antifungals Clotrimazole
Antigout Sulfinpyrazone
Antihistaminics Azatadine, Loratadine, Oxomemazine
Corticosteroids Cortisol, Dexamethasone, Prednisone,
Pregnenolone-16a-carbonitrile
Proton pump inhibitors Omeprazole, Lansoprazole
Sex hormones Testosterone
Estrogens Estradiol
Progestagens Progesterone
Others Metyrapone, Benzoflavone, Troglitazone
Lovastatin
Adapted from Rendic and Di Carlo, 1997
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Table 1.8 Inhibitors of the CYP3A4 gene
Drug class Inhibitor
Antibacterial 
Imidazole antifimgals
Antiarrythmics
Antidepressants
Corticosteroids 
Calcium channel blockers 
Antiestrogen 
Antiviral 
Sedatives, Hypnotics 
H2 receptor antagonist 
Immunosuppressants 
Others
Erythromycin, Triacetyloleandomycin 
Ketoconazole, Itraconazole, Miconazole, 
Fluconazole 
Quinidine, Amiodarone 
Fluoxetine, Fluvoxamine, Nefazodone, 
Norfluoxetine 
Gestadone, Dexamethasone, Prednisolone 
Deltiazem, Verapamil, Nifedipine 
Tamoxifen 
Indinavir, Ritonavir 
Midazolam 
Cimetidine 
Cyclosporin, Tacrolimus 
Cannabinoids, grapefruit juice
Adapted from Michalets, 1998
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1.5 Steroid hormone receptors
Steroid hormones (Figure 1.3) exert profound effects on differentiation, development and 
homeostasis in higher eukaryotes through interaction with nuclear receptors (Kliewer et 
al., 1998). Steroid hormones are cholesterol derivatives that serve as signalling molecules 
to co-ordinate the expression of complex gene programmes (glucocorticoid responsive 
genes) in higher eukaryotes. These molecules exert their effects by diffusing into cells 
and interacting with specific intracellular receptors (Kliewer etal., 1998).
The steroid hormone receptors comprise a subfamily within a larger superfamily of 
structurally related proteins (Evans, 1988; Mangelsdorf and Evans, 1995). This 
superfamily also includes receptors for nonsteroidal, lipophilic molecules such as thyroid 
hormone/ retinoids/ vitamin D, the peroxisome proliferator activated receptors, and the 
largest category, receptors for which no ligand is known, or orphan receptors (Kumar and 
Thompson, 1999).
In the absence of their cognate ligands, the steroid hormone receptors remain sequestered 
in the cytoplasm through interaction with large multiprotein complexes containing heat 
shock proteins (Pratt, 1993). However, the binding of ligand causes the steroid hormone 
receptor to be released from this complex and translocated into the nucleus (Pratt, 1993). 
Once inside the nucleus, the activated receptors regulate the expression of target genes by 
binding as homodimers to short DNA sequence motifs, termed hormone response 
element (HREs) (Glass, 1994). Hence steroid hormone receptors function as ligand- 
activated transcription factors (Lemon and Freedman, 1999).
The nonsteroid receptors differ from their steroid hormone receptor counterparts in 
several respects (Mangelsdorf and Evans, 1995). First, the nonsteroid hormone receptors 
are not sequestered in the cytoplasm in the absence of their cognate ligands but instead 
reside within the nucleus. Second, whereas steroid hormone receptors generally bind to 
their HREs as homodimers, most of the nonsteroid hormone receptors identified to date 
bind to DNA as heterodimers with the 9-cis retinoic acid receptors (RXR) (Glass, 1994 & 
Mangelsdorf and Evans, 1995). Finally, the two classes of receptors recognize different 
types of HREs: steroid hormone receptors generally bind to HREs composed of two half­
sites organized as a pair in a palindrome with a three nucleotide spacer, whereas
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nonsteroid hormone receptors preferentially bind to HREs composed of two half-sites 
organized as a direct repeat (DR), with the number and composition of the nucleotide 
separating the half-sites serving as important determinants of receptor selectivity.
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Figure 1.3 Synthesis of steroid hormones
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1.5.1 The human glucocorticoid receptor (hGR)
The glucocorticoid receptor (GR) belongs to the superfamily of the ligand-modulated 
transcription factors (Mangelsdorf et ah, 1995) which regulate gene transcription by 
activation as well as by repression (Beato et ah, 1995 & Wallberg et ah, 1999). The GR 
is activated on binding of glucocorticoids (GCs) in various tissues, including lung, liver, 
bone marrow, immune system and brain, and thus plays a central role in many 
physiological and developmental processes (De Kloet et ah, 1998 & Evans-Storms and 
Cidlowski, 1995 & Schmid et ah, 1995). So, GR is found in almost every cell, and the 
level of GR expression in a tissue determines its cellular responsiveness to the hormones 
(Ghosh et ah, 2000).
Glucocorticoid actions and their receptor reactivity are tightly regulated through a 
feedback mechanism, thus, GR is typically down-regulated by an excess of 
corticosteroids (through stress response or exogenous administration) and up-regulated 
by adrenalectomy (Ghosh et ah, 2000). Additional findings indicate that this auto­
regulation process involves transcriptional, post-transcriptional, and post-translational 
modifications (Dong et al., 1988 & Reul et ah, 1989). The extent of these regulations is 
known to vary considerably between tissues and cell types, or as a consequence of 
ageing, disease state, drug treatment, physiological stress, and exposure to environmental 
toxicants (Bamberger a/., 1998).
The human glucocorticoid receptor (hGR) has been cloned and sequenced (Hollenberg et 
ah, 1987). There are 2 forms of hGR, termed hGRa and hGRp. The hGRp, which is 
formed by alternative splicing of the hGR pre-mRNA, does not bind glucocorticoid 
ligands and is transcriptionally inactive (Bamberger et ah, 1995).
The ligand binding domain of the GR (believed to span 300 amino acid) is located near 
the carboxyl terminal region of the molecule, although the specific sequence required for 
hormone binding has not been clearly defined. This region is complex and is believed to 
contain regions required for dimérisation, transcription activation, interaction with heat 
shock protein (HSPs) and nuclear localisation (McDonnell et ah, 1993).
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The DNA binding domain of the GR (highly conserved amongst the steroid receptor 
family) is located in the middle of the protein and contains nine cysteine residues (Evans, 
1988 & McDonnell et ah, 1993). The region folds into a “two-fingers” structure 
stabilised by zinc ions connected to cysteines to form 2 tetrahedrons; the zinc-fingers 
represent the basic structure by which the DNA-binding domain recognises specific 
nucleic acid sequences (McDonnell et ah, 1993 & Wingard et ah, 1991). These specific 
sites on DNA are referred to as glucocorticoid response elements and are short cz5-acting 
sequences which function in a position and orientation-independent fashion and thus 
behave as transcriptional enhancers (Evans, 1988).
The consensus sequence for a GRE is GGTACAnnnTGTTCT (Beato, 1989). The GR 
also recognises a consensus TGTTCT half site arranged as a pair in a palindrome. This 
latter sequence is also recognised by progesterone, testosterone and aldosterone receptors 
(McDonnell a/., 1993).
The GR is transcriptionally inactive in the absence of ligand binding and is present inside 
the cell as large oligomeric complexes, of which one molecule is associated with 2 
molecules of HSPs, HSP70 and HSP90 (Bamberger et ah, 1995). When a ligand binds, it 
induces a conformational change, which displaces these inhibitory proteins and enables 
the receptor to interact with DNA (McDonnell et ah, 1993). The intracellular mechanism 
of action of glucocorticoid receptor is summarised in Figure 1.4.
The molecular mechanism of GR function is still not clear and it is possible for the GR to 
activate or to down regulate the transcription of a gene (Celander et ah, 1996 & Langer 
and Ostrowski, 1988 & McDonnell et ah, 1993). In genes that are classically induced by 
glucocorticoids, such as tyrosine amino transferase (TAT), and mouse mammary tumour 
virus gene (MMTV), glucocorticoids (e.g. DEX) produce transcriptional induction of 
gene expression (Dogra et ah, 1998), whereas antiglucocorticoids, (e.g. RU-486) do not 
induce these genes, and also block their inductions by glucocorticoids (Evans, 1988 & 
Quattrochi et ah, 1995 & Wright and pain 1994).
Studies on CYP3A23 gene fragments expressed in primary cultures of adult rat 
hepatocytes and tested for DNA-protein interactions showed that CYP3A23 induction by 
dexamethasone and pregnenolone 16a-carbonitrile involved the glucocorticoid receptor
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or a protein induced by glucocorticoids indirectly interacting with proteins constitutively 
bound to an enhancer element consisting of a direct repeat of 7-bp separated by two 
nucleotides in the 5'-flanking region of the gene (Quattrochi et al., 1995).
Analysis of proteins bound to CYP3A23 enhancer through the use of UV-cross-linking 
revealed two rat liver nuclear proteins with molecular masses of approximately 130 and 
100 kDa, as well as several proteins of molecular masses between 45 and 60 kDa, that 
specifically bind to the direct repeat in the CYP3A23 enhancer (Quattrochi et ah, 1998).
The induction of rat liver CYP3A1 differs from classical glucocorticoid gene regulation 
in part because both glucocorticoids and antiglucocorticoids such as pregnenolone 16a- 
carbonitrile induce CYP3A1 through transcriptional gene activation (Quattrochi et al., 
1995). The activation of CYP3A1 gene transcription by glucocorticoids may involve 
proteins already bound to the controlling element in the CYP3A1 gene through a 
mechanism in which glucocorticoid receptor in the presence of hormone does not bind 
directly to CYP3A1 DNA (Quattrochi etal., 1995).
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Figure 1.4 Role of the glucocorticoid receptor in gene regulation 
(Adapted from Gilman, 1996)
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CBG; Corticosteroid binding globulin, GR: Glucocoticoid receptor,
S: Steroid hormone, HSP90: The 90-kDa heat shock protein, HSP70: 
The 70-kDa heat shock protein, IP: The 56-kda immunophilin, GRE: 
Glucocorticoid response element.
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1.5.2 The pregnane X receptor (PXR)
A novel orphan nuclear receptor in the mouse, termed the pregnane X receptor (mPXR), 
is activated by several steroids, including naturally occurring steroids such as 
pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids, 
and combines features of both the steroid and nonsteroid hormone nuclear receptors 
(Kliewer et ah, 1998). The mPXR exists as 2 isomers, mPXR.1 and mPXR.2, the latter 
being identical to mPXR.1 except for the deletion of a stretch of 123 nucleotides 
extending from base pairs 661 to 783. The mPXR.1 and mPXR.2 are differentially 
activated by steroids. Notably, PXRl is efficiently activated by pregnenolone 16a- 
carbonotrile (PCN, a glucocorticoid receptor antagonist) that induces the expression of 
CYP3A family of steroid hydroxylase and modulates sterol and bile acid biosynthesis in 
vivo (Kliewer etal., 1998).
Kliewer et al. (1998) provided evidence that the orphan nuclear receptor mPXR is 
responsible for mediating the inductive effects of PCN and dexamethasone (DEX, a 
glucocorticoid receptor agonist) on CYP3A gene expression. First, both PCN and DEX 
are efficient activators of the mPXR.1 isoform. Second, mPXR.l binds efficiently as a 
heterodimer with RXR to the conserved DR-3 motif identified in the CYP3A1 and 
CYP3A2 gene promoters as glucocorticoid and PCN response elements. Thirdly, 
mPXR.1 expression was detected in only a few tissues, including liver, intestine, and 
kidney which are the primary tissues in which CYP3A genes are expressed and induced 
in response to either DEX or PCN treatment (Debri et al., 1995). These data supported 
the existence of a novel signalling pathway for synthetic glucocorticoids and provided a 
mechanistic explanation for how both GR agonists and antagonists can exert similar 
effects on CYP3 A gene expression.
Lehmann et al. (1998) identified the human homologue of the mPXR, termed human 
PXR (hPXR), that binds to the rifampicin/dexamethasone response element, a 20 bp 
region residing ~150bp upstream of the transcription initiation site of the CYP3A4 
promoter, as a heterodimer with the 9-cis retinoic acid receptor RXR. The 
rifampicin/dexamethasone response element contains two everted copies of the
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AG(G/T)TCA motif, typically recognized by members of the nuclear receptor 
superfamily, separated by six nucleotides (ER6) (Pascussi et ah, 1999).
The longest hPXR clone isolated in a screen of a human liver cDNA was 2146 bp in 
length which encoded a new member of the nuclear receptor superfamily that was 96% 
and 76% identical to the mPXR. 1 in the DNA binding domain (DBD) and ligand binding 
domain (LED), respectively (Figure 1.5).
The hPXRTRXR complex is activated by dexamethasone, rifampicin, and a variety of 
other, structurally diverse compounds previously shown to modulate CYP3A4 gene 
expression, with rifampicin being the most potent activator. Several naturally occurring 
steroids also activated the hPXR, including pregnenolone and progesterone (Lehmann et 
ah, 1998). The hPXR mRNA is expressed most abundantly in the liver and is also present 
in the colon and small intestine (Lehmann et ah, 1998). Figure 1.6 summarizes the role of 
hPXR in drug-drug interactions and steroid metabolism.
A hPXR variant mRNA has been identified (Dotzlaw et ah, 1999) in both normal and 
neoplastic breast tissues that contains an in-frame deletion of 111 nucleotides 
corresponding to a deletion of nucleotides 823-933 of the wild-type hPXR mRNA, as 
numbered in Lehmann et ah (1998). This variant is most likely generated by alternative 
splicing mechanism in which 37 amino acids (residues 174-210) are deleted in the 
putative ligand-binding domain (Figure 1.7).
The protein predicted to be encoded by this variant hPXR mRNA, assuming there are no 
other alterations in the mRNA, would be 397 amino acids, unlikely to bind ligand or have 
a markedly altered ligand profile compared to that of the wild-type hPXR (Dotzlaw et ah, 
1999).
An element similar to the CYP3A4 ER6 is present in the promoter of CYP3A7 but the 
sequence of this element, hereafter referred to as CYP3A7 ER6-Itoh, (Itoh et ah, 1992) 
reveals three mutations with respect to the CYP3A4 ER6 sequence, two of them 
disrupting both half-sites of the element. No trans-activation of PXR was observed in co­
transfection experiments using plasmid constructs in which the reporter gene is under the 
control of the CYP3A7 ER6-Itoh element (Blumberg et ah, 1998) concluding that these
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mutations are responsible for the lack of inducibility of CYP3A7 in response to 
xenobiotics. However, in contrast to this sequence, Pascussi et al. (1999) reported that the 
3' half site of the CYP3A7 ER6 element is not mutated and is functional and responsive 
to xenobiotics known to activate hPXR.
Zhang et al. (1999) reported the molecular cloning, tissue distribution, and xenobiotic 
regulation of a rat PXR, designated rPXR-1. The rPXR-1 is closely related to its mouse 
orthologue, sharing 95% amino acid identity but only 79% identity with the hPXR, 
providing the molecular basis that rats and mice have a similar CYP3 A induction profile 
but differ from humans (Zhang et al., 1999). The rPXR-1 is expressed abundantly in the 
liver, intestine, and, to a lesser extent, kidney, lung and stomach. The tissue distribution 
and the relative abundance of rPXR-1 mRNA among these tissues resemble those of 
CYP3 A, suggesting that PXR is important not only for induction but also for constitutive 
expression of this enzyme (Zhang etal., 1999).
The rabbit PXR is roughly equally divergent from the human and rodent PXR (Jones et 
al., 2000). This small degree of divergence is unprecedented for nuclear receptor 
orthologues (Jones et al., 2000). Rabbit PXR is most abundantly expressed in the liver, 
with PXR mRNA also detected in tissues of the gastrointestinal tract (Jones et al., 2000).
The structural diversity of the compounds that activate PXR is unprecedented for a 
nuclear receptor. The molecular weights for these compounds ranged from 232 
(phénobarbital) to 823 (rifampicin) (Jones et al., 2000). Phthalic acid and nonylphenol 
which are endocrine disrupting chemicals stimulated PXR-mediated transcription at 
concentrations comparable to those at which they activate estrogen receptor-mediated 
transcription using a transient reporter gene expression assay in COS-7 cells (Masuyama 
et ah, 2000). These data suggest that endocrine disrupting chemicals may affect the 
endocrine functions by altering the steroid hormone metabolism through PXR 
(Masuyama etal., 2000).
A PXR-null mouse was generated with the mutant allele having a deletion of two exons 
including amino acid residues 63-170 of the DNA-binding domain and showed no 
alteration of the basal expression of CYP3A gene (Xie et al., 2000). However, the 
CYP3A gene was no longer induced in response to the prototypic rodent-specific CYP3A
40
inducers, pregnenolone- 16a-carbonitrile (PCN) and dexamethasone which establishes 
that PXR is an essential mediator of CYP3A xenoregulation in vivo (Xie et ah, 2000).
Transfection of the steroid and xenobiotic receptor (SXR) into primary rat hepatocyte 
cultures where no PXR vector was added resulted in significant induction of CYP3A23 
by drugs known to be active in humans including rifampicin (RIF), clotrimazole (CTZ), 
phénobarbital and pregnenolone whereas activation by PCN remained unchanged (Xie et 
al., 2000). Hence, transfection of SXR is sufficient to convert the induction response 
characteristics of the hepatocytes from rat to human (Xie et ah, 2000).
Mutating either one or both of the half-sites of the direct repeat (DR3) which form the 
CYP3A23 PXR response element abolished the PXR- and SXR-mediated activation of 
CYP3A23 by PCN, RIF and CTZ. In contrast, replacement of the DR3 element by an 
inverted repeat element from the human CYP3 A4 promoter rescued inducibility by PCN, 
RIF and CTZ (Xie et ah, 2000) indicating that SXR/PXR and their response elements are 
essential in determining patterns of CYP3A inducibility.
Both RIF and CTZ caused induction of mouse CYP3A11 mRNA in the liver of the PXR- 
null/SXR transgenic mice but not the wild-type mice whereas PCN induced CYP3A11 
equally in wild-type and transgenic mice (Xie et ah, 2000). The dynamics and 
reversibility of rodent CYP3A11 mRNA changes in transgenic animals were consistent 
with changes in the enzyme levels in humans (Xie et ah, 2000). The CYP3A gene was 
induced in the PXR-null/SXR transgenic mice by RIF (a human-specific inducer) but not 
PCN. Hence, SXR alone can reconstitute CYP3A xenoregulation and confer a human 
profile of inducibility to PXR-deficient mice (Xie et ah, 2000).
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Figure 1.5 Amino acid sequence comparison between hPXR.1 and mPXR.1
(Adapted from Lehmann et al., 1998)
hPXR.l
mPXR.l
41 107 141 434
DNA Ligand
1 38 104 138 431
96% 76%
Amino acid sequence comparison between hPXR.l and mPXR.l. 
Numbers indicate percent amino acid identity in the DNA binding 
domains (DBDs) and ligand binding domains (LBD).
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Figure 1.6 Role of the hPXR in drug-drug interactions and 
steroid metabolism (Adapted from Kliewer et al., 1999)
Drug B Steroids
Drug A Pregnane X
CYP3A gene
HO-Drug B HO-Steroids
Model for the role of PXR in drug-drug interactions and steroid metabolism. PXR binds as a 
heterodimer with RXR to a response element in the CYP3A gene promoter. Activation of 
PXR by various drugs or its natural ligand "Pregnane X" results in increased levels of 
CYP3A enzyme activity that, in turn, results in the hydroxylation of various drugs and 
endogenous steroids.
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Figure 1.7 hPXR.1 (wild-type) and hPXR.2
(Adapted form Dotzlaw et ah, 1999)
1 41 107 141 174 210 434
hPXR.1 ■ H
1 41 107 141 y 397
hPXR.2 H
Diagrammatic representation of the protein predicted to be encoded by the 
variant hPXR mRNA hPXR 1 represents the wild-type human PXR and 
hPXR.2 represents the deleted PXR variant. Numbers represent the amino 
acid residues. DBD, DNA-binding domain; LBD, ligand-binding domain.
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1.5.2.1 Differential activation of mouse, rat, rabbit and human PXRs
The macrolide antibiotic rifampicin is a much more better inducer of CYP3A expression 
in rabbit hepatocytes than rat hepatocytes (Jones et ah, 2000). Conversely, pregnenolone 
16a-carbonitrile (PCN) induced CYP3A expression in rat hepatocytes but not rabbit 
hepatocytes. Dexamethasone also activates the rabbit PXR whereas RU-486, cyproterone 
acetate (CPA) and spironolactone activated the rat PXR (Jones et ah, 2000). In general, 
activation of the rat and rabbit PXR agreed with the reported induction of CYP3A 
expression in primary hepatocytes from these same species (Jones et ah, 2000).
It had been suggested that the activation profiles of the rabbit and human PXR are likely 
to be similar. Indeed, the human and rabbit PXRs were both efficiently activated by 
rifampicin as well as by RU-486, clotrimazole, /raw5-nonachlor, and phénobarbital (Jones 
et ah, 2000). However, the rabbit PXR was much more sensitive than its human 
orthologue to activation by the synthetic steroids dexamethasone, PCN, CPA, and 
spironolactone (Jones et ah, 2000).
Troglitazone, a PPARy ligand, which is known to increase CYP3A4 activity and to 
enhance the metabolism of other drugs in patients (Michalets, 1998) was found to 
activate both human and rabbit PXRs but had little effect on the rat and mouse PXRs.
Given their high degree of sequence identity, it was not surprising that the rat and mouse 
PXRs had very similar activation profiles, although there were subtle differences.
The sequence comparison of PXR among species is shown in Figure 1.8.
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Figure 1.8 Sequence comparison of PXR among species
(Adapted from Jones et ah, 2000)
DNA binding domain
Percent sequence similarity
Rabbit Mouse Human
Rabbit
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Ligand binding domain
Percent sequence similarity
Rabbit Mouse Human
Rabbit
Mouse
Human
The percent amino acid identities and differences are 
indicated for the PXR from different species in drug 
binding domain (DBD) and ligand binding domain (LBD)
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1.6 Genetic Polymorphisms
1.6.1 Introduction
Biotransfonnation enzymes play an important role in the metabolism of xenobiotics that 
thus may be either bioactivated or bioinactivated by metabolism (Wormhoudt et ah, 
1999). A wide interindividual variability in the levels and activities of biotransformation 
enzymes exists among humans, as has been shown for a number of enzymes, both ex vivo 
and in vivo (Boobis, 1996 & Shimada et ah, 1994). Examples of such interindividual 
variabilities include the metabolism of xenobiotics to which people have been exposed 
therapeutically, occupationally, or through the diet (Wormhoudt et ah, 1999).
Ingelman-Sundberg et ah (1999) stated the main causes for variation in drug metabolism 
as: 1. genetic polymorphisms, 2. induction or inhibition due to concomitant drug 
therapies or environmental factors, 3. physiological status, 4. Disease states. Of these, the 
first two appear to be of major importance for the occurrence of adverse effects or lack of 
therapeutic efficiency in many cases (Wormhoudt et ah, 1999).
High variability in the metabolism of xenobiotics can sometimes be attributed to 
mutations within the gene coding for the enzyme responsible for its metabolism (Daly et 
ah, 1993). Polymorphisms are either differences (insertions or deletions) or mutations in 
either the regulatory or the coding region of the gene (Griffiths et ah, 1993). Changes 
within the regulatory region can affect the modulation of expression of the gene both by 
endogenous and exogenous compounds thus altering the rate of transcription of the gene, 
whereas alterations in the coding region can lead to aberrant mRNA splicing and/or 
changes in the amino acid sequence of the protein resulting in altered catalytic activities 
(Daly et ah, 1993 & Shimada et ah, 1994). Some mutants, the so called nul alleles, even 
lead to enzyme deficiency, which means that the activity of the corresponding enzyme is 
totally absent (Guengerich and Shimada, 1991).
This genetically determined interindividual variability in drug and xenobiotic metabolism 
is thus one important factor that determines the variability of xenobiotic-related toxicity, 
adverse drug reactions, as well as the efficiency of the drug (Figure 1.9A) (Tucker, 1994). 
Because the biotransformation enzymes might also be involved in the bioactivation and
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bioinactivation of genotoxic compounds, genetic polymorphisms of these enzymes are 
thought to be one of the susceptibility factors in cancer risk (Figure 1.9B) (Venitt, 1994). 
Therefore, mutated genes encoding biotransformation enzymes are called susceptibility 
genes, which should be distinguished from (proto) oncogenes, in that susceptibility genes 
require exposure to certain compounds in order to have an effect on cancer risk 
(Caporaso and Goldstein, 1995).
The idea that genetic polymorphism possibly determines the risk of cancer is based on the 
assumption that chemical exposure, subsequent metabolism, and some kind of interaction 
of a reactive metabolite and cell constituent steps in the initiation of tumour formation 
(Wormhoudt et ah, 1999). Thus, metabolism of (pro) genotoxic compounds is important 
in the complex series of steps from initial chemical exposure to final tumour formation 
(Wormhoudt e/a/., 1999).
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Figure 1.9 Effects of genetic polymorphisms of biotransformation enzymes 
(Adapted fromWormhoudt et ah, 1999)
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Prodrug / Protoxin Drug / Toxin
Bioactivation Bioinactivation
1f f
Active drug / Toxin Inactive drug or non-
toxic metabolite
1f
Pharmacological or toxicological effects
B
Progenotoxin Genotoxin
Bioactivation I
Genotoxin
Bioinactivation
I Non-genotoxic metabolite
Genotoxic effect
1
Tumour
A- Effects on metabolism of (pro)drugs and (pro)toxins 
B- Effects on metabolism of (pro)genotoxic compounds
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A number of molecular genetic mechanisms causing genetic polymorphism of 
biotransformation enzymes are known to exist. First, the complete gene encoding a 
biotransformation enzyme might be absent. Second, the expression of the gene may be 
lost or impaired due to mutations in the regulatory parts of the gene. Third, due to 
mutations at intron-exon boundaries, the pre-mRNA might be spliced incorrectly. Fourth, 
non-critical amino acids in the protein may have been mutated, causing a change in the 
activity of the enzyme. Fifth, critical amino acids in the protein may have been mutated, 
causing an inactive enzyme (Daly et al., 1993 & Shimada et al., 1994 & Wormhoudt et 
a l, 1999).
1.6.2 Polymorphic cytochrome P450 genes
Several human cytochrome P450s are known to be subjected to genetic variation (Meyer 
and Zanger, 1997). The metabolic capacity of the CYP enzyme system is not equal in all 
members of a population (Ozawa, 1997). In particular, there is clear evidence for 
impaired metabolic functions relating to CYP2D6 and CYP2C19 isoforms in relatively 
small percentages of certain ethno-geographical populations, whereas similar examples of 
genetic polymorphism arising from allelic variants in P450 genes are suspected for 
CYPlAl, CYP1A2, CYP2A6 and CYP2E1 (Raunio and Pelkonen, 1995) and CYP2C9 
(Meyer and Zanger, 1997).
It is possible that all human P450s are subject to interindividual variation such that "poor 
metabolizer" and "extensive metabolizer" phenotypes may exist throughout human 
populations, which has important implications for the pharmaceutical industry, and is 
likely to lead to the routine evaluation of patients (Gonzalez and Idle, 1996). The relative 
distribution of variant alleles for the cytochrome P450s differs markedly between ethnic 
groups, making the extent and characteristics of genetically determined differences in 
drug response quite specific for the global region in question (Ingelman-Sundberg et ah, 
1999).
Alleles that cause defective, qualitatively altered, diminished or enhanced rates of drug 
metabolism have been identified for several of the cytochrome P450 enzymes (Ingelman- 
Sundberg et al., 1999). Completely inactive alleles have been found for CYP2D6, 
CYP2C19 and CYP2A6. Defective alleles can be the result of gene deletions, gene
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conversions with related pseudogenes and single base mutations causing frameshift, 
missense, nonsense or splice-site mutations (Ingelman-Sundberg et al., 1999). The 
homozygous presence of such alleles leads to a total absence of active enzyme and an 
impaired ability to metabolize drugs specific for the drug-metabolizing enzymes, defined 
as a poor metabolizer (PM) phenotype (Ingelman-Sundberg et al., 1999).
The first P450 polymorphism was reported for the CYP2D6 gene (Nakamura et al., 
1987). This gene is important in the metabolism of a number of clinically important drugs 
such as cardiovascular agents (debrisoquine and propranolol), psychotropic drugs 
(imipramine and thioridazine), as well as other compounds, such as codeine (Daly et al., 
1993 and Hirvonen et al., 1993). Approximately 5-10% of Caucasians and 1% of Asian 
populations catalyse the oxidation of debrisoquine and other CYP2D6 substrates at a 
reduced rate (Nakamura et al., 1987). Twenty-one different polymorphisms have been 
identified within the coding region of the CYP2D6 to date (Hirvonen et ah, 1993). 
CYP2D6 poor metabolizers have been correlated with increased drug mediated toxicity 
and decreased carcinogenesis in some lung cancers (Hirvonen et ah, 1993), although the 
latter is still an issue of considerable debate.
Another CYP enzyme demonstrated genetic polymorphism is the CYP2E1 (Nedelcheva 
et ah, 1996) which is responsible for variation in the metabolism of low molecular weight 
carcinogens, such as nitrosamines (Hayashi et ah, 1991). The presence of insertion 
mutation was associated with greater metabolic ability of CYP2E1 but only among 
individual who were either obese or had recently consumed ethanol (McCarver et ah, 
1998).
Not only can expression of CYP3A isoforms change over a lifetime, but the amount of 
different isoforms of CYP3A may vary between individuals (Oesterheld, 1998). This 
leads to large variations in metabolizing capacities between individuals because CYP3A 
isoforms metabolize both unique substrates and overlapping substrates at differing rates 
(Oesterheld, 1998).
The interindividual variability in the expression of CYP3A4 (Westlind et ah, 1999) is 
very high (20- to 40- fold), which may account (amongst other factors) for a large 
interindividual differences in the disposition of drugs that are metabolized by this enzyme
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(Ball et ah, 1999). This variability can account for individuality in the efficacy and safety 
of some drugs that are metabolized by this enzyme (Lemaire et ah, 1990). CYP3A4 
inhibitors and inducers have been identified, and these can contribute importantly to 
interindividual variability in CYP3A4 levels (Rendic and Di Carlo, 1997).
Moreover, CYP3A4 expression is known to be affected by many factors, for example, 
cytokines, disease states, drug transporter expression, diet and age (Wilkinson, 1996). 
The polygenic multifactorial nature of CYP3A4 expression adds to the complexity of 
delineating the possible role of any one factor on CYP3A4 phenotype in an individual at 
a given time (Ball et ah, 1999). This contrasts with the classic polymorphic P450s, for 
example, CYP2D6 and CYP2C9 in which single gene mutations account for much of the 
observed phenotypic variability in these enzymes (Daly, 1995 & Meyer and Zanger 
1997).
Only recently has a CYP3A4 genetic variant (CYP3A4-V) been reported in the non­
coding region of the gene (Rebbeck et ah, 1998). This variant is in the promoter region of 
the CYP3A4 gene in the so-called nifedipine-specific element (NFSE), located at -287 to 
-296 base pairs from the start site of the CYP3A4 gene. The function of this element in 
the promoter region is currently unknown, nonetheless, this CYP3A4 variant appears to 
be associated with a lower incidence of cancer treatment-related leukemias and a higher 
clinical stage and grade of prostate tumours (Felix et ah, 1998 & Rebbeck et ah, 1998).
Von Moltke et ah (2000) reported an unusually low clearance and long elimination half- 
life of alprazolam and trazodone, two CYP3A substrate drugs, by a healthy 40-year-old 
Caucasian male following single-dose oral administration in clinical pharmacokinetic 
studies. Sequence analysis of a 592 base-pair segment upstream from the CYP3A coding 
region of this subject revealed no variation from the wild-type in the nucleotide present at 
position -290, previously suggested to influence expression and/or activity of CYP3 A.
Four alleles for the CYP3A4 have been reported in three racial groups (Sata et ah, 2000). 
The first allele was designated CYP3A4*1B (an A -> G point mutation in the 5'-flanking 
region of the human CYP3A4 gene NFSE) with a frequency of 4.2% in white population, 
66.7% in the black subjects but was not found in the Chinese subjects. A second variant
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allele, designated CYP3A4*2, having a Ser222Pro change, was found at a frequency of 
2.7% in the white population and was absent in the black and Chinese subjects analyzed. 
Compared with the wild-type enzyme, the CYP3A4*2 variant had a lower intrinsic 
clearance for the CYP3A4 substrate nifedipine but was not significantly different from 
the wild-type enzyme for testosterone 6P-hydroxylation. Another rare allele, CYP3A4*3, 
was found in a single Chinese subject who had a Met445Thr change in the conserved 
haem-binding region of the P450, although the functional consequences of this are not 
known. The wild-type allele was designated CYP3A4*1A.
1.6.3 Approaches to study genetic polymorphism
A number of approaches are possible for investigating the effects of genetic 
polymorphisms of biotransfonnation enzymes on the metabolism and toxicity of drugs 
and xenobiotics (Wormhoudt etal., 1999) (Table 1.8). Metabolism of xenobiotics can be 
measured in vitro/ex vivo using, for example, cell lines or human tissue samples that 
express the wild-type or mutated genes encoding biotransfonnation enzymes. This 
approach is particularly useful with enzymes for which only toxic or carcinogenic 
substrates are known (Wormhoudt et al., 1999). Alternatively, metabolism can be 
measured in vivo using a panel of volunteers that have been genotyped or phenotyped 
with respect to the genetic polymorphism of interest, in which case the compound of 
interest itself can be used or, alternatively, isoform substrate for the particular isoform of 
interest (Wormhoudt etal., 1999).
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Table 1.9 Methods for the measurement of the effects of genetic polymorphisms of 
hiotransformation enzymes on xenobiotic metabolism and toxicity
Metabolism
In vitro
Ex vivo
In vivo
Cell lines expressing wild-type and mutated enzymes 
Assess metabolism of compounds of interest 
Assess metabolism of isoform specific substrates 
Human tissue samples to measure the metabolism 
of compounds of interest or isoform specific 
substrate
Genotyped or phenotyped panel of human volunteers 
Measure, for example, urinary metabolites of the 
compound of interest (if it is nontoxic) or 
alternatively of isoform specific substrates 
approved for human in vivo studies
Toxicity/pharmacology
In vitro/ex vivo
In vivo
Measurement of a toxicological or pharmacological 
effect (subcellular fractions or human tissue samples) 
Measurement of a toxicological or pharmacological 
effect in clinical studies
Genotoxicity
Ex vivo
Ex vivo/in vitro
DNA adducts or mutations in, for example, white blood 
cells or exfoliated bladder cells from genotyped or 
phenotyped human volunteers 
Parameters reflecting genetic damage using human 
tissue samples or cell lines 
Structural aberrations in chromosomes 
Micronuclei 
Aneuploidy
Sister chromatid exchange
Adapted from Wormhoudt et al. (1999)
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1.7 Aims of my PhD project
My first aim was to study the mechanism of induction of CYP3A4 gene by a number of 
steroids and xenobiotics by transfecting HepG2 cells with a CYP3A4-pSPAP reporter 
gene construct. Specifically, the role of the antiglucocorticoid RU-486, the human 
glucocorticoid receptor and the human pregnane X receptor in the steroids and 
xenobiotics induction of CYP3A4 will be examined.
The second aim of my project was to isolate approximately 308 bp of the 5' upstream 
regulatory region of the CYP3A4 gene which was previously shown to have base pair 
changes in either the HNF-5 or the estrogen response elements (Dr Nick Plant, personal 
communication). Sequence confirmation of the isolated regions followed by cloning into 
a secretory placental alkaline phosphatase (SEAP) expression vector to study the 
functional effect of these mutations on the transactivation of CYP3A4 gene by steroids 
and xenobiotics.
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CHAPTER 2 - MATERIALS AND METHODS
2.1 Materials
2.1.1 Chemicals
All chemicals and reagents used in the experimental work were of the highest purity 
available and were purchased from Sigma chemical company unless listed below. 
Boehringer Mannheim
Multipurpose agarose 
Flowgen
Metaphore agarose 
Fisher Scientific UK
Sodium Chloride
Oxoid
Bacteriological Agar (Agar No. 1)
Phosphate buffered saline (PBS) tablets 
Tryptone 
Yeast extract 
Pharmacia Biotech 
Dextran T70 
Scotlah
Bisracrylamide stock solution 2% w/v 
Acrylamide stock solution 40% w/v 
Amersham Lifesciences
[a-^^P] dATP, 3000Ci/mmol specific activity 
Procedures mvolvmg the use of radiochemicals were carried out in accordance with the 
guidelines set out in the "Local Rules for Protection against Ionising Radiation", 
published by the University of Surrey Safety Office.
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2.1.2 Enzymes and DNA markers
Promega
Restriction enzymes
Calf intestinal alkaline phosphatase (CIAP)
1Kb DNA Ladder (fragment sizes: 10000, 8000, 6000, 5000, 4000, 3000,
2500, 2000, 1500, 1000, 750, 500, 250)
T4 DNA Ligase 
T4 DNA Polymerase 
Taq DNA Polymerase 
Stratagene
Pfu DNA Polymerase
2.1.3 Kits
ICN
Aurora Alkaline Phosphatase Chemiluminescent Reporter Gene Assay Kit 
Promega
Wizard Maxipreps DNA purification system 
Wizard Minipreps DNA purification system
Qiagen
Endofree plasmid maxi kit 
QIAprep spin miniprep kit 
QIAquick gel extraction kit 
Stratagene
RecoverEase DNA isolation kit
2.1.4 Single stranded conformational polymorphism equipment
Flowgen
Vertical gel apparatus 
Glass plates 
Combs 
Spacers
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Whatman 3MM papers
2.1.5 Cell culture reagents
European Collection o f Animal Cell Cultures (ECACC)
HepG2 cells - A human hepatocyte carcinoma, originally established from a 15 
years old male Caucasian, was supplied as a frozen culture in passage 90. This 
was regarded in this study as passage zero, and all passage numbers given refer to 
number of passages from that point. On receipt of the frozen culture the cells were 
grown up in bulk and aliquots were frozen in passage 5 to be used as a bank for 
all subsequent work.
Gibco BRL Life Technologies
Non-essential amino acids 
Gentamycin (lOmg/ml in water)
L-glutamine 200mM (lOOx)
Fetal bovine serum
Minimum essential media (MEM)
MEM with Earle's salts, without L-glutamine 
MEM with Earle's salts, without L-glutamine, without phenol red 
Trypsin-EDTA
2.1.6 Plasticware and disposable
Beckman
Polypropylene centrifuge tubes 
Polypropylene centrifuge bottles
Falcon
50ml polypropylene tubes
Greiner
Transparent microplate sealers 
Sterile inoculating loops 
90mm petri dishes 
Cryovials
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Nalgene
0.22|jM Filter units 
Nunclon Life Technology
Tissue culture flasks 
Packard
96 well plates: Optiplate (white) and View plates
Scotlah
0.5 and 1.5ml microcentrifuge tubes
2.1.7 Instrumentation
Chemiluminescent assays were carried out on a Lumicount plate reader (Packard) 
Spectrophotometric assays were carried out on GENEQUANT (Pharmacia 
Biotech)
GeneAmp®PCR system (PE Applied Biosystems)
2.1.8 Human liver samples
Human liver samples were obtained from Keystone Tissue Bank, PA, USA, which were 
phenotyped for CYP3A4 activity (midazolam 1'-hydroxylase activity) by Dr. Dave 
Moore (Hoffman-La Roche, Nutley, New Jersey, USA) and kindly supplied to our 
laboratory. The samples (5 males and 6 females) exhibited a 14.1 fold ranges in 
midazolam hydroxylase activity. Values of the midazolam hydroxylase activity ranged 
from 133pmoles/min/mg to 1873pmoles/min/mg, with a mean value of 563 
pmoles/min/mg.
2.1.9 Bacteria and plasmids
Clontech
Kcoli competent cells, high efficiency 
All of the following plasmids carry the ampicillin resistance (amp^ gene to enable 
selection for bacteria containing the plasmid during culture
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Clontech
pSEAP2-Promoter vector 
Promega
pGEM-T Easy vector 
Stratagene
pSG5 vector
The pSG5-hGR vector was a gift from AstraZeneca, Alderley Park, England (Dr. 
Jonathan Tugwood). The pSG5-hPXR was a gift from Dr. S. Kliewer (Glaxo Wellcome, 
Research Triangle Park, NC, USA). The pCMV-cSPAP reporter plasmid (referred to as 
pCMV throughout this study) was a gift from Glaxo Wellcome (Dr. Mike Tarbitt); the 
p3A4-CMV-SPAP reporter construct (referred to as p3A4 throughout this study) was 
engineered from pCMV-cSPAP in our laboratory by Dr. Janet Williams (Williams, 
1997).
Restriction maps of the plasmids are given in Figures 2.1 to 2.7.
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Figure 2.1 Functional map of pGEM-T Easy vector
Xmn I 2009
Nae\
2710Sea I 1890
T7 If1 ori 1 St
A pa\ 
AatW 
Sph I 
A/col 
BsfZI 
Nol\ 
Sac II 
EcoR I
14
pGEM®-T Easy 
Vector
(3018bp)
lacZ
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Nat\ 
BstZ\ 
P st\ 
Sa/1 
Nde I 
Sac I 
BstX I 
N si\
€4
77
90
109
118
127
141t  SP6
T7 and SP6 = RNA polymerase promoters flanking a multiple cloning site 
which contains multiple restriction enzyme sites, Ampr = ampicillin 
resistance, ori = origin of replication
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Figure 2.2 Functional map of pSEAP2-promoter, 
an alkaline phosphatase reporter plasmid
TB
MCSA(1-41) 
SV40 ori
- MCS B (245-264)
 ' BamH 1(481)
Not 1(4833) 
ti ori
SEAP cDNA
pSEAP-promoter
4900 bp
Ampr .
Ase 1(3377)
Xba i(1794) 
SV40PolyA 
Sal i(2062)
pUC ori
Ampr = ampicillin resistance, fl ori = origin of replication of the 
filamentous phage fl, SV40 = semian virus, MCS = multiple cloning site.
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Figure 2.3 Functional map of pCMV-cSPAP reporter vector
Spe 1(5964)
Sal 1(5334)
CMV PromoterORI
Eco RI (978)
Ampr
pCMV-cSPAP
5976 bp
SPAR cDNA 
Eco R I (1652)Sea 1(4379)
Xba 1(2254)
SV40 t-intron &poly(A) sites
Ampr = ampicillin resistance, SPA? cDNA = secretory placental alkaline 
phosphatase gene, ORI = origin of replication, CMV = eukaryotic 
cytomegalovirus strong promoter
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Figure 2.4 Functional map of p3A4-CMV-cSFAP reporter vector
CYP3A4(-1078to-57)
Spe 1(5964) 
Sal 1(5934) 
OR!
Spe 1(1086)
CMV Promoter
Ampr
SPAP cDNA
SV40 t-intron & poly (A) sites
Xba 1(3284)
Ampr = ampicillin resistance, SPAP cDNA = secretory placental 
alkaline phosphatase gene, ORI = origin of replication, CMV = 
eukaryotic cytomegalovirus promoter
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Figure 2.5 Functional map of pSGS vector
SV40
Sal
B-globin intron
ori f1
pSG5
4176
^  EcoR I, BamH I, Bgl 
Poly A 
Sal l/Xba IAmpr
Ampr = ampicillin resistance, SV40 =SV40 promoter, ori = origin of 
replication, ori fl = origin of replication of the filamentous phage fl, 
T7 = RNA polymerase promoter, ORI = origin of replication
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Figure 2.6 Functional map of pSG5-hGR expression vector
SV 40 Promoter
EcoR I (1044)
Hind III (1416)
pSG5-hGR
6833 lapAmpr
Hind III (1970)
Hind III (2338) 
hGRalpha
Pst I (2848)EcoR I (3801)
Ampr = ampicillin resistance, hGR cDNA = human glucocorticoid receptor 
cDNA
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Figure 2.7 Functional map of pSG5-hPXR expression vector
Cla 1(374)
Ampr
EcoR 1(1043)
hPXR cDNA
on
Poly A BamH 1(2360)
Xba 1(2520)
Ampr = ampicillin resistance, ori = origin of replication, hPXR cDNA = 
human pregnane X receptor cDNA
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2.2 General microbiology
2.2.1 Sterilisation by autoclaving
All materials prepared for use in procedures involving the handling of nucleic acids, or 
bacterial or mammalian cell culture were sterilised using a Rodwell series 32 automatic 
autoclave. Sterilisation was carried out for 20 minutes at 121°C at a pressure of I51b/in .^
2.2.2 Preparation of glycerol stocks
Overnight cultures in LB medium containing lOOpg/ml ampicillin were prepared. ISOpl 
of sterile glycerol was added to SSOpl of bacterial culture in a sterile 1.5ml 
microcentrifuge tube; the tube was vortexed briefly to ensure complete mixing of the 
content before freezing the stocks at -80°C.
2.2.3 Growth of bacterial cultures
A sterile inoculating loop was scraped across the surface of a frozen stock, and then 
streaked onto an ampicillin (lOOpg/ml) LB agar plate and incubated overnight at 37°C. A 
single colony was then picked using a sterile loop and inoculated into 5ml LB medium 
containing 100|j,g/ml ampicillin. This mini-culture was incubated in a rotatory incubator 
at 225rpm at 37°C overnight (16-18 hour). For subsequent maxi-culture, SOOpl of the 
miniculture was added per 250ml of LB medium containing 100p,g/ml ampicillin and 
then incubated overnight (12-16 hour) in a rotatory incubator at 225rpm at 37°C.
2.2.4 Transformation of bacteria
Overnight ligation reactions were transformed into JM109 competent cells, an E. coli 
strain which provides a stable replication of high copy number plasmids. The JM109 
enables blue/white screening of recombinant plasmids.
Frozen competent cells were removed from -70°C and placed on ice for 5 minutes and 
then were gently mixed by flicking the tube. 3 pi DMSG was added to 200pl competent 
cells and 20pl was used for each transformation. 2 pi of the ligation reaction was then
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added and the reactions were incubated on ice for 30 minutes. The suspension was then 
heat shocked for 1 minute at 42°C in a waterbath, and immediately placed on ice for 10 
minutes. ISOpl LB media was added, and the cells incubated at 37°C in a shaking 
incubator (ISOrpm) for 1.5 hours before being spread onto LB agar plates containing 
lOOpg/ml ampicillin, 0.5mM IPTG and 40pg/ml X-Gal. The plates were incubated 
overnight at 37°C.
Control transformations:
1. Negative control transformation (no DNA) was carried through the same procedure to 
ensure no contamination occurring during the transformation process.
2. Positive control transformation using Ipl of the control DNA supplied with the kit to 
determine the transformation efficiency.
White colonies were picked for plasmid isolation using the miniprep plasmid DNA 
purification method (section 2.3.1) then diagnostic restriction digest (using Pvu H) was 
performed to check the presence of the insert. Alteration in the base sequence was 
checked by single strand conformational polymorphism analysis and the sequence was 
confirmed by automated sequencing (SOOng of DNA and 20ng of pUC/M13 primer) 
using an ABI373 automated sequencer and the dye terminator cycle sequencing ready 
reaction kit (PE Biosystem, UK). Sequencing was carried out in duplicate in both forward 
and reverse directions to confirm mutations.
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2.3 DNA extraction
2.3.1 Miniprep plasmid DNA purification
The pelleted bacterial cells was suspended in 250pl buffer PI (resuspension buffer), 
250pl buffer P2 (lysis buffer) was added and the tube was gently inverted for 4-6 times. 
350pl buffer N3 (neutralisation buffer) was added and the tube was immediately but 
gently inverted 4-6 times and centrifuged for 10 minutes at 13,000 xg. The supernatant 
was applied to the QIAprep column (placed in a 2ml collection tube), centrifuged for 1 
minute at 13,000 xg, the flow-through was discarded. The spin column was washed with 
0.5ml buffer PB, centrifuged for 1 minute, the flow-through was discarded, the column 
then was washed with 0.75ml buffer PE, centrifuged for 1 minute and the flow-through 
was discarded. The tube was further centrifuged for an additional 1 minute at 13,000 xg 
to remove the residual wash buffer.
The C^Aprep column was placed in a clean 1.5ml microcentrifuge tube and 50pl buffer 
EB (lOmM tris-HCl, pH 8.5) was added to the center, left to stand for 1 minute and 
centrifuged for 1 minute at 13,000 xg
2.3.2 Endotoxin-free maxiprep plasmid DNA purification
Endotoxins are lipopolysaccharide (LPS) components of the lipid portion of the outer 
layer of the cell membranes of Gram-negative bacteria such as E-coli (Rietschel and 
Brade, 1992) and their presence in plasmid preparations decreases the transfection 
efficiency in sensitive cells (Weber et al., 1996). DNA purified with the Endofree 
Plasmid Maxi Kit contains only negligible amounts of LPS (less than 0.1 endotoxin 
units/fxg plasmid DNA) due to the use of a special endotoxin removal buffer that prevents 
LPS molecules from binding to the resin in the purified tips. DNA purified by this 
method can be used directly for transfection without the need for ethanol precipitation 
(Robbins a/., 1996).
The bacterial cells containing the plasmid of interest were pelleted by centrifugation at
6,000 xg for 15 minutes at 4°C after which the pellet was resuspended in 10ml buffer PI 
[resuspension buffer, 50mM tris-HCl (pH 8.0), lOmM EDTA, 100 jiig/ml RNase]. 10ml 
buffer P2 (lysis buffer, 200mM NaOH, 1%SDS) was added and the solution mixed by
70
gentle inversion 4-6 times, and incubated at room temperature for 5 minutes. 10ml chilled 
buffer P3 [neutralisation buffer, 3M K acetate (pH 5.5)] was added to the lysate, and 
mixed immediately by inversion (4-6 times). The lysate was poured into a QIA filter 
Maxi Cartridge and incubated at room temperature for 10 minutes after which it was 
gently pushed through the QIA filter and the filtrate collected in 50ml tubes. 2.5ml buffer 
ER was added and mixed by inversion of the tube approximately 10 times. The solution 
was incubated on ice for 30 minutes, during which 10ml buffer QBT [column equilibrium 
buffer, 750mMNaCl, 50mM MOPS (pH 7), 15% isopropanol, 0.15% triton X-100] was 
applied to a QIAGEN-tip 500 for equilibration. The column was allowed to empty by 
gravity flow. The cleared lysate was then applied to the tip and allowed to enter the resin 
by gravity flow, after which the resin was washed with 2x30 ml buffer QC [wash buffer, 
1.6mM NaCl, 50mM tris-HCl (pH 8.5), 15% isopropanol] The DNA was eluted with 
15ml buffer QN [elution buffer, 1.6mMNaCl, 50mM MOPS (pH 7), 15% isopropanol]. 
10.5ml of room temperature isopropanol was added to the eluted DNA, the solution was 
then mixed and centrifuged immediately at 15,000 xg for 30 minutes at 4°C. The 
supernatant was discarded and the DNA pellet was washed with 2.5 ml of endotoxin-ffee, 
room temperature 70% ethanol and centrifuged at 15,000 xg for 10 minutes. The 
supernatant was carefully discarded and the pellet was air-dried for 5 minutes then 
resuspended in 500pl of endotoxin-ffee TE buffer.
2.3.3 Isolation of genomic DNA
The RecoverEase DNA Isolation Kit quickly isolates high-molecular-weight genomic 
DNA from a variety of tissues without organic solvent extractions or ethanol 
precipitation. The procedure involves physical disaggregation of the tissue, coarse 
filtration, and isolation of the cell nuclei by centrifugation, followed by incubation with a 
highly active protease solution containing proteinase K to predigest the cellular protein. 
Digestion continues as the DNA preparation is transferred to a convenient free-floating 
dialysis cup that allows overnight dialysis of the digested peptides across a 
semipermeable membrane.
50-80mg of the liver tissue sample was homogenised in a chilled Wheaton Dounce tissue 
grinder containing 5ml ice-cold lysis buffer to release the cell nuclei. The homogenate 
was passed through a sterile cell strainer into a sterile 50ml conical tube, and 3ml of the 
ice-cold lysis buffer was used to wash the tissue grinder (total 8ml). The tube was
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centrifuge at 1100 xg for 12 minutes at 4°C, the supernatant was carefully discarded and 
the tube was drained for 1 minute on paper towel. The digestion solution was prepared by 
adding 20|il Rnace-it ribonuclease cocktail/ml of digestion buffer. 70p,l of prepared 
digestion solution was added to the cell nuclei pellet and the tube was gently rocked to 
dislodge the pellet. The conical tube was placed in a 50°C water bath, 70pl of pre­
warmed (2-5 minutes) proteinase K solution was added to the free floating pellet, the tube 
was gently swirled to mix and incubated for 45 minutes (the tube was gently swirled 
every 10-15 minutes).
DNA was then dialysed against IxTE for 16 to 48 hours using the provided dialysis cup. 
On completion of the dialysis, genomic DNA was transferred into a sterile 
microcentrifuge tube using a wide-bore pipette tip and stored at 4°C.
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2.4 Molecular biology
2.4.1 Quantification of DNA
The purity and concentration of a plasmid DNA preparation was determined by 
measuring the UV absorbance of a diluted aliquot over the wavelength of 260nm using 
the spectrophotometer. Samples were diluted in MilliQ water and were measured against 
a water blank.
2.4.2 Ethanol precipitation of DNA
Ethanol precipitation was used as a method to purify and/or concentrate samples of DNA 
if poor concentrations were obtained.
A 0.1 volume of 3M sodium acetate (pH 5.0) and 2 volumes of pre-chilled (-20°C) 100% 
ethanol were added, mixed well and the mixture was chilled to -20°C for 30 minutes to 
allow the precipitate to form. The precipitate was then pelleted by centrifugation at
14,000 xg and 4°C. for 30 minutes, supernatant was discarded and the pellet was washed 
with lOOpl 70% ethanol, followed by centrifugation at 14,000 xg for 10 minutes. The 
pellet was then air-dried for 5 minutes and resuspended in 200pl 0. IxTE or sterile water. 
Concentration of the DNA was determined by the spectrophotometer.
2.4.3 Agarose gel electrophoresis
Agarose gel electrophoresis of DNA was carried out according to the standard protocol 
described by Sambrook et al. (1989). 0.7 to 1.5% agarose was dissolved in IxTAE. For 
staining the DNA, ethidium bromide was included in the gel (0.5|ig/ml). Samples were 
mixed with 6 x loading dye prior to running, and the gels were run at 2.5V/cm. The DNA 
in the stained gel was visualised by exposure to UV light using a transilluminator (Model 
TM20, Genetic Research Instrumentation Ltd.) and Polaroid type 667 (positive) film. The 
film was exposed for 8  seconds with an aperture of f32 and an orange filter.
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2.4.4 Recovery of DNA from agarose gel
After electrophoresis of DNA samples on an agarose gel (0.7%), the bands of interest 
were excised from the gel using a sterile scalpel and then purified using GenElute™ 
Agarose Spin Columns (Supelco) or Qiagen Gene Extraction Kit.
2.4.4.1 QIAquick gel extraction protocol
Three volumes of buffer QG (solubilisation buffer) were added to one volume of the 
excised gel fragment and incubated at 65°C for 1 0  minutes (or until the gel slice has 
completely dissolved). One gel volume of 1 0 0 % isopropanol was added and mixed, and 
the sample was applied to a QIAquick spin column placed in a 2ml collection tube and 
centrifuged for 1 minute at 10,000 xg. The flow-through was discarded, 0.5 ml buffer QG 
was added and centrifuged for 1 minute at 10,000 xg. 0.75ml buffer PE was then added 
and centrifuged for 1 minute at 10,000 xg to wash the DNA. The flow-through was 
discarded and the tube was centrifuged for an additional 1 minute at 10,000 xg. The 
QIAquick column was placed into a clean 1.5ml microcentrifuge tube, 50pl buffer EB 
(wash buffer, lOmM tris-HCl, pH8.5) was added to the center of the column to elute the 
DNA and centrifuged for 1 minute at 10,000 xg.
2.4.4.2 GenElute™ agarose spin column protocol
The spin column (placed on top of eppendorf tube) was washed with lOOpl TE (lOmM 
tris, pH 8.0/lmM EDTA), centrifuged at 12,000 xg for 5 seconds and the TE was 
discarded. The excised agarose gel slice containing the DNA was placed in the washed 
column (placed on top of eppendorf tube) and centrifuged for 1 0  minutes at 1 2 ,0 0 0  xg.
2.4.5 Restriction enzyme digest of DNA
Restriction endonucleases recognise and cut specific sequences (usually 4-8 bp) in double 
stranded DNA molecules. The recognition sites are usually palindromic and the enzymes 
used cut both strands of DNA to give fragments with either overhanging (sticky) or blunt
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ends. Each enzyme is supplied with an appropriate buffer which contained a varying 
amount of salt.
Restriction digests were set up as follows:
DNA 0.2-Ipg
Bovine serum albumin, acetylated (Img/ml) 2pl
lOx restriction enzyme buffer 2 pl
Restriction enzyme 10 units *
Nuclease free water to20p,l
*1 unit of restriction enzyme activity is defined as the amount of enzyme required 
to conapletely digest Ipg of substrate DNA in 60 minutes
Reactions were incubated at 37°C for a minimum of 1 hour (usually left overnight). 
Restriction enzymes used in this study are listed in Table 2.1
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Table 2.1 Restriction enzymes used in the study and 
their recognition sequences
Enzyme Recognition sequence Buffer
Acc65 I G'^GTACC D
B ell T^GATCA C
BgllL A'^GATCTT D
N otl GC^GGCCGC D
Pvu n CAG^CTG B
Seal AGT'^ACT K
Spel
A T T A G T
B
Taql
T T G A
E
X bal
T T T A G A
D
The symbol ( a )  denotes the site at which the enzyme cuts the DNA
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2.4.6 Déphosphorylation of DNA
The SEAP vector was prepared for cloning by restriction digest with two enzymes, Acc 
651 and Bgl II using the same procedure described before (section 2.4.5) then the cut ends 
were dephosphorylated to prevent self-religation by removing the phosphate group from 
the 5-ends of the linearised plasmid DNA strands using calf intestinal alkaline 
phosphatase (CIP).
Dephosphorylation reaction;
DNA (10 pmol of 5'-ends) 40|xl
CIAP lOx reaction buffer 5 pi
Diluted CIAP (O.Olu/pl) 5pl
The CIAP was diluted in CIAP Ix reaction buffer immediately before use and any unused 
enzyme was discarded. The reaction was incubated at 37°C for 30 minutes. An additional 
O.Olu CIAP/pmol of ends was added and incubated for an additional 30 minutes at 37°C. 
The reaction was stopped by adding 300pl of CIAP stop buffer. A phenol : chloroform 
extract was then undertaken by adding an equal volume of phenol : chloroform lisoamyl 
alcohol, 25:24:1, vortexed and centrifuged at 14000 xg for 10 minutes. The upper 
aqueous phase of the extract was then precipitated with ethanol.
The formula used for calculating the picomoles of ends of linear double-stranded DNA 
is:
(pg DNA/kb size of DNA) x 3.04 = pmol of ends.
2.4.7 Ligation of DNA insert into plasmids
The amplified, purified DNA insert fragments were subcloned into the pGEM-T Easy 
vector (Figure 2.1) and then to the pSEAP vector (Figure 2.2). pGEM-T Easy vector 
provides a quick one-step cloning system for the direct insertion of a PCR product to 
easily confirm its sequence identity. The vector was supplied as a linear molecule with 3' 
T overhangs at the insertion site to greatly improve the efficiency of ligation of a PCR
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product into the plasmid by preventing recircularization of the vector and providing a 
compatible overhang for PCR products generated by the Taq polymerase enzyme. The 
pGEM-T Easy vector contains multiple restriction sites within the MCS which allow for 
the release of the insert by digestion with a single restriction enzyme.
The SEAP2-Promoter vector contains the SV40 early promoter upstream of the SEAP 
gene to ensure proper, efficient processing of the SEAP (secreted alkaline phosphatase) 
transcript in eukaryotic cells. A synthetic transcription blocker (TB), composed of 
adjacent polyadenylation transcription pause sites, located upstream of the MCS reduces 
background transcription. The vector backbone also contains an fl origin for single­
stranded DNA production, a pUC of replication, and an ampicillin resistance gene for 
propagation and selection in E. coli. The reporter gene product (SEAP) is secreted into 
the media and so the media samples can be taken and assayed by a simple 
chemiluminescent assay. The system also does not require lysis of the cell prior to 
measurement of activity and therefore allows multiple readings to be taken throughout 
the course of the experiment.
To calculate the appropriate amount of PCR product (insert) to be included in the ligation 
reaction, the following equation was used:
ng of vector X size (kb) of insert r-^_____    X msert/vector molar ratio = ng of insert
size (kb) of vector
The ligation reactions were set up as 1:1 and 1:3 molar ratios of PCR product to vector, 
where the insert size was ~0.3kb and the vector size was ~3kb 
Ligation reaction (1:1):
Vector DNA Ipl (50ng)
Insert DNA 50ng
T4 DNA ligase Ipl
Ligase 1 Ox buffer l|il
Nuclease free water to final volume 1 Op,l
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Control ligations
1- Positive controls were set up with the control insert DNA supplied with the kit which 
allowed assessment of the ligation efficiencies. Typically, approximately 100 
colonies should be observed, 10-30% of which are blue and greater than 60% should 
be white.
2- Background control was set up with 50ng pGEM-T Easy vector and no insert which 
allow determination of the number of background blue colonies resulting from non-T- 
tailed or undigested pGEM-T Easy vector alone. 10-30 blue colonies will, typically, 
be observed.
Ligations were left overnight at 4°C.
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2.5 PCR-mediated amplification of a 308bp fragment of the upstream regulatory 
region of the CYP3A4 gene
The polymerase chain reaction (PCR) is an in vitro technique which allows the 
amplification of a specific deoxyribonucleic acid (DNA) region that lies between two 
regions of known DNA sequence. PCR amplification of DNA is achieved by using 
oligonucleotide primers (also known as amplimers). The primers are extended on single­
stranded denatured DNA (template) by a DNA polymerase, in the presence of 
deoxynucleoside triphosphates (dNTPs) under suitable reaction conditions. This results in 
the synthesis of new DNA strands complementary to the template strands. Amplification, 
as the final number of copies of the target sequence, is expressed by the formula (2”-2n)x, 
where
n = number of cycles
2n = first product obtained after cycle 1 and second products obtained after cycle 2 with 
undefined length
X = number of copies of the original template
Potentially, after 20 cycles of PCR there will be 2^°-fold amplification, assuming 100% 
efficiency during each cycle. Optimal conditions for amplification are dependent on the 
nature of the particular primer and the target DNA sequence used. Alteration of primer, 
dNTPs or magnesium concentration, as well as the thermocycling protocol, may be 
required.
2.5.1 PCR from genomic DNA
lOpl PCR reactions were prepared using lOOng genomic DNA.
PCR master mix (for 15 PCR reactions)
Nuclease free water SOpl
5mM dNTPs 20[il
PCR buffer* 20pl
Primers (3A4-301A&3A4+7B) 20pl of each (25ng/pl)
Taq polymerase enzyme 3 pi
80
*PCR buffer (670mM Tris EDTA (pH 8.8), 160mM (NK^i SOa, 67.5mM MgC^ 
7% p-mercaptoethanol, 3.2pgBSA)
Control reactions were set up without template DNA to confirm that no contamination 
had occurred during the PCR reactions.
Samples were placed in the PCR machine (Perkin elmer) and the cycling conditions were 
80°C for 1 minute 
94°C for 10 seconds 
55°C for 30 seconds >. 30 cycles
72°C for 30 seconds 
72° C for 5 minutes.
When the PCR reaction cycles were complete, the lOpl reaction sample was run on 0.7% 
agarose gel to check the size of the amplified DNA then the DNA was extracted from the 
gel using either the QIAquick gel extraction or the GenElute agarose spin column 
method.
Sequences of the primers used in this study are shown in Table 2.2.
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2,5.2 Generation of restriction sites for cloning using PCR
Frequently, the ends of the insert DNA do not contain a suitable restriction enzyme site. 
This problem can be solved by using PCR to generate a site at the desired location. For 
this technique, the restriction enzyme site is designed into the 5 -end of the PCR primer 
and because certain restriction enzymes insufficiently cleave recognition sequence 
located at the end of a DNA fragment, it is advisable to include at least four additional 
bases in front of the restriction recognition site which will result in efficient cleavage. 
Primers with Acc 651 and Bgl II restriction sites were used to amplify the CYP3 A4 insert 
from the 3 A4-pGEM-T Easy vector by PCR using the same procedure described before 
(section 2.5.1) but with the use of Pfu DNA polymerase enzyme which is a proofreading 
DNA polymerase isolated from Pyrococcus furiosus which exhibits the lowest error rate 
of any thermostable DNA polymerase known to date. This feature makes the Pfu DNA 
polymerase enzyme the ideal choice for a variety of techniques requiring high-fidelity 
DNA synthesis by PCR which is important regarding isolation of the mutant fragments of 
the CYP3A4 from the pGEM-T Easy vector after sequence confirmation.
The cycling conditions were
80°C for 1 minute 
94°C for 10 seconds ^
55°C for 30 seconds >- 35 cycles
72°C for 30 seconds 
72° C for 5 minutes.
The PCR products were then purified using the Wizard™ PCR Preps Purification system 
which provides a reliable and quick method of effectively purifying double-stranded PCR 
products from contaminants, including primer-dimers and amplification primers.
To each completed PCR reaction, lOOpl direct purification buffer, was added and 
vortexed briefly to mix. 1ml of resin was added to the mix and vortexed briefly 3 times 
over one minute period. For each PCR product, one of the provided syringe barrels was 
attached to a minicolumn and inserted into the vacuum manifold.
The resin/DNA mix was pipetted into the syringe barrel and a vacuum was applied to 
draw the resin/DNA mix into the minicolumn. The vacuum was then stopped, 2ml of 
80% isopropanol added to the syringe barrel, the vacuum was re-applied and was 
continued for 30 seconds after the mix was pulled onto the minicolumn to dry the resin.
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The minicolumn was then transferred to a 1.5ml microcentrifuge tube and centrifuged for 
2 minutes at 8,000 xg to remove any residual isopropanol. The minicolumn was again 
transferred to a new 1.5ml microcentrifiige tube, 50pl TE buffer added to the middle of 
the minicolumn, left for 2 minutes and the tube centrifuged at 10,000 xg for 1 minute to 
elute the bound DNA fragment.
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2.6 Mutation detection
2.6.1 Single stranded conformational polymorphism (SSCP)
SSCP is one of the most frequently used screening methods for mutation detection (but 
not characterisation) and probably the most commonly used (Broly et al., 1995). This is 
due to the fact that in exon sized fragments of DNA the majority of mutations are 
detected in a single analysis without any special equipment, theory or reagents.
Principle (Figure 2.8)
SSCP analysis is based on the principle that the electrophoretic mobility of a molecule 
within a gel matrix is sensitive to the size, charge, and shape of the molecule. Under 
nondenaturing, or native, conditions single-stranded DNA has a folded structure that is 
imposed by intramolecular interactions dictated by its sequence. A single nucleotide 
difference between two similar sequences is sufficient to alter the folded structure of one 
relative to the other. This conformational change is detected as a mobility difference upon 
gel electrophoresis. The sensitivity of the method allows detection of most single 
nucleotide differences in a fragment composed of several hundred nucleotides.
A PCR was carried as mentioned before (section 2.5.1) using the 3A4-pGEM-T Easy 
vector as a DNA template. Ipl of [a-^^P]dATP (1 lOTBq/mmol) was added to the master 
mix for labelling the amplified fragments. After adding the loading dye (50% formamide, 
7M urea, 2mM EDTA, IxTBE and water) to the PCR products, 3.5pi of each sample was 
run on 10% acrylamide gel
10% acrylamide gel (62.5:1 Bis- acrylamide) in 500ml was prepared as follows,
5% glycerol 
10% acrylamide 
IxTBE
0.14% ammonium persulfate (APS) and 1.4% TEMED were added 
The gel was then run for 16 to 18 hours at 5-8W in IxTBE.
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2.6.2 Development of the SSCP film
The gel was removed from the glass plates, transferred to a filter paper and exposed to a 
Kodak BIOMAX film for 7-14 days at -80°C without intensifying screens. The film was 
then developed by placing in the developer solution with shaking until the black lines of 
ssDNA appeared (~5 minutes). The film was then transferred to 5% glacial acetic acid to 
stop the process of development and was then transferred to the rapid fix solution for 
permanent fixation and removal of the light sensitivity of the film. Finally the film was 
washed in water and air dried.
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Figure 2.8 Principle of the single stranded conformational 
polymorphism (SSCP) analysis
Normal Mutant
Melt
Chill
Melting and chilling the mutant and wild type samples results in the single strand 
DNA folding into specific shapes. The specific shapes of the sense and antisense 
strands of the mutant can differ from the specific shapes of the corresponding wild 
type strands. These differences in specific shape of the corresponding strands lead 
to their separation on non-denaturing gels. (Adapted from Cotton, 1997)
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2.7 Cell culture
Human HepG: (hepatoma) cells (ECACC No 85011430) were grown in 75cm  ^ flasks 
with filter lids (vented) in 5% CO2 in air at 37°C. Cells were cultured in minimum 
essential medium (MEM with Earle’s salts) supplemented with 10% (v/v) fetal calf serum 
(FCS), 2mM L-glutamine, 1% (v/v) gentamycin and 1% (v/v) non essential amino acids. 
Cells were seeded as 2-3x10"  ^ cells/cm^ using trypsin/EDTA. All cell culture media, 
phosphate buffered saline (PBS) and trypsin were pre-heated to 37°C in a water bath 
prior to use in cell culture procedures.
2.7.1 Subculture of cells
Cells were split every 4-5 days (85% confluent) depending on their rate of growth. The 
medium was removed by aspiration, cells washed with 5ml PBS to remove the dead cells 
and any remaining medium then the PBS was removed by aspiration. 2ml Ix trypsin- 
EDTA solution was added to detach the cells from the flask. The flask was incubated at 
37°C for 5 minutes until almost all the cells were detached (this was helped by gently 
tapping the side of the flask), and 10ml MEM was added to inactivate the trypsin. The 
required amount of cell suspension (counted using a haemocytometer) was then taken and 
transferred to a new flask and new medium was added to a final volume of 20ml.
2.7.2 Counting of cells
For routine counting, a flask of confluent cells was trypsinised and then resuspended in 
10ml of medium. The number of cells per ml was determined using a haemocytometer by 
placing 2 drops of trypsinised cells under a coverslip on the haemocytometer. The 
number of cells in the center grid was then counted manually and the number of cells 
present per ml of cell suspension was calculated (the number of cells in the grid area 
multiplied by 10, 000 gives the number of cells/ml). HepGi cells frequently grow in 
clumps, making both accurate counting and seeding difficult. In the cases where the 
trypsinised cells appear to be clumping badly the clumps were broken up by gently 
passing the cells through a sterile 0.8mm-bore needle with a syringe. Excessive force 
during this stage resulted in poor cell viability, so was avoided when possible.
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2.7.3 Storage of cells in liquid nitrogen
A flask of actively growing cells was trypsinised and resuspended in 20ml MEM. The 
cells were pelleted by centrifugation at 1,000 xg for 5 minutes and then resuspended in 
91% FCS and 9% DMSO to a final concentration of 4x10^ cells/ml. This suspension was 
dispensed into cryovials in 1ml aliquots and frozen at -80°C overnight before placing in 
liquid nitrogen for storage.
2.7.4 Recovery of cells from liquid nitrogen
A cryovial was incubated in the waterbath at 37°C for 1 minute, wiped with 70% ethanol, 
and the contents poured into a sterile cetriflige tube (20ml) containing 10ml pre-warmed 
MEM. The cells were pelleted by centrifugation at 1,000 xg for 5 minutes after which the 
pellet was resuspended in 20ml MEM and transferred to a 75 cm  ^ vented cell culture 
flask.
2.7.5 Charcoal treatment of fetal calf serum
Fetal calf serum (FCS) may contain steroid and hormonal contamination (Jackson et al., 
1997 & Nakama et al., 1995) which could affect the assessment of induction of the 
CYP3A4 gene. To remove steroid and hormonal contaminants, FCS was pre-treated with 
dextran coated charcoal (DCC) (Fenske, 1991).
500mg activated charcoal and 50mg dextran T70 were added to 500ml FCS and the 
mixture stirred for 30 minutes. The charcoal was pelleted by centrifugation at 1,500 xg 
for 15 minutes after which the supernatant was passed through 0.45pm filter to remove 
any remaining solids and then was filter sterilised under vacuum by passing through a 
0.22p filter.
2.7.6 Optimised calcium phosphate transfection
DNA may be introduced into cultured mammalian cells by a number of different 
methods. One of the most widely used methods is the calcium phosphate precipitation 
method as it is cheap, can achieve an acceptable transfection efficiency and may be 
applied to many different cell lines (Graham and Van Der Eb, 1973).
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The calcium phosphate precipitation method (Jordan et al., 1996) was optimised by Ogg, 
1998. In this method the uptake of DNA by cells in the culture is enhanced by presenting 
the DNA as a calcium phosphate-plasmid co-precipitate.
The transfection protocol took place over a five day period as follows:
Day 1 Seeding ofHepG: cells
Day 2 Change the media and transfect the cells
Day 3 Change the media and assay the SPAP activity and dose the cells
Day 4 Cells incubated
Day 5 Assay the media for SPAP activity
Day 1 => Seeding of HepG2 cells. Cells between passage number 7 and 12 only were 
used to ensure a constant phenotype. The cells were prepared and counted as mentioned 
before (sections 2.7.1 & 2.7.2) and were diluted to a concentration of 6x10^ cell/ml in 
MEM. Cells were seeded in 96-well plates using 40pl of cell suspension plus 80pl of pre- 
warmed MEM per well. Plates were placed in a humidified container in the cell culture 
incubator at 37°C in 5% CO2 for 24 hours.
Day 2 => One hour prior to transfection, the medium was removed and replaced by fresh 
medium (120pl/well) and plates returned to the incubator. During this time, the 
transfection mix was prepared on ice as temperature is a critical parameter in precipitate 
formation. 2ml of precipitate was standardly prepared, this may be adjusted up and down 
depending on the experimental requirements.
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Concentrations for the precipitation reaction
2M CaCl2 lOOpl
DNA (dissolved in TE buffer) 25pg
O.lxTE To 1ml
To initiate precipitation reaction
2xHBS 1ml
To terminate precipitation reaction
Cell culture medium 28ml
To initiate the precipitation reaction 1ml 2x HBS was added and mixed by pipetting. 
Precipitate was formed during a 1 minute incubation on ice, and this was terminated by 
adding 28ml of pre-warmed cell culture medium. The reaction mixture was quickly 
mixed by inversion of the tube and 80|il was added and made up to 120pl with cell 
culture media. Plates were placed in a humidified container and the returned to the cell 
culture incubator.
Day 3 => Dosing the cells. lOOOx stocks of xenobiotics or steroids used were prepared in 
the appropriate solvents (Table 2.5). Drug solutions and solvent controls were 
added to the cell culture medium to give a final concentration of 0.1% solvent. All 
solutions were freshly prepared in the day of dosing. The removed transfection 
media was used for the 24 hours post-transfection alkaline phosphatase assay
Day 4 => Cells incubated.
Day 5 => Media were taken for reporter gene assay (72 hours post-transfection) by 
Chemiluminescent Alkaline Phosphatase Assay (Aurora Kit, ICN Pharmaceuticals).
A summary of the transfection protocol is shown in Figure 2.9
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Figure 2.9 Transient transfection protocol
HepG2
cells
Seed
Transient
Transfection
✓
24 hours post-transfection
■ SPAP secreted into culture media
■ Samples transferred to 96-well 
optiplate
■ Alkaline phosphatase activity 
assayed with chemiluminescent 
substrate and plate reader
Inducer
PCMV-cSPAP 
reporter 
plasmid
3A4RE
CMV
SPAP
hGR,
hPXR
72 hours post-transfection
■ Re-assay induced SPAP activity
■ Normalised for transfection 
efficiency against 24 hours 
activity to obtain the specific 
chemical effect (SCE).
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2.7.7 Chemiluminescent detection of SPAP protein activity
Reporter genes code for proteins that may easily be distinguished from the normal protein 
expressed by the host cell. In the case of secreted placental alkaline phosphatase the 
reporter protein is distinguishable by measurement of its catalytic activity, which is 
separable from similar host cell catalytic activities by the use of carefully defined 
reaction conditions. In my studies, the alkaline phosphatase reporter assay was used as a 
measure of the level of transcriptional activation of the CYP3A4 gene by different 
inducers.
Sufficient amount of dilution, assay (mixture of differential alkaline phosphatase 
inhibitors) and reaction (luminescence enhancer) buffers were allowed to equilibrate to 
room temperature. 25 pi of the medium was used per well of a 96-well optiplate 
(polystyrene microplates). SOpl of Ix dilution was added to each well and the plates 
incubated at 65°C for an hour to destroy endogenous alkaline phosphatase activity. Plates 
were then removed, incubated on ice for 2 minutes, then left to reach room temperature 
(about 15 minutes). 60pl of assay buffer was added and the samples were incubated for 5 
minutes at room temperature. 60pl of the reaction buffer was then added and left for 10 
minutes before the plates were analysed for chemiluminesence using the Lumicount plate 
reader. Each plate was read every 10 minutes until the alkaline phospatase activity started 
to drop. A positive control was used which is a known amount of alkaline phosphatase 
calculated to produce slightly brighter light emission than the brightest sample. The ideal 
gain and photomultiplier settings were determined on the first plate only and were then 
fixed at those values so that all plates in the series were assayed under identical 
conditions.
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Table 2.3 Concentrations and solvents used for xenobiotics and steroids
Compound Solvent Concentrations examined 
(pM)
Aldosterone Acetone 0 .1 ,1, 10, 100
p-N^hthoflavone DMSO 1,10, 30, 50
Carbamazepine Ethanol 1, 10, 30, 50
Cholesterol Chloroform 1, 10, 100
Ciprofibrate Ethanol 1,10, 30, 50
Clotrimazole Ethanol 1,10, 30, 50
Corticosterone Chloroform 1,10,100
Cortisone Acetone 1,10,100
Cyproterone Acetate Ethanol 1,10, 30, 50
Dexamethasone DMSO 0.1, 0.5 , 1, 5, 10, 30, 50, 100
Estradiol DMSO 1, 10, 100
Fexofenadine Methanol 1,10, 30, 50
Hydrocortisone Methanol .05, .1, .5, 1, 5,10, 25, 50
Ketoconazole Ethanol 1,10, 30, 50
Lovastatin Ethanol 0.05, 0.1, 0.5, 1, 5, 10, 50, 100
Metyr^one DMSO 1, 10, 30, 50
Phenobaibitone DMSO 1, 10, 30, 50
Phenytoin DMSO 1,10, 30, 50
Pioglitazone Methanol 1, 10, 30, 50
Pravastatin Ethanol 1, 10, 30, 50
Pregnenolone 16a-caibonitrile DMSO 1, 10, 30, 50
Progesterone Ethanol 1,10, 100
Rifairq)icm DMSO 0.1, 0.5 ,1 , 5,10, 30, 50,100
RU-486 Ethanol .01, .05, .1, .5, 1
Simvastatin Ethanol 1, 10, 30, 50
Spironolactone Ethanol 1, 10, 30, 50
Sulfinpyrazone DMSO 1, 10, 30, 50
Testosterone Ethanol 0.1, 1, 10,100
Troglitazone Methanol 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20
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2.7.8 Data analysis of reporter gene assay
In vitro transactivation assays have been used for many years in the investigation of how 
chemicals cause changes in the expression of specific genes. The most common type of 
experiments is the use of transient transfection of reporter gene construct into a suitable 
cell line. This is then followed by dosing with test compound, measurement of reporter 
gene production, and comparison to control cells. At each step of this protocol, biological 
and experimental variation may be present and this will generate poorly reproducible 
results, and potentially erroneous interpretations, unless this variation is taken into 
account in the data analysis step (Plant et al., 2000). Examples of such variation include 
initial transfection efficiency, activation by factors endogenous to the host cell line, and 
chemical-specific effects such as proliferative or cytotoxic effects.
Thus, various controls were included in the transient transfection experiment:
1- For alkaline phosphatase assays, some medium from the untransfected cells was 
carried through the heat deactivation and assay procedures to make sure that heat 
deactivation is adequate (values should not be different to the reagent blank).
2- Cells that were transfected but not chemically dosed to highlight any difference in the 
basal expression between p3A4 and pCMV.
3- A solvent control was included to ensure that the solvents have no effects on the 
regulatory region.
4- Control plasmid (pCMV) was included to allow removal of non-specific effects of 
chemical and/or cell line on the reporter gene assay that is not directly attributed to 
the DNA fragment under study.
All measured reporter gene activities were first converted to logarithmic values, hereafter 
denoted by x. The advantage of this transformation is two fold. First, the logarithm of a 
positive measurement is almost always closer to being normally distributed than the 
untransformed measurement, thus providing better justification for standard statistical 
analysis. Second, ratios are of primary interest in the present context, and the logarithm 
of a ratio of two quantities equals the difference of their logarithms, and standard 
statistical methods based on t-tests involve differences.
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SPAP activity was measured at day 3 and day 5 of the transfection protocol, pre- and 
post-dosing, from the same well. SPAP activity was therefore represented as a change 
from the day 3 reading to the day 5 reading for each determination (Equation 1)
Relative change in SPAP activity = (xs - xg), (1)
Where xg and xg are paired SPAP activities for each determination.
Replicates of each experimental point (usually 8 in a 96-well plate) result in multiple 
values for the change in SPAP activity from day 3 to day 5. These can be combined to 
find a mean change ((xs - and the variance of that change (VARpiasmid)
The change in gene expression due to chemical action on the region of DNA under study 
is derived by substracting the mean change for the two plasmids (Equation 2)
Chemical effect on DNA insert = [(xg - xg)pgA4 - (xs - xg)pCMv] treated (2)
The change in gene expression due to the region of DNA under study, but not by the 
action of the chemical, was calculated by substraction of the plasmid values in the 
absence of xenobiotics (Equation 3). This controls for action of chemicals endogenous to 
the host cell on the reporter gene construct.
Non-chemical effect on DNA insert = [(xs - xg)pgA4 - (xs - xg)pCMv] vehicle (3)
The values from Eqs (2) and (3) may be treated in two ways to gain separate units of 
information. By dividing Eq (2) by Eq (3), the nonchemical effects were removed, 
resulting in a specific chemical effect (SCE) measurement. Since variance is equal to the 
square of the standard deviation, it is also possible to derive a compound standard 
deviation based upon the sum of the variances of each set of readings (Equations 4 and 5)
Specific chemical effect = Eq. (2)/ Eq (3) (4)
Standard deviation =
[ ( Y A R t r e a l e d p 3 A 4 ) _ |_ ( Y ^ ^ v e h i c l e p 3 A 4 ) _ ^ ( Y A R t r e a t e d p C M V ) _ |_ ( Y ^ j ^ v e h i c l e p C M V ) ]  1 /2
Alternatively, the statistical significance of the difference may be determined by inserting 
the specific chemical effect (Eq. 2), the nonchemical effect (Eq. 3), and the standard 
deviation (Eq. 5) into the student /-test formula (Equation 6).
/-value = (Eq. 2 - Eq 3/Eq 5) (6)
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Computer modelling of the analysis system presented herein has shown that relatively 
large changes in SPAP activity, giving SCE values of up to 44, may not be statistically 
significant, due to the compound variation present within the system.
However, this statistical model provides a much more comprehensive analysis of sources 
of variation and produces a /-value that corresponds to the significance of solely specific 
chemical effect, and not nonspecific effects.
Use of this approach has allowed more confident interpretation of such assays, and thus 
increase their usefulness as biological tools (Plant et al., 2000).
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CHAPTER 3 - STEROID INDUCTION OF CYP3A4-DEPENDENT 
REPORTER GENE EXPRESSION
3.1 Introduction
CYP3A4 gene is selectively expressed in the liver and intestine and its expression in both 
of these tissues is markedly induced in response to treatment tvith a variety of compounds 
including steroids (Kliewer et al., 1999). In addition, CYP3A4 is responsible for the 6p- 
hydroxylation of several endogenous steroids (Waxman et al., 1991) and participates, 
with a minor contribution from CYP1A2, in the 2- and 4-hydroxylation of estradiol 
(Aoyamae/a/., 1990).
Studies of closely related rat hepatic P450s have demonstrated that hormonal factors are 
the predominant determinants of constitutive expression of these enzymes (Liddle et ah, 
1998). Moreover, there is evidence suggesting that differences in steroid hormone levels 
may be responsible for some of the variability in CYP3A4 activity (Tsunoda et al., 1998). 
Low concentrations of either estrogen or progesterone may predispose an individual to 
decreased CYP3A4 activity (Tsunoda et al., 1998).
In the current study, nine steroids (dexamethasone, cholesterol, progesterone, 
hydrocortisone, cortisone, corticosterone, testosterone, estradiol and aldosterone) were 
examined regarding their effects on the induction of CYP3A4-dependent reporter gene 
expression. The effects of the human glucocorticoid receptor (hGR), and/or IpM RU-486 
(also known as mifepristone), and/or the human pregnane X receptor (hPXR) on the 
steroid induction of CYP3A4 were also examined. Concentrations of steroids examined 
are shown in Table 2.5.
Transient transfection experiments were carried out as described m the Materials and 
Methods chapter (section 2.7.6). pSPAP-CMV (Figure 2.3) and pSG5 (Figure 2.5) 
vectors were used as control plasmids to make sure that the effect obtained is specific to 
the CYP3A4 regulatory region. Secretory placental alkaline phosphatase activity was 
measured using the chemiluminescence SPAP assay (section 2.7.7) and data were 
analysed as described iu the Material and Methods chapter (section 2.7.8).
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In all transfection experiments the following abbreviations were used:
3A4: p3A4-CMV-cSPAP reporter gene construct
3A4+hGR: p3 A4-CMV-cSPAP + pSG5-hGR expression vector
3A4+RU-486: p3A4-CMV-cSPAP + RU-486
3A4+hGR+RU-486: p3A4-CMV-cSPAP + pSG5-hGR + RU-486
3 A4+hGR+hPXR : p3 A4-CMV-cSPAP + pSG5-hGR + pSG5-hPXR expression vector
Results obtained are presented as follows:
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3.2 Effect of dexamethasone on CYP3A4-dependent reporter gene expression
Dexamethasone (Figure 3.1), a synthetic glucocorticoid, is widely used as an anti­
inflammatory and immunosuppressant agent, particularly in cases where water retention 
is undesirable such as cerebral oedema (Rang et al., 1999). It is also the drug of choice 
for suppression of adrenocorticotrophic hormone (ACTH) production (Rang et ah, 1999). 
Dexamethasone is an inducer of the CYP3A subfamily in several species (Liddle et ah, 
1998) and acts at the transcriptional level (Barwich et al., 1996) as well as by mRNA 
stabilisation (Jang and Benet, 1997).
Figure 3.1 Chemical structure of dexamethasone
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A full dose-response curve for dexamethasone induction of the CYP3A4 reporter gene 
construct was undertaken using 0.1, 0.5, 1, 5, 10, 30, 50 and lOOjjM concentrations both 
in the absence and presence of co-transfected hGR and hPXR.
As shown in Figure 3.2, dexamethasone was observed to cause a concentration- 
dependent increase in CYP3A4-dependent reporter gene expression which was enhanced 
by co-transfection with hGR and hPXR. In the basal system (no co-transfected receptors), 
the minimum concentration at which significant induction was observed was 50pM 
(P<0.05), although significant inductions have been observed in my studies with 
concentrations as low as 30pM (data not shown).
Co-transfection with hGR and hPXR enhanced CYP3A4 induction by dexamethasone 
with the minimum concentration at which significant induction was observed was IpM 
(P<0.05) and the maximum induction was observed at a lOOpM concentration (P<0.01), 
over the concentration range examined.
A degree of cytotoxicity was observed at the lOOpM concentration of dexamethasone, 
based on lower total reporter gene expression from both the pCMV and the p3 A4 reporter 
constructs was observed at this concentration.
Table 3.1 shows the Imax, EC50 and intrinsic activation of dexamethasone.
As shown in Figure 3.3, dexamethasone (50|jM) caused a significant induction of 
CYP3A4 with a specific chemical effect of 14 which increased to 23 on co-transfection 
with hGR (P<0.05 and P<0.01, respectively). In another transfection experiment, the 
specific chemical effect for dexamethasone induction of CYP3A4 reporter gene 
expression was 2.2, 3.9, 3.2 (P<0.05), and 5.2 (P<0.01) for the basal, hGR co­
transfection, hPXR co-transfection and hGR and hPXR combined co-transfection, 
respectively.
Dexamethasone has previously been used in our laboratory as a classical inducer of 
CYP3A4 (Williams, 1997 & Ogg, 1998) which induced CYP3A4-dependent reporter 
gene expression in a concentration-dependent fashion with a 50pM concentration
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producing the maximum fold induction of all the concentrations examined. Therefore, 
this concentration was used as a positive control for the responsiveness of the CYP3 A4 to 
the steroids examined.
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Figure 3.2 Influence of hGR and hPXR combined co-transfection on 
dexamethasone-dependent CYP3A4 reporter gene expression
75n ■ Basai
A +hGR/+hPXR
50-
25-
0.10 1.00
Dexamethasone (|iM)
10.00 100.00
Data shown as SCE (specific chemical effect), where n = 8  replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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Table 3.1 Imax» ECso and intrinsic activation values for dexamethasone
Imax ECso Intrinsic activation
(^M) (Imax /  E C so )
Basal +bGR/bPXR Basal +bGR/bPXR Basal +bGR/bPXR
6.3+0.8 47.4±3.2 2.7±1.7 1.9+0.7 2.4 24.8
The original data for the dose-response curve was driven from 8  replicates carried 
out in one experiment. The dose-response curve was reiteratively fitted to this 
data. Accordingly, the errors reported above are a combination of 
experimental/analytical errors, in addition to the curve-fitting procedure.
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Figure 3.3 Specific chemical effect of dexamethasone on CYP3A4 reporter gene
expression and the influence of hGR co-transfection
20 .
UJ
O
(0
10 -
□ 3 A4 
■ 3A4+GR
Dexamethasone (50pM)
Data shown as SCE (specific chemical effect), where n = 8  
replicate data points derived from one experiment. Statistical 
significance is indicated by stars, where * = P<0.05, ** = P<0.01, 
both relevant to the solvent control
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3.3 Effect of cholesterol on CYP3A4-dependent reporter gene expression
Cholesterol can be obtained from the diet or it can be synthesized de novo with the liver 
being the major site of synthesis, although appreciable amounts are also formed by the 
intestine (Rang et al., 1999). An adult on a low cholesterol diet typically synthesizes 
about SOOmg/day (Stryer, 1995). The rate of cholesterol formation is highly responsive to 
the amount of cholesterol absorbed from dietary sources via a negative feedback 
mechanism.
Cholesterol is the precursor for the synthesis of glucocorticoids (Figure 1.3) (Rang et al.,
1999). The first step, the conversion of cholesterol to pregnenolone, is the rate-limiting 
step and is regulated by ACTH (Gilman, 1996). Some of the reactions in the synthesis 
can be inhibited by drugs, for example, metyrapone (prevents the p-hydroxylation at Cl 1 
and thus the formation of hydrocortisone and corticosterone), aminoglutethimide and 
ketoconazole (Rang et al., 1999).
As shown in Figure 3.4, cholesterol caused a significant induction of CYP3A4 reporter 
gene expression at 10|oM concentration with a specific chemical effect of 9.5 (P<0.05). 
Cholesterol (IpM) caused a significant induction of the CYP3A4 gene when hGR was 
co-transfected, with a specific chemical effect of 9.7 (P<0.05) which increased to 13 
(P<0.05) with the lOpM concentration. There was some degree of cytotoxicity observed 
at lOOjoM concentration (slightly lower total reporter gene expression from both pCMV 
and p3A4 reporter constructs).
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Figure 3.4 Specific chemical effect of cholesterol on CYP3A4 reporter gene 
expression and the influence of hGR co-transfection
12
Ü 8 
CO
4 .
□  3 A4 
■ 3A4+GR
1 10 
Cholesterol (pM)
100
Data shown as SCE (specific chemical effect), where n = 8  replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.4 Effect of progesterone on CYP3A4-dependent reporter gene expression
Progesterone is synthesized from pregnenolone (which is derived from cholesterol) in a 
two step reaction; the 3-OH group of pregnenolone is oxidised to a 3-keto group and the 
double bond is isomerised to a double bond (Stryer, 1995). The plasma level of 
progesterone ranges between Inmol/L in the follicular phase to 30nmol/L in the luteal 
phase (in female) (Williams and Marks, 1996).
Progestins are widely prescribed both orally and parentally as hormone replacement 
therapy, for contraception, and as hormonal therapy for certain cancers (Tsunoda et ah, 
1998). Few studies have examined the effects of progestins on drug metabolism. 
Progesterone has been shown to activate the in vitro metabolism of carbamazepine (Kerr 
etal., 1994) and estradiol (Kerlan etal., 1992), both of which are CYP3A4 substrates.
As shown in Figure 3.5, in the absence of hGR, progesterone caused a concentration- 
dependent increase in CYP3 A4 reporter gene expression with specific chemical effects of 
25, 30.8 and 42.7 for the 1, 10 and lOOpM concentrations, respectively which was 
significant only at 10 and lOOjuM (P<0.05 and 0.01, respectively). With hGR co­
transfection, the three doses of progesterone examined caused significant induction of the 
CYP3A4 gene with specific chemical effects of 121, 107 and 185.7 for the 1, 10 and 
lOOpM concentration, respectively (P<0.05, 0.05 and 0.01, respectively).
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Figure 3.5 Specific chemical effect of progesterone on CYP3A4 reporter gene
expression and the influence of hGR co-transfection
200 n
150
iUo  100 - 
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□ 3 A4 
■ 3A4+GR
10
Progesterone (pM)
100
Data shown as SCE (specific chemical effect), where n = 8  replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.5 Effect of hydrocortisone on CYP3A4-dependent reporter gene expression
Hydrocortisone (cortisol) is a major glucocorticoid synthesized from progesterone by 
hydroxylation at C-17, C-21 and C-IL C-17 must be hydroxylated before C-21, whereas 
hydroxylation of C-11 may occur at any stage (Stryer, 1995). The enzymes catalyzing 
these hydroxylations are highly specific, as shown by some inherited disorders of steroid 
metabolism (White, 1994). The normal serum level of hydrocortisone ranges from 200 to 
750nmol/L (Williams and Marks, 1996).
In addition to its metabolic effects (carbohydrate and protein metabolism), 
hydrocortisone has anti-inflammatory and immunosuppressive activity, and it is for these 
actions that it is most commonly used therapeutically (Rang et a/., 1999). Hydrocortisone 
has a plasma half-life of 90 minutes, though its main biological effects occur only after 2- 
8  hours (Rang e ta l, 1999).
A full dose-response curve for hydrocortisone (0.05, 0.1, 0.5, 1, 5, 10, 25 and 50pM 
concentrations) was undertaken for the induction of CYP3A4, both in the absence and 
presence of hGR and /or hPXR.
As shown in Figure 3.6, in the absence of any added receptors, hydrocortisone caused a 
concentration-dependent increase in the CYP3A4-dependent reporter gene expression 
which showed the same pattern with single co-transfection with either the GR or PXR, 
being significant at lOpM concentration (P<0.05). Simultaneous co-transfection with 
both receptors brought up the level of significance to IpM concentration (P<0.05).
Table 3.2 shows the Imax, EC50 and intrinsic activation values for hydrocortisone.
As shown in Figure 3.7, hydrocortisone (lOpM) caused a significant induction of 
CYP3A4 reporter gene expression when GR was co-transfected with a specific chemical 
effect of 55 (P<0.01).
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Figure 3.6 Influence of hGR and hPXR combined co-transfection on 
hydrocortisone-dependent CYP3A4 reporter gene expression
30
2 0
1 0
0 -
0.
■ Basd ▲ +hGR 
•  +hPXR * +hGR/hPXR
01 10.00 100.00
Hydrocortisone (p.M)
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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Figure 3.7 Specific chemical effect of hydrocortisone on CYP3A4 reporter gene
expression and the influence of hGR co-transfection
50 .
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O 30  ^
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■ 3A4+GR
1 10
Hydrocortisone (pM)
100
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.6 Effect of cortisone on CYP3A4-dependent reporter gene expression
Cortisone is a receptor-inactive 11 keto derivative of cortisol produced by the enzyme 
lip-hydroxysteroid dehydrogenase (Gilman, 1996). Cortisone is considered as an inert 
metabolite of hydrocortisone (Fujitaka et ah, 1997) and it is not used as an anti­
inflammatory because of its mineralocorticoid effects (Rang et ah, 1999). The blood level 
of cortisone increases from l-5|ig/dL in the normal adult person to 1-lOpg/dL in the 
pregnant women at term (Tietz, 1987)
As shown in Figure 3.8, both in the absence and presence of GR, cortisone did not induce 
CYP3 A4 gene expression at any of the concentrations used.
114
Figure 3.8 Specific chemical effect of cortisone on CYF3A4 reporter gene expression
and the influence of hGR co-transfection
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Data shown as SCE (specific chemical effect), where n = 8 replicate 
data points derived from one experiment. Data were not statistically 
significant in relation to the solvent control
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3.7 Effect of corticosterone on CYP3A4-dependent reporter gene expression
Corticosterone, one of the main glucocorticoids, is derived from progesterone which is 
initially converted to deoxycorticosterone, a reaction catalyzed by the cytochrome P4502i 
(CYP21), and is then oxidised by the cytochrome P450aido (CYPaldo) to yield 
corticosterone (Gilman, 1996). Normal serum level of corticosterone is 2.5-60 nmol/L 
(Williams and Marks, 1996).
As shown in Figure 3.9, in the absence of hGR, corticosterone caused a significant 
induction of CYP3A4-dependent reporter gene expression only with the lOpM 
concentration with a specific chemical effect of 10 (P<0.05) which was increased to 15.7 
on co-transfection with hGR (P<0.01). Some degree of cytotoxicity occurred with the 
lOOpM concentration.
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Figure 3.9 Specific chemical effect of corticosterone on CYP3A4 reporter gene 
expression and the influence of hGR co-transfection
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.8 Effect of testosterone on CYP3A4-dependent reporter gene expression
The synthesis of androgens starts with the hydroxylation of progesterone at C-17. The 
side chain consisting of C-20 and C-21 is then cleaved to yield androstendione, an 
androgen. Testosterone, the main natural androgen, is formed by reduction of the 17-keto 
group of androstendione (Stryer, 1995). All androgens contain 19 C atoms. The plasma 
level of testosterone is 1.5nmol/L (in male) (Williams and Marks, 1996).
Testosterone is converted to dihydrotestosterone in most target cells by a 5a-reductase. 
Both testosterone and dihydrotestosterone modify gene transcription by the same 
mechanisms as other steroids (Rang et ah, 1999).
Although a clear consensus sequence has not been defined for the androgen receptor, a 
glucocorticoid response element (GRE) can mediate induction of transcription by 
androgens (Cato et al., 1987 & Ham et al., 1988). This sequence was later identified as to 
be comprised of two imperfect 6-bp indirect repeats 5'-GGA/TACANNNTGTTCT-3' 
which was almost identical to the consensus GRE sequence, 5 -GGTACANNNTGTTCT- 
3' (Roche et al., 1992).
As shown in Figure 3.10, testosterone produced significant induction of the CYP3A4 
gene with specific chemical effects of 32.8, 35.7 and 39 for the 0.1, 1, and lOpM 
concentrations, respectively (P<0.05) with the lOOpM causing apparent cytotoxicity. The 
presence of hGR increased the specific chemical effects to 145.6, 158 and 164 for the 0.1, 
1, and lOpM concentrations, respectively (P<0.01) and cytotoxicity was observed with 
the lOOpM concentration.
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Figure 3.10 Specific chemical effect of testosterone on CYP3A4 reporter gene
expression and the influence of hGR co-transfection
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.9 Effect of estradiol on CYP3A4-dependent reporter gene expression
Estrogens are synthesized from androgens (Figure 1.3) by the loss of the C-19 angular 
methyl group and the formation of an aromatic A ring. This reaction requires NADPH 
and O2. Endogenous and exogenous estrogens undergo oxidative metabohsm by hepatic 
microsomal cytochrome P450 (Martucci and Fishman, 1993). Aromatic hydroxylation at 
either the C2 or C4 positions is a major route of estrogen metabolism in humans and 
other mammals, although there is less 4-hydroxylation than 2-hydroxylation (Ohe et al.,
2000). Estrogen 2- or 4-hydroxylion is catalyzed primarily by the CYP3A family with 
some contribution by the CYPIA family (Ohe et al., 2000).
Estradiol (17p~estadiol) is an estrogen formed from testosterone (Stryer, 1995). Its 
plasma level varies during different times of the menstrual cycle being 0.2nmol/L in the 
early follicular phase, 1.2nmol/L in the late follicular phase and 0.6nmol/L in the mid 
luteal phase (Williams and Marks, 1996). The carcinogenicity of estrogens is known to 
be related to their metabolism to reactive catechols as well as to their action as agonists at 
the estrogen receptor (ligand-activated transcription factor) (Yager and Liehr, 1996). 
CYP3A4 which catalyzes the aromatic hydroxylation of estrogens does not catalyze 
quinol formation (responsible for carcinogenicity) from estradiol (Ohe et ah, 2000).
As shown in Figure 3.11, estradiol (lOpM) produced a significant induction of CYP3A4 
gene with a specific chemical effect of 15.8 (P<0.05). On the other hand, the three 
concentrations of estradiol examined caused significant induction of CYP3 A4 when hGR 
was co-transfected with specific chemical effect of 13, 16.8 and 13 for the 1, 10 and 
lOOjjM concentrations (P<0.05, 0.01 and 0.05, respectively).
120
Figure 3.11 Specific chemical effect of estradiol on CYP3A4 reporter gene 
expression and the influence of hGR co-transfection
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.10 Effect of aldosterone on CYP3A4-dependent reporter gene expression
The major mineralocorticoid hormone aldosterone is secreted from the zona glomerulosa 
of the adrenal cortex and is synthesized from cholesterol (Figure 1.3) via a series of 
hydroxylations and oxidations (Boon et al., 1997). The enzymes involved in these 
reactions are mostly members of the cytochrome P450 superfamily. The initial step in the 
synthesis of aldosterone is the hydroxylation of progesterone at C-21. The resulting 
deoxycorticosterone is hydroxylated at C-11. The oxidation of the C-18 angular methyl 
group to an aldehyde then yields aldosterone (Stryer, 1995).
Normal serum levels of aldosterone are 200-1000pmol/L (ambulant; standing) and 30- 
400pmol/L (supine; recumbent) (Williams and Marks, 1996). The interaction of renin, 
angiotensin and aldosterone is important in the regulation of extracellular fluid volume, 
blood pressure and the balance of sodium and potassium. A change in one of these 
variables leads to changes in the others (Tietz, 1987). Like other steroids, aldosterone 
binds to specific intracellular receptors. Unlike the glucocorticoid receptors which occur 
in most tissues, aldosterone receptors occur in only a few target tissues such as the kidney 
and in the epithelia of the colon and bladder (Rang et al., 1999).
As shown in Figure 3.12, in the absence of hGR, only the 10 and lOOpM concentrations 
of aldosterone caused significant induction of CYP3A4 gene with specific chemical 
effects of 12 and 8.6, respectively (P<0.05), whereas 1, 10 and lOOpM concentrations 
caused significant induction of CYP3A4 gene in the presence of hGR with specific 
chemical effects of 20.5, 31 and 23.5, respectively (P<0.05, 0.01 and 0.05).
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Figure 3.12 Specific chemical effect of aldosterone on CYP3A4 reporter gene
expression and the influence of hGR co-transfection
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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3.11 Effect of mifepristone (RU-486) on CYP3A4-dependent reporter gene
expression
Mifepristone (RU-486) (Figure 3.13) is a synthetic potent progesterone antagonist that 
also exhibits some antiglucocorticoid activity (Wingard et ah, 1991). It is used clinically 
as an antiprogestin agent for medical abortion in the first trimester of pregnancy (Spitz 
and Bardin, 1993). It is also used in the treatment of breast cancer, prostate cancer, 
meningioma, uterine leiomyoma and the treatment of Cushing's syndrome (Spitz and 
Bardin, 1993). RU-486 binds to the progesterone receptor, preventing binding by 
endogenous progesterone. It also binds weakly to the androgen receptor and tightly to the 
GR (with a higher affinity than dexamethasone) (Wingard et ah, 1991).
RU-486 has been shown to be metabolized to several metabolites by cytochrome P450 
(Chasserot-Golaz et ah, 1990). Recently, CYP3A4 was identified as the principal enzyme 
catalyzing the N-demethylation of the llp-dimethylaminophenyl group and the 
hydroxylation of the 17a-propynyl group, the major metabolic pathways in human liver 
microsomes (Jang et ah, 1996). The hydroxylation of the 17a-propynyl group catalyzed 
by CYP3A4 suggests that the carbon-carbon triple bond may be positioned at the active 
site of the enzyme (He et ah, 1999).
As shown in Figures 3.14 and 3.15, four concentrations of RU-486 (0.01, 0.05, 0.1 and 
0.5pM) were examined regarding the induction of CYP3A4 reporter gene expression 
both in the absence and presence of dexamethasone (50pM). RU-486 alone caused 
significant induction of CYP3A4 gene at 0.5pM concentration with a specific chemical 
effect of 16.8 (P<0.05).
Addition of dexamethasone 50|iM with RU-486 caused significant induction of CYP3 A4 
gene at all the concentrations examined with specific chemical effects of 17.5, 19.9, 20 
and 23.9 for the 0.01, 0.05, 0.1 and 0.5pM concentrations, respectively (P<0.05 and 
0 .01).
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Figure 3.13 Chemical structure of mifepristone (RU-486)
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Figure 3.14 Specific chemical effect of RU-486 on CYP3A4 reporter gene expression 
in the absence and presence of SOpM dexamethasone
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated 
by stars, where * = P<0.05, ** = P<0.01, relevant to the solvent control
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The effect of RU-486 (IpM) both alone and with hGR co-transfection on the steroid 
induction of CYP3A4 gene was also examined.
No induction of CYP3A4 reporter gene expression was observed on adding both RU-486 
and hGR together with all the steroids examined except with testosterone 1, 10, and 
lOOpM concentration (Table 3.3).
Addition of RU-486 with dexamethasone (50pM) produced a significant induction of 
CYP3A4 reporter gene expression with a specific chemical effect of 21 (P<0.05) (Table 
3.3). By contrast, addition of RU-486 with cholesterol did not produce significant 
induction of CYP3A4 reporter gene expression at any of the concentrations examined 
(Table 3.3).
Both 1 and lOpM concentration of progesterone, testosterone, and estradiol produced 
significant induction of CYP3A4 reporta" gene expression (P<0.05) when examined in 
the presence of RU-486 (Table 3.3).
Only the lOpM concentration of hydrocortisone, cortisone, and corticosterone produced 
significant induction of CYP3A4 reporter gene expression (P<0.05) when RU-486 was 
added (Table 3.3).
Addition of RU-486 with aldosterone produced significant induction of CYP3A4 reporter 
gene expression at 1, 10 (P<0.05), and lOOpM concentration (P<0.01) (Table 3.3).
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Table 3.3 Effect of RU-486 both alone and with hGR co-transfection on the steroid
induction of CYP3A4-dependent reporter gene expression
Steroid (pM)
SCE & Stat Sig
Steroid (pM)
SCE & Stat Sig
+RU-
486
+RU-486
/hGR
+RU-
486
+RU-486
/hGR
Dexamethasone Hydrocortisone
50 21* 9.3 1 17.9 12.8
Cholesterol 10 30.3* 19.1
1 7 3.8 100 16.6 6.0
10 6.2 6.6 Cortisone
100 6.2 4.2 1 6.3 4.6
Progesterone 10 27.1* 5.8
1 42.4* 61.3 100 17.1 1.8
10 34.7* 62.4 Corticosterone
100 5.1 7.8 1 2.0 6.3
Testosterone 10 8.2* 8.9
0.1 28.2 7.8 100 2.8 7.5
1 28.3* 80.3* Aldosterone
10 37.4* 108.1* 0.1 3.7 2.3
100 6.5 114.7* 1 22.4* 3.5
Estradiol 10 27.7* 6.7
1 20.5* 7.2 100 35.6** 5.2
10 16.9* 11.0
100 14.5 8.9
Data shown as SCE (specific chemical effect), n = 8 replicate data points derived from 
one experiment. Statistical significance (Stat Sig) is indicated by stars, where * = P<0.05, 
** = p<0.01, both relevant to the solvent control
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CHAPTER 4 - ISOLATION OF A 308 BASE PAIR FRAGMENT OF 
THE UPSTREAM REGULATORY REGION OF THE CYP3A4 GENE
4.1 Introduction
Although a wide interindividual variation exists in levels of expression of CYP3A4 as 
assessed by direct analysis of liver microsomes (Shimada and Guengerich 1989) and 
through the use of in vivo probe drugs (Lown et al., 1995), there is limited evidence for a 
functional polymorphism that involves this P450. Sata et al. (2000) described a variant 
allele of CYP3A4, designated CYP3A4*2, having a Ser222Pro change which was found 
at a frequency of 2.7% in the white population and was absent in the black and Chinese 
subjects analyzed. Compared with the wild-type enzyme, the CYP3A4*2 variant had a 
lower intrinsic clearance for the CYP3A4 substrate nifedipine but was not significantly 
different from the wild-type enzyme for testosterone 6|3-hydroxylation.
This section of my work was to determine if interindividual variation in human liver 
CYP3A4 expression could be rationalised by mutations in the CYP3A4 promoter. This 
was achieved by single stranded conformational polymorphism (SSCP) analysis of the 
CYP3 A4 promoter, in conjunction with initial work undertaken by Dr. Nick Plant.
The initial aim of this work was to analyse the CYP3A4 gene to detect mutations in the 
promoter of this gene. 11 human liver samples were obtained from Keystone Tissue 
Bank, PA, USA, which came with clinical records indicating that they had not been 
exposed to drugs that might affect CYP3A levels, either by induction or by inhibition. 
The liver samples were phenotyped for CYP3A4 activity (midazolam I'-hydroxylase 
activity) where they exhibited a 14.1 fold range in midazolam hydroxylase activity. 
Values of the midazolam hydroxylase activity ranged from 133pmoles/min/mg to 1873 
pmoles/min/mg, with a mean value of 563pmoles/min/mg. These latter data were 
supplied by Dr. Dave Moore, Hoffman-La Roche, Nutley, NJ, USA.
To determine whether to screen coding or promoter region of the CYP3 A4 gene. Western 
blot analysis was carried out on microsomes prepared from frozen liver samples by the 
method of Guengerich (Guengerich, 1989) and CYP3A4 protein concentration was
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determined by the method of Miller (Miller, 1959). Microsomal protein was separated on 
10% SDS-PAGE (lOpg/lane) and equal loading varified by Ponceau S staining (Sigma, 
UK). Proteins were transferred to PVDF membrane (Amersham, UK) for one hour at 
200V. CYP3A4 protein was then detected using an anti-peptide antibody (Kind gift of Dr 
Rob Edwards, ICMS, London, UK) which is specific to the CYP3A4 isoenzyme by 
chemiluminescence (Amersham, ECL). CYP3A4 protein expression varied throughout 
the samples (Figure 4.1). So, it was hypothesised that mutations in the promoter region of 
the gene could be a contributory factor to this variation.
Thus, the promoter region of the gene was then screened for mutations. The Ikb fragment 
first isolated by Hashimoto (Hashimoto et ah, 1993) was divided into seven overlapping 
amplimers, each of ~200bp. SSCP analysis was carried out on genomic DNA from all 
liver samples. Figure 4.2 shows the result of SSCP analysis of the CYP3A4 5' flanking 
region. Within the first 308bp (-301 to +7bp) upstream of the transcription start site two 
band shifts were identified and were confirmed by direct genomic sequencing. Both 
mutations were found to lie within putative ^aw^-activating factor binding sites, being a 
heterozygotic mutation in the hepatic nuclear factor 5 binding site (HNF-5) (-196 to -187 
bp of the CYP3A4 upstream regulatory region) and a homozygotic mutation in the 
estrogen response element (ERE) (-210 to -198 bp of the CYP3A4 upstream regulatory 
region) (Figure 4.3).
Subsequent to the above initial work carried out by Dr. Nick Plant (University of Surrey), 
my work was to isolate these two mutations from the genomic DNA in order to 
investigate the functional impact of such mutations on the regulation of the CYP3A4 
gene. Secretory placental alkaline phosphatase reporter gene constructs were made 
containing the region (-301 to +7bp) of the CYP3A4 promoter for the wild type and the 
two mutant variations.
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Figure 4.1 Western blot analysis of the CYP3A4 protein in human
liver microsomes
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lOfig of total protein was loaded per lane, and separated by SDS-PAGE. CYP3A4 
protein detected using a monospecific peptide antibody, and visualised by 
chemiluminescent detection (Amersham, UK). Unique donor ID is shown across 
the top of diagram, and the relevant CYP3A activity across the bottom, CYP3A 
activity was determined by the 1’-hydroxylation of midazolam. Molecular weight 
markers are shown in lanes 1 and 8, with sizes, in kDa, adjacent to lane 1.
Data provided by Dr. Nick Plant, University of Surrey.
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Figure 4.2 Mutation analysis (SSCP) of the CYP3A4 promoter region
2 3 IS u 15» *7®t 1» 3» n  Sample 2 s ss u m isir» tt
Single strand conformational polymorphism (SSCP) analysis was carried out as 
described in Materials and Methods. Products were separated on 10% acrylamide 
gel, and gels opposed to film for 16 hours. Band shifts indicative of possible 
mutations are shown by arrows.
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Figure 4.3 Wild & mutant HNF-5 and ERE regions
TTGTTTA TTGCTTA
Wild HNF-5 Mutant HNF-5
AGTAACATTGATT AGTAACGTTGATT
Wild ERE Mutant ERE
Diagrammatic presentation of the base pair changes (underlined bases) in the 
CYP3A4 promoter from the wild HNF-5 (T to C at -191 bp) and ERE (A to G 
at -204 bp) regions to the mutant variants
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4.2 PCR amplification of the wild type and mutant CYP3A4 promoter 308 bp 
fragments from human liver genomic DNA
PCR reactions were carried out as described in the Materials and Methods chapter 
(section 2.5.1) to amplify approximately 308bp segment of the CYP3A4 upstream 
regulatory region from genomic DNA prepared from human liver samples (section 2.3.3). 
The primers used for these reactions were the 3A4-301A and 3A4+7B (Table 2.2).
As shown in Figure 4.4, PCR products of approximately 300bp in size were amplified 
under the cycling conditions described in Materials and Methods chapter (section 2.5.1). 
Negative controls (no DNA template) were included to ensure no contamination of the 
PCR products.
PCR fragments were excised from the gel, purified from the agarose using either the 
QIAquick gel extraction (section 2.4.4.1) or the GenElute agarose spin column method 
(section 2.4.4.2) and the DNA concentrations were calculated spectrophotometrically 
(section 2.4.1).
4.3 Cloning and transformation of the CYP3A4 wild type and mutant PCR products
The amplified, purified PCR products were then ligated into a pGEM-T Easy vector as 
described in the Materials and Methods chapter (section 2.4.7). pGEM-T Easy vector 
allows one step cloning without the need for modification of the PCR products. Positive 
and background control ligations were as described in the Materials and Methods chapter 
(section 2.4.7).
The overnight ligation reactions were transformed into JM109 competent cells (section 
2.2.4) and negative and positive transformation controls were included as previously 
described. White colonies were picked for overnight culture and subsequent plasmid 
isolation using the miniprep protocol (section 2.3.1).
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Figure 4.4 The amplified fragments (308bp*) of the wild type 
and mutant CYP3A4 promoters
1 2 3 4 5 6 7 8 9 10 11 12
250bp. m m  m: ‘m 308bp
* The 308 bp fragments were from -301 to +7bp in the CYP3A4 promoters.
PCR products amplified from genomic DNA were electrophoresed on 1%
agarose gel (w/v) and ethidium bromide stained
Lane 1 ; 1Kb DNA ladder marker
Lane 2: negative control (no DNA was added)
Lane 3 - lane 12: amplified DNA fragments from the wild (lane 3 to lane 6) 
and mutant (lane 7 to lane 12) samples
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4.4 Pvu n  restriction digestion of CYP3A4-pGEM-T Easy recombinants
The plasmid DNA minipreps were then digested with Pvu II (section 2.4.5) to check the 
presence of the insert and to confirm its sequence identity.
As shown in Figure 4.5, Pvu II has two recognition sites at 65 Ibp and 3218bp in the 3A4- 
pGEM-T Easy vector. Hence, digestion of the vector with Pvu II enzyme should produce 
two fragments; a small fragment of 760bp in size (corresponding to the PCR insert) and a 
larger fragment of 2567bp in size (corresponding to the vector) (Figure 4.6) on 
electrophoresis on a 1.0% (w/v) agarose gel and visualisation under UV illumination.
4.5 Single stranded conformational polymorphism (SSCP) analysis
SSCP analysis (section 2.6.1) was then performed on all the 3A4-pGEM-T Easy clones 
as a screening method for the samples with mutations which were indicated by band 
shifts (Figure 4.7). Samples which showed band shifts were sent for automated 
sequencing using M13 forward or reverse primers (Table 2.2) to confinn the presence of 
the mutations. The sequencing revealed an A to G transition in the putative estrogen 
response element and a T to C transition in the putative hepatocyte nuclear factor 5 
response element which correspond to positions 204 and 19 Ibp of the upstream 
regulatory region of CYP3A4 gene, respectively (Figure 4.8).
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Figure 4.5 Pvu II recognition sites in 3A4-pGEM-T Easy vector
P v u  II (3218
P v u  n  (651
CYP3A4(-301:+7)pGEM-T Easy 
3327 hp
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Figure 4.6 Pvu II digests of 3A4-pGEM-T Easy vector containing the wild type
and mutant 308 bp inserts
1 2 3 4 5 6 7 8 9  10
BOOObp
750bp
2567bp
760bp
Digested 3A4-pGEM-T Easy vectors were electrophoresed on 1% 
agarose gel (w/v) and ethidium bromide stained 
Lane 1 1Kb DNA ladder marker
Lane 2 lane 10 digested vector showing two bands of 2567bp and 
760 in size corresponding to the vector and the 308 bp insert, 
respectively, of the wild (lane 2 to lane 4) and mutant (lane 5 to lane 
10) samples
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Figure 4.7 Mutation screening (SSCP) of the CYP3A4 promoter 
of the human liver samples
1 2 3  4 5 6 7 8  91011
band
shift*
band
shift
band shift
10% acrylamide gel for the 3A4-pGEM-T Easy vector showing band 
shifts for human liver samples 3, 6, and 11
* Observed band shifts are indicative of possible mutations. Different 
band shift patterns were observed for the different mutations
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Figure 4.8 Automated sequencing of the mutant 
CYP3A4 inserts
: lA I  »
I m
A
i I
<>■!?
f t
Ta^G  transition
AACCCTTGGACTCCCAGTAACGTTGATT
TTGGGAACCTGAGGGTCATTGCAACTAA
Putative estrogen response element
T^C transition
GAGTTGGTTATGATACCTCATAAAATAT
CTCAACGAATACTATGGAGTATTTTATA 
Putative HNF-5 binding site
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4.6 Cloning of PCR products from pGEM-T Easy vector into pSEAP2-Pro 
expression vector
The CYP3A4 308bp promoter inserts were then re-amplified from the 3A4-pGEM-T 
Easy vector by PCR using 3A4-301A(Æc65 I) and 3PsA-^7B{Bgl H) (Table 2.2) as 
primers to create restriction sites at the amplified DNA ends which were then digested 
with Acc65 I and Bgl H. Variable incubation times (as recommended in the 
manufacturer's manual) were tried for digestion of the PCR products to prepare them for 
ligation. Table 4.1 shows the percentage of cleavage at 2 and 20 hours.
The pSEAP expression vector was digested by Acc65 I and Bgl II to create sticky ends 
for ligation of the inserts. The cut ends were then dephosphorylated to prevent self­
religation (section 2.4.6). Ligation reactions were carried out as described in the 
Materials and Methods chapter (section 2.4.7) and the overnight ligations were 
transformed into JM109 competent cells (section 2.2.4). White colonies were picked for 
plasmid isolation and the presence of CYP3 A4 inserts was confirmed by the following:
1. PCR using pSEAP 4790A and pSEAP 34B primers (Table 2.2) (Figure 4.9). A band 
size of approximately SOObp was detected in the presence of 3 A4 insert.
2. Diagnostic restriction digest of the 3A4-pSEAP by Acc65 I and EcoR. I or Acc65 I 
and Pvu n. Figure 4.10 shows the recognition sites for these enzymes in the 3A4- 
pSEAP vector. Restriction digest with Acc65 I and EcoK I (Figure 4.11-A) yielded 
two fragments of approximately 4610bp and 560bp in size, whereas restriction digests 
with Acc65 I and Pvu II (Figure 4.11-B) yielded two fragments of approximately 
4400bp and 770bp in size corresponding to the vector and insert respectively.
3. The orientation of the insert in the vector was confirmed by restriction digest using 
Pst I (Figure 4.12). The Pst I enzyme cuts the 3A4-pSEAP vector at three sites; 382, 
5069 and 5102bp (Figure 4.13) with the last two sites within the insert. With the 
correct orientation, three DNA bands are expected; 33 (will not be detected), 450 and 
4687bp in size.
4. Automated sequencing which confirmed the presence of the mutations as shown 
before in Figure 4.8.
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Table 4.1 Cleavage close to the end of DNA fragments by ^ cc651 and Bgl II
Enzym e
O ligonucleotide Chain
% o f cleavage
sequence length
2 hours 20 hours
Acc6S I GGGTACCC 8 0 0
GGGGTACCCC 10 >90 >90
CGGGGTACCCCG 12 >90 >90
B g m CAGATCTG 8 0 0
GAAGATCTTC 10 75 >90
GAAAGATCTTCC 12 >90 >90
Base pairs in bold face represent the restriction sites for both enzymes while 
the normal face base pairs represent the extra bases which added to stabilize 
the enzymes
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Figure 4.9 Diagnostic PCR analysis for the presence of a 3A4 insert
in the pSEAP vector
PCR products amplified from 3A4-pSEAP vector were 
electrophoresed on 1% agarose gel and ethidium bromide 
stained
Lane 1: 1Kb DNA ladder marker 
Lane 2-7, 9,11: samples with no insert 
Lane 8: sample with the HNF-5 mutant insert 
Lane 10: sample with the ERE mutant insert
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Figure 4.10 Recognition sites for ^ cc651, EcoR I and Pvu II
in the 3A4-pSEAP vector
3A4(-301:+7) E coR l(239)
jPwin(453)Acc 651 (4850)
CYP3A4('301:+7)pSEAP
5170 bp
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Figure 4.11 Diagnostic restriction digest of the wild type and mutant
3A4-pSEAP vector
A- Acc65 I and EcoR I digests
1 2 3 4 5 6 7 8 9 10 11 12 13
4000bp 4610bp
560bp
1% agarose gel electrophoresis for the restriction digest of 3A4-pSEAP vector 
Lane 1: 1Kb DNA ladder marker
Lane 2-13: digested vector showing two bands of 4610bp and 560 in size 
corresponding to the vector and insert (wild type in lane 2 to 5 and mutant in 
lane 6 to 13) respectively
B- Acc6S I and Pvu II digests
4000bp
750bp
1 2 3 4 5 6 7 8 9 10 11 12 13
4400bp
770bp
1% agarose gel electrophoresis for the restriction digest of 3 A4-p SEAPvector 
Lane 1: 1Kb DNA ladder marker
Lane 2-13: digested vector showing two bands of 4400bp and 770 in size 
corresponding to the vector and insert (wild type in lane 2 to 5 and mutant in 
lane 6 to 13) respectively
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Figure 4.12 Orientation of CYP3A4 inserts in 3A4-pSEAP vector
1 2 3 4  5 6 7 8 9  10 11121314
5000bp 4687bp
1% agarose gel electrophoresis for the restriction digest of 3 A4-pSEAP vector by Pst I 
Lane 1 ; 1Kb DNA ladder marker 
Lane 2: undigested vector
Lane 3-14: digested vector showing two bands of 4687bp and 450 in size 
corresponding to the vector and insert (wild type in lane 3 to 5 and mutant in lane 8 to 
14 excluding lane 10) respectively
Samples 6, 7, and 10 were excluded because the digestion reactions did not work
Figure 4.13 Recognition sites for the Pst I in the 3A4-pSEAP vector
P srl(382)
3M(-301 ;+7) 
Pst\ (5069) 
\Pst\ (5102
CYP3A4(-301:+7)pSEAP
5170 bp
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4.7 Functional analysis of the CYP3A4 promoter mutations
In order to investigate the functional impact of the putative HNF-5 and estrogen response 
elements mutations on the expression of the CYP3A4 gene, secretory alkaline 
phosphatase reporter gene constructs were made containing the region -301bp to +7bp, 
for both the wild type and the two mutant variations.
Transient transfection experiments were carried out as described in the Materials and 
Methods chapter (section 2.7.5) on this short region of the CYP3A4 flanking DNA (- 
301bp to +7bp), as this region had been confirmed as being devoid of other mutations, 
and the use of a shorter promoter sequence would produce a more simple model to 
interpret.
The three reporter gene constructs were examined with known inducers of CYP3A4, 
namely the xenobiotics rifampicin and dexamethasone (5, 10, 25, 50, 100, and 200pM 
concentrations), and the endogenous steroids estradiol and hydrocortisone (0.1, 0.5, 1, 5, 
10, and 25pM concentrations). Dose response curves were constructed for these 
compounds, and Imax, EC50 and intrinsic activation values were calculated.
As shown in Figure 4.14, dexamethasone was observed to cause a concentration- 
dependent increase in the CYP3A4-dependent reporter gene expression but the level of 
significance (P<0.05) started at 25pM for the wild and ERE-mutant constructs (specific 
chemical effect of 13.1 and 13.6, respectively) but was at 50pM for the HNF5-mutant 
construct (specific chemical effect of 12.9).
Table 4.2 shows the Imax, EC50 and intrinsic activation values for dexamethasone.
As shown in Figure 4.15, hydrocortisone caused significant induction of CYP3A4- 
dependent reporter gene expression for the wild type and the ERE-mutant constructs at 
concentrations of 10 (specific chemical effect of 28, and 23) and 25|jM  concentrations 
(specific chemical effect of 31.3, and 28.2). Hydrocortisone did not induce the HNF5- 
mutant construct at any of the concentrations examined.
Table 4.3 shows the Imax, EC50 and intrinsic activation values for hydrocortisone.
147
As shown in Figure 4.16, rifampicin caused a concentration-dependent increase in the 
CYP3A4-dependent reporter gene expression which was significant at 50 (P<0.05 with 
specific chemical effect of 12.5, 11.5, and 11.6) and lOOpM concentrations (P<0.01 with 
specific chemical effect of 16.9, 15.7, and 15.6) for the wild type, HNF5-mutant, and 
ERE-mutant constructs, respectively.
Table 4.4 shows the Imax, EC50 and intrinsic activation values for rifampicin.
As shown in Figure 4.17, estradiol, on the other hand, caused induction of CYP3A4- 
dependent reporter gene expression for the wild type and the HNF5-mutant constructs at 
concentrations 10 (P<0.05 with specific chemical effect of 16.9, and 15) and 
25pM (P<0.05 with specific chemical effect of 19, and 16.8). Estradiol did not cause a 
significant induction of the ERE-mutant construct at any of the concentrations examined. 
Table 4.5 shows the Imax, EC50 and intrinsic activation values for estradiol.
In conclusion, the mutations have no effect on the activation of the reporter gene 
constructs by the antibiotic rifampicin, a PXR ligand (Goodwin et al., 1999 & Lehmann 
et al., 1998). Estradiol produced a markedly lower Imax with the ERE-mutant construct 
than either wild type or HDNF5-mutant constructs, although the EC50 value was 
unaffected. A 50% reduction in the Imax for HNF5-mutant wasrobserved upon dosing with 
the naturally occurring glucocorticoid hydrocortisone. There was a reduction in the Imax 
for the HNF5-mutant with the synthetic analogue dexamethasone; once again the EC50 
value was not affected.
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Figure 4.14 Concentration-dependent activation of the wild-type and mutant
CYF3A4 reporter gene constructs by dexamethasone
30-,
Wild type 
HNFS-mut 
ERE-mut2 0 -
10 -
100 1000
Dexamethasone (pM)
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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Table 4.2 Imax? ECso and intrinsic activation values for dexamethasone-dependent 
activation of wild type and mutant CYP3A4 promoters
CYP3A4 construct Imax ECso
(fiM)
Intrinsic activation 
(Imax /  ECso)
Wild-type 18±2.3 6.Ü3.9 3
HNFS-mut 13.1Ü.5 7.5±4 1.7
ERE-mut 18.2Ü.8 9.4±3.9 1.9
The original data for the dose-response curve was driven from 8 replicates carried 
out in one experiment. The dose-response curve was reiteratively fitted to this data. 
Accordingly, the errors reported above are a combination of 
experimental/analytical errors, in addition to the curve-fitting procedure.
The same applies to Tables 4.S-4.5.
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Figure 4.15 Concentration-dependent activation of the wild-type and mutant
CYP3A4 reporter gene constructs by hydrocortisone
40n
Wild type
HNFS-mut
ERE-mut30-
20 -
10 -
1.00
Hydrocortisone ( { i M )
0.10 10.00 100.00
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 4.3 Imax» ECso and intrinsic activation values for hydrocortisone- dependent 
activation of wild type and mutant CYP3A4 promoters
CYP3A4 construct Imax ECso
(pM)
Intrinsic activation 
(Imax /  E C so )
Wild-type 29.6±2 0.6±0.2 48.3
HNF5-mut 13±1 0.9±0.3 14.4
ERE-mut 26.2±2.6 1.1±0.5 23.6
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Figure 4.16 Concentration-dependent activation of the wild-type and mutant
CYP3A4 reporter gene constructs by rifampicin
20 -,
E Wild type 
A HNFS-mut 
o ERE-mut
10 100 
Rifampicin (pM)
1000
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 4.4 Imax? ECso and intrinsic activation values for rifampicin-dependent 
activation of wild type and mutant CYP3A4 promoters
CYP3A4 construct Imax ECso
( p M )
Intrinsic activation 
(Imax /  E C so )
Wild-type 15.8±2.2 I4.5±7.8 1.1
HNFS-mut 13.7±2.3 12±8 1.1
ERE-mut 13.5±2.1 10.4±6.8 1.3
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Figure 4.17 Concentration-dependent activation of the wild-type and mutant
CYP3A4 reporter gene constructs by estradiol
Wild type
HNFS-mut
ERE-mut
10 -
0.10 1.00
Estradiol (|iM)
10.00 100.00
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 4.5 Imax» ECso and intrinsic activation values for estradiol-dependent 
activation of wild type and mutant CYP3A4 promoters
CYP3A4 construct Imax EC50
(pM)
Intrinsic activation 
(Imax /  ECso)
Wild-type 18.5Ü.2 1±0.3 18.5
HNFS-mut I6.5±1.7 1.5±0.6 11
ERE-mut 11.6±0.S 0.9±0.3 12.9
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CHAPTER 5 - REGULATION OF THE CYP3A4 GENE BY 
hGR/hPXR LIGANDS
5.1 Introduction
Expression of the CYP3A4 gene is markedly induced both in vivo and in primary 
hepatocytes in response to treatment with a variety of compounds (Lehmann et al., 1998). 
Many of the most efficacious inducers of CYP3A4 expression are commonly used drugs 
such as the glucocorticoid dexamethasone, the antibiotic rifampicin, and the antimycotic 
clotrimazole (Lehmann et al., 1998). The inducibility of CYP3A4 expression levels 
coupled with the broad substrate specificity of the CYP3A4 protein represents a basis for 
drug interactions in patients undergoing combination drug therapy.
Many attempts have been made to develop in vitro assays to profile efficiently the effects 
of new compounds on CYP3A4 expression levels and to investigate the molecular basis 
for the induction of CYP3A4 gene expression (Lehmann et al., 1998).
A novel human orphan member of the nuclear hormone receptor superfamily termed 
human PXR (hPXR) has recently been cloned and it is activated by a variety of known 
inducers of CYP3A4 expression (Lehmann et al., 1998). hPXR is predominantly 
expressed in liver and intestine and binds to a rifampicin/dexamethasone response 
element in the CYP3A4 promoter (residing ~ 150bp upstream of the transcription 
initiation site) as a heterodimer with the 9-cis retinoic acid receptor RXR (Blumberg et 
al., 1998). The hPXR appears to mediate steroid and drug induction of CYP3A (Schuetz 
et al., 2000).
The glucocorticoid receptor (GR) belongs to a superfamily of ligand-modulated nuclear 
steroid hormone receptors that can regulate gene transcription by activation as well as by 
repression (Beato et al., 1995). Glucocorticoids (both agonists and antagonists) induce 
CYP3A4 in humans in vivo (Watkins et al., 1985) and in cultured hepatocytes (Strom et 
al., 1996), and this induction leads to clinically important drug-drug interactions when 
glucocorticoids are administered with other CYP3A4 substrates (Schuetz et al., 2000). 
The GR controls the expression of both PXR and RXRa which provides an explanation
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for the previous observations in animals and humans that CYP3A gene expression is 
negatively regulated during inflammation and/or infections (Pascussi et al., 2000). Hence, 
both GR and PXR are required for CYP3A induction (Schuetz et al., 2000).
In this chapter, 17 different compounds were examined regarding their effects on the 
CYP3A4-dependent reporter gene expression both without and with the combined co­
transfection of hGR and hPXR receptors.
Compounds were chosen as two separate groups with the first group included classical 
CYP3A4 inducers (dexamethasone, rifampicin, sulfinpyrazone, phénobarbital, 
spironolactone, phenytoin, carbamazepine and metyrapone) and the second group 
included putative CYP3A4 inducers (lovastatin, simvastatin, pravastatin, cyproterone 
acetate, clotrimazole, troglitazone, pioglitazone, pregnenolone 16a-carbonitrile and 
fexofenadine). Negative control compounds, p-naphthoflavone (CYPIA inducer), 
ciprofibrate (CYP4A inducer), and ketoconazole (CYP3 A4 inhibitor), were also included.
These experiments were attempted towards the end of my experimental work and time 
did not permit me to undertake full dose-response curves (8 different concentrations) for 
all 17 compounds. Therefore, all compounds^ were initially investigated at four 
concentrations (1, 10, 30 and 50foM) and this was followed up by examining 
dexamethasone, rifampicin, lovastatin and troglitazone over an eight point concentration 
range.
The four point curves were analysed by both linear and non-linear regression analyses, 
and taking both r^  values in account, I could determine if the four data points were on the 
linear or curvi-linear portion of the dose-response curve. In this four point model, data 
were only accepted for further analyses if the r^  value for a curvi-linear fit was higher 
than that for a linear fit. On this basis, lovastatin and troglitazone were excluded from 
further comparative consideration from the four point model because the r  ^value for a 
linear was greater than that for a curvi-linear fit.
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The validity of this approach was confirmed when the four point versus eight point dose- 
response curves for dexamethasone were analysed, which yielded similar values for 
intrinsic activation (Imax / EC50) (Table 5.1)
Transient transfection experiments were carried out as described in the Materials and 
Methods chapter (section 2.7.6). Secretory placental alkaline phosphatase activity was 
measured using the chemiluminescence SPAP assay (section 2.7.7) and data were 
analysed as described in the Material and Methods chapter (section 2.7.8).
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Table 5.1 Intrinsic activation values for dexamethasone in four point
and eight point models
Intrinsic Activation (Imax /  ECso)
Four point model Eight point model
Basal +hGR/hPXR Basal +hGR/hPXR
2.2 27.5 2.4 25
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5.2 Classical inducers of CYP3A4 gene
This section will be divided into two subsections, namely the effects of rifampicin and 
other compounds (sulfinpyrazone, phénobarbital, spironolactone, phenytoin, 
carbamazepine and metyrapone) on the CYP3A4-dependent reporter gene expression. 
Dexamethasone-dependent transactivation of the CYP3A4 gene has previously been 
considered in this thesis (section 3.1).
5.2.1 Effect of rifampicin on CYP3A4-dependent reporter gene expression
Rifampicin (Figure 5.1) is a macrocyclic antibiotic used mainly in the treatment of 
tuberculosis; it may also be used to treat other infections due to both Gram-positive and 
Gram-negative organisms (Rang et al., 1999). Another use for rifampicin is the treatment 
of biliary infections because it is excreted in bile (Wingard et al., 1991).
The mechanism of action of rifampicin is via inhibition of the DNA-directed RNA 
polymerase of mycobacteria and other micro-organisms by binding to the P-subunit of 
the polymerase, forming a stable drug-enzyme complex, leading to suppression of 
initiation of chain formation in RNA synthesis (Gilman, 1996 & Wingard etal., 1991).
Rifampicin is an inducer of the CYP3A subfamily in several species including the rabbit 
and man both in vivo and in in vitro but not in the rat (Barwick et al., 1996), and induces 
CYP3A6 and CYP3A4 at the transcriptional level. Rifampicin activates both human and 
rabbit PXRs but not mouse and rat PXRs (Jones et al., 2000).
It has been reported that rifanyicin was capable of inducing a CYP3A23 reporter 
construct transfected into rabbit hepatocytes demonstrating that its failure to induce 
CYP3A23 in vivo in rat and in primary culture of rat hepatocytes must be due to the lack 
of species specific cellular factors (Barwick et al., 1996). Rifampicin also induced both 
CYP3A4 and CYP3A7 mRNA in primary human hepatocyte cultures (Greuet et al., 
1996) and CYP3A7 mRNA and protein in HepG2 cells (Guzelian, 1994). In a very recent 
study, rifampicin caused induction of CYP3A23 in primary rat hepatocytes cultures
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transfected with the steroid and xenobiotic receptor (SXR) and CYP3A m PXR- 
null/SXR transgenic mice (Xie et al., 2000).
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Figure 5.1 Chemical structures of classical CYP3A4 inducers
Rifampicin
N
N
NH
Sulfinpyrazone
CH
o
Phénobarbital
H N
O
Spironolactone Phenytoin
C H ,  O
C - N H .
Carbamazepine Metyrapone
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As shown in Figure 5.2, rifampicin 50|jM  (used as a positive control in transfection 
experiments) produced induction of CYP3A4-dependent reporter gene expression with 
specific chemical effects of 13, 15.8, 26.7 and 33 for the basal system (CYP3A4 
construct alone), co-transfection with hGR, co-transfection with hPXR, and co­
transfection with both respectively, which were only significant with the hPXR and 
hGR+hPXR co-transfections (P<0.01). Hence, rifampicin induced CYP3A4 expression 
mainly through interaction with PXR receptor.
A full dose-response curve for rifampicin induction of the CYP3A4 reporter gene 
construct was generated using 0.1, 0.5, 1, 5, 10, 30, 50 and lOOpM concentrations of 
inducer, both in the absence and presence of co-transfected hGR and hPXR receptors.
As shown in Figure 5.3, rifampicin was observed to produce a concentration-dependent 
increase in CYP3A4-dependent reporter gene expression which was enhanced by 
combined co-transfection with hGR and hPXR. In the basal system (no co-transfected 
receptors), the minimum concentration at which significant induction was observed was 
30jjM (P<0.05), although significant induction have been observed with concentrations 
as low as lOpM (data not shown).
The combined co-transfection with hGR and hPXR enhanced CYP3A4 induction by 
rifampicin with the minimum concentration at which significant induction was observed 
being IpM (P<0.01) and the maximum induction with 100|jM  concentration (?<0.01), 
over the concentration range examined.
A degree of cytotoxicity was observed at the lOOpM concentration of rifampicin, as 
indicated by lower total reporter gene expression from both the pCMV and the p3A4 
reporter constructs (data not shown).
Table 5.2 summarises the Imax, ECso and intrinsic activation values for rifampicin.
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Figure 5.2 Induction of CYP3A4-dependent reporter
gene expression by rifampicin
40
30 -
O 20  ^
(O
10
□  Basai
■ 3A4+HGR
□  3A4+hPXR 
a3A4+hGR/+hPXR
Rifampicin (50pM)
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where ** = P<0.01, relevant to the solvent control
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Figure 5.3 Influence of hGR and hPXR on the CYP3A4-dependent
reporter gene expression by rifampicin
75 - ,
B asai
+hGR/+hPXR
50 -
25 -
1.00 
Rifampicin (^M)
10.00 100.000.10
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated 
by stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent 
control
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Table 5.2 l^ ax» ECso and intrinsic activation values for rifampicin
Imax ECso(llM) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
8.2±1.3 48.4±3.7 2.9±2.3 1.2+0.5 2.8 39.7
The original data for the dose-response curve were driven from 8 replicates carried 
out in one experiment. The dose-response curve was reiteratively fitted to this data. 
Accordingly, the errors reported above are a combination of experimental/analytical 
errors, in addition to the curve-fitting procedure.
The same applies to Tables 5.3-5.15.
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5.2.2 Effect of other compounds on the CYP3A4-dependent reporter gene
expression
Sulfinpyrazone (Figure 5.1) is a potent uricosuric agent (inhibits renal tubular 
reabsorption of uric acid) used in the treatment of chronic gout (Reynolds, 1993). It is 
also a competitive inhibitor of platelet cyclooxygenase (blocking the synthesis of 
thromboxane A2) and is thus used to reduce platelet adhesiveness in some vascular 
disorders (Wingard et ah, 1991). It is extensively bound to plasma albumin (98-99%) and 
displaces other anionic drugs (for example coumarin) from the same binding sites 
(Harder and Thurmann, 1996). Sulfinpyrazone has been shown to increase levels of 
CYP3A-dependent catalytic activity assessed by measurement of cyclosporin oxidation 
(Pichard et ah, 1990) and theophylline clearance (Upton, 1991).
As shown in Figure 5.4, four concentrations of sulfinpyrazone were examined for 
CYP3A4, induction both in the basal and receptor co-transfected systems. In the basal 
system, only 30 and 50pM concentrations caused significant induction of CYP3A4- 
dependent reporter gene expression (P<0.01). On co-transfection with hGR and hPXR, 
the level of significance was at 50pM concentration (P<0.05) which may signify that 
these receptors have no role in the induction of CYP3A4 by sulfinpyrazone.
Table 5.3 summarises the Imax, EC50 and intrinsic activation values for sulfinpyrazone.
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Figure 5.4 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by sulfinpyrazone
ü  10 
CO
□  3A4 
g3A4+hGR+hPXR
1 10 30
Sulfinpyrazone (pM)
50
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.3 Imax, ECgo and intrinsic activation values for sulfinpyrazone
Imax E C soCiliM ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
19.6±1.7 13.9+2.8 15.7+4 7.9+6.1 1.3 1.8
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Phénobarbital (Figure 5.1) is a barbiturate mainly used as an anti-seizure agent either 
alone or in combination therapy (Wingard et al., 1991). It has been used as a sedative in a 
variety of disorders such as nervous and anxiety states, chorea and thyrotoxicosis, 
however this use has been largely replaced by other sedatives (Wingard et ah, 1991).
Phénobarbital has been reported to induce CYP3A in human subjects and human 
hepatocyte cultures (Lake et al., 1996) and also increased the urinary excretion of the 
CYP3A4 activity markers 6 beta-hydroxycortisol and the ratio of 6 beta-hydroxycortisol 
to cortisol (Koup et ah, 1998). Phénobarbital increased CYP3A2 mRNA in rat (Tapner et 
ah, 1996) and CYP3A7 mRNA and protein expression in HepG2 cells (Schuetz et ah, 
1993b).
As shown in Figure 5.5, four concentrations of phénobarbital were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In the 
basal system, only 30 and 50pM concentrations caused significant induction of CYP3A4- 
dependent reporter gene expression (P<0.05). On co-transfection with hGR and hPXR, 
significant induction of CYP3 A4-dependent reporter gene expression was observed at the 
lOpM concentration (P<0.05) which may signify a role for these receptors in the 
induction of CYP3A4 by phénobarbital.
Table 5.4 shows the Imax, ECso and intrinsic activation values for phénobarbital.
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Figure 5.5 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by phénobarbital
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.4 Imax, ECso and intrinsic activation values for phénobarbital
Imax E C s o ( p M ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
16.9+2.6 41.3+15.3 17.2+7.3 9.6+12.7 0.98 4.3
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Spironolactone (Figure 5.1), an antimineralocorticoid, is a synthetic hormone used 
clinically as a potassium sparing diuretic which exerts its effect by antagonising the 
action of aldosterone in the distal tubule (Rang et ah, 1999). It is mainly used in the 
treatment of refractory oedema in patients with congestive heart failure, nephrotic 
syndrome, or hepatic cirrhosis (Reynolds, 1993).
Spironolactone has been reported to induce CYP3A in rats (Heuman et al., 1981) and 
CYP3A mRNA levels in primary rat and human hepatocyte cultures (Kocarek et al.,
1995). Recently, the PXR receptor has been demonstrated to play a role in the 
spironolactone-mediated induction of CYP3A23 (Schuetz a/., 1998).
As shown in Figure 5.6, four concentrations of spironolactone were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In the 
basal system, only the 30 and 50pM concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.05 and 0.01, respectively). On co- 
transfection with hGR and hPXR, significant induction of CYP3A4-dependent reporter 
gene expression was observed with all the concentrations examined (P<0.05 for the IpM 
and 0.01 for the 10, 30, and 50pM) which may signify a role for these receptors in the 
induction of CYP3A4 by spironolactone.
Table 5.5 shows the Imax, ECso and intrinsic activation values for spironolactone.
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Figure 5,6 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by spironolactone
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.5 Imax, ECso and intrinsic activation values for spironolactone
Im a x E C 5o ( p M ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
9+0.9 13.2±7 9.1+3.4 1.1+4 0.99 11.7
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Phenytoin (Figure 5.1) is a very effective anticonvulsant used in the treatment of epilepsy 
and all types of partial and tonic-clonic seizures. It is frequently used in conjunction with 
phénobarbital (Griffin, 1996).
Phenytoin has been reported to induce CYP3A in vivo in rats and humans (Thummel et 
al., 1994). It has also been reported to increase levels of CYP3A-dependent catalytic 
activity assessed by measurement of cyclosporin A oxidation in primary cultures of 
human hepatocytes (Pichard et al., 1990) and the urinary excretion of 6 beta- 
hydroxycortisol and the ratio of 6 beta-hydroxycortisol to cortisol in humans (Koup etal.,
1998). Phenytoin increased the expression of CYP3A7 mRNA in HepG2 cells (Schuetz 
etal., 1993b).
As shown in Figure 5.7, four concentrations of phenytoin were examined for their ability 
to induce CYP3A4, both in the basal and receptor co-transfected systems. Both in the 
basal system and with co-transfection of receptors, only 30 and 50pM concentrations 
caused significant induction of CYP3A4-dependent reporter gene expression (P<0.05 and 
P<0.01, respectively), with no difference between the two conditions which would 
suggest that these receptors have no role in the induction of CYP3 A4 by phenytoin.
Table 5,6 shows the Imax, ECso and intrinsic activation values for phenytoin.
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Figure 5.7 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by phenytoin
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.6 Imax, ECso and intrinsic activation values for phenytoin
Imax E C so C liM )
«
Intrinsic activation
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
15.8+1.1 27.5±8.7 17.6+3 25.1+18 0.9 1.1
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Carbamazepine (Figure 5.1) is one of the most frequently used antiepileptic drugs in the 
treatment of partial and tonic-clonic epileptic seizures. It is also used in the treatment of 
trigeminal neuralgia and psychiatric disorders (Gilman, 1996).
Carbamazepine induces CYP3A in human (Tomlinson et ah, 1996) and has been shown 
to increase levels of CYP3A-dependent catalytic activity (assessed by measurement of 
cyclosporin A oxidation) in primary cultures of human hepatocytes (Pichard et al., 1990).
As shown in Figure 5.8, four concentrations of carbamazepine were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In the 
basal system, only 10, 30 and 50pM concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.01). On co-transfection with hGR and 
hPXR, significant induction of CYP3A4-dependent reporter gene expression was 
observed with all the concentrations examined (P<0.05 for the 1 pM and 0.01 for the 10, 
30, and 50pM) which would suggest a role for these receptors in the induction of 
CYP3A4 by carbamazepine.
Table 5.7 shows the Imax, ECso and intrinsic activation values for carbamazepine.
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Figure 5.8 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by carbamazepine
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.7 Imax, ECso and intrinsic activation values for carbamazepine
Imax E C so C p M ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
8.1+0.5 14.1+0.5 1.6+0.6 0.9+0.2 5 16.4
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Metyrapone (Figure 5.1) is an inhibitor of steroid lip-hydroxylase activity, which is 
required for the formation of cortisone and hydrocortisone from their precursors. It is 
used clinically as a diagnostic agent to investigate the function of the anterior lobe of the 
pituitary gland and in the investigation and treatment of Cushing's syndrome (Reynolds, 
1993).
Metyrapone has been demonstrated to be a transcriptional inducer of the rat 
CYP3A1/CYP3A23 genes, possibly acting independently of the GR (Wright et ah,
1996). It also induced the expression of CYP3A4 likely through the activation of hPXR 
in human hepatocytes (Harvey et ah, 2000).
As shown in Figure 5.9, four concentrations of metyrapone were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. Both in 
the basal system and with co-transfection of receptors, only 30 and 50pM concentrations 
caused significant induction of CYP3A4-dependent reporter gene expression (P<0.05). 
The level of significance was P<0.01 with the 50pM concentration in the presence of co­
transfected receptors which may signify that these receptors have a role in the induction 
of CYP3A4 by metyrapone.
Table 5.8 shows the Imax, ECso and intrmsic activation values for metyrapone.
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Figure 5.9 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by metyrapone
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Data shown as SCE (specific chemical effect), where n = 8. replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.8 Imax, ECso and intrinsic activation values for metyrapone
Imax E C so C p M ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
12.8+1.3 20.9+3 6.4+2.8 6.6±4 2 3.2
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5.3 Putative CYP3A4 inducers
This section is divided into three subsections for the effect of statins, effect of 
thiazolidinediones, and effect of other compounds (cyproterone acetate, clotrimazole, 
pregnenolone 16a-carbonitrile and fexofenadine) on CYP3A4-dependent reporter gene 
expression. For these compounds there are evidences that they are CYP3A4 inducers 
which come from human hepatocyte induction studies and drug-drug interactions.
5.3.1 Effect of statins on CYP3A4-dependent reporter gene expression
The statins are reversible inhibitors of the microsomal enzyme HMG-CoA reductase, 
which converts HMG-CoA to mevalonate. This is an early rate-limiting step in 
cholesterol biosynthesis so inhibition leads to decreased intracellular cholesterol 
biosynthesis (Goldstein and Brown, 1990). Lovastatin, simvastatin and pravastatin 
(Figure 5.10) were the first three HMG-CoA reductase inhibitors to be approved for 
therapeutic use in several countries (Transon et ah, 1996).
Lovastatin is orally administered as a lactone prodrug in human which is extensively 
metabolised in the liver by CYP3A4 to inactive metabolites and to its active metabolite 
lovastatin acid (Albengres et ah, 1998). Lovastatin has been reported to activate hPXR 
(Lehmann et al., 1998) and induce P450 mRNAs when added to primary cultured rat 
hepatocytes (Kocarek fl/., 1993).
Simvastatin is also given orally as a lactone prodrug which is converted to the active 
form, simvastatin hydroxy acid (Mauro, 1993). Hepatic CYP3A plays an important role 
in the metabolism of simvastatin (Vyas et al., 1990). It has been reported that multiple 
dose administration of simvastatin leads to a significant induction of CYP3 A measured as 
excretion of 6p-hydroxycortisol (Mckenney, 1988).
Pravastatin is administered in open hydroxy acid ring form and is not dependent on 
enzyme metabolism in order to become pharmacologically active (Pan, 1991). Pravastatin 
was reported to increase levels of urinary 6p-hydroxycortisol and free cortisol and the
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6p-hydroxycortisol/free cortisol ratio (CYP3A activity markers) in humans (Karayalcin 
etal., 1991).
In vitro studies have demonstrated that lovastatin, simvastatin and pravastatin have 
moderate affinities for CYP2C9, CYP3A4 and CYP2D6. In particular, CYP3A4 is the 
isoform that is shared by several other drugs (such as cyclosporin and erythromycin) so 
serious interactions (myopathy and rhabdomyolysis) have been described during 
concomitant use of these compounds (Lennemas and Fager, 1997).
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Figure 5.10 Chemical structures of the statins
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A full dose-response curve for lovastatin (ester form) induction of the CYP3A4 reporter 
gene construct was generated using 0.05, 0.1, 0.5, 1, 5, 10, 50 and 100|jM  concentrations 
both in the absence and presence of co-transfected hGR and hPXR
As shown in Figure 5.11, lovastatin was observed to cause a concentration-dependent 
increase in CYP3A4-dependent reporter gene expression which was enhanced by co- 
transfection with hGR and hPXR In the basal system (no co-transfected receptors), the 
minimum concentration at which significant induction was observed was 5pM (P<0.05).
Co-transfection with hGR and hPXR enhanced CYP3 A4 induction by lovastatin with the 
minimum concentration at which significant induction was observed being IpM (P<0.05) 
and the maximum induction was observed at a lOOpM concentration (P<0.01), over the 
concentration range examined.
A degree of cytotoxicity was observed at lOOpM concentration of lovastatin as indicated 
by lower total reporter gene expression from both the pCMV and the p3A4 reporter 
constructs.
Table 5.9 shows the Imax, ECgo and intrinsic activation values for lovastatin.
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Figure 5.11 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by lovastatin
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.9 Imax, ECso and intrinsic activation values for lovastatin
Imax E C so C iiM ) Intrinsic activation
(Im ax /  E C s o )
Basal +bGR/bPXR Basal +bGR/bPXR Basal +bGR/bPXR
25.7+2.6 100.3+6.8 2.3+1.1 0.5+0.2 11.4 222.9
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As shown in Figure 5.12, four concentrations of simvastatin (ester form) were examined 
for their ability to induce CYP3A4, both in the basal and receptor co-transfected systems. 
In the basal system, only the 30 and SOpM concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.05 and 0.01, respectively). On co- 
transfection with hGR and hPXR, significant induction of CYP3A4-dependent reporter 
gene expression was observed with the lOpM concentration (P<0.05 for the 10 and 30pM 
and 0.01 for the 50pM) which may signify a role for these receptors in the induction of 
CYP3A4 by simvastatin.
Table 5.10 shows the Imax, EC50 and intrinsic activation values for simvastatin.
In contrast to the other statins examined, pravastatin (ester form) was not found to induce 
CYP3A4-dependent reporter gene expression over the concentration range examined 
(data not shown) so it was excluded from further analysis.
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Figure 5.12 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by simvastatin
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.10 Imax, ECso and intrinsic activation values for simvastatin
Im a x E C s o C l i M ) Intrinsic activation 
(Im ax / ECso)
Basal +bGR/bPXR Basal +bGR/bPXR Basal +bGR/bPXR
31.3+4.8 81.5+8.3 17.4+7 G.8+0.6 1.8 100.5
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5.3.2 Effect of thiazolidinediones on the CYP3A4-dependent reporter gene
expression
Thiazolidinediones (TZDs) are a new class of oral antidiabetic agents which selectively 
enhance or partially mimic certain actions of insulin, causing a slowly generated 
antihyperglycaemic effect in Type 2 (noninsulin dependent) diabetic patients (Day,
1999). The TZDs include troglitazone and pioglitazone (Figure 5.13), ciglitazone, 
englitazones, and others.
TZDs stimulate transcriptional events in adipocytes by activating a specific nuclear 
receptor, the peroxisome proliferator-activated receptor gamma (PPARy) which is 
expressed mainly in white and brown adipocytes, where it is complexed to the retinoid X 
receptor (RXR) within the nucleus (Pfahl and Chytil, 1996). Binding of the T2Ds to the 
receptor causes a conformational change in the PPAR-RXR complex, displacing a co­
repressor and allowing activation of specific genes (Day, 1999).
Troglitazone biotransformation in humans involves sulfation, glucuronidation and 
oxidation (Loi et ah, 1999). The sulfate conjugate (Ml) is the most abundant metabolite 
(7 to 10 times that of the parent drug) and the glucuronide conjugate (M2) is the least 
abundant metabolite (20 to 40% of the parent). Both of these metabolites are 
pharmacologically inactive (Day, 1999). The oxidative metabolite (quinone metabolite, 
M3) is similar to that of the parent drug (Izumi et ah, 1996) and is an active metabolite 
(Day, 1999).
Although troglitazone is reported not to be metabolized by human CYPlAl, CYP1A2, 
CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, it has been demonstrated to be a 
potential inducer of CYP3A4 at clinically relevant concentrations (Physicians Desk 
reference, 1999 & Sparano and Seaton, 1998). Consequently, with concomitant 
troglitazone therapy, there is a significant decrease in cyclosporin (Kaplan et ah, 1998), 
terfenadine and ethynylestradiol (Koup et ah, 1998 & Physicians Desk reference, 1999) 
concentrations in humans. Moreover, troglitazone has been demonstrated to increase 
immunoreactive CYP3A protein and the activity of CYP3A in primary cultures of human 
hepatocytes, comparable to that caused by rifampicin (Ramachandran et al., 1999).
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Troglitazone has been suggested to be non-enzymatically converted to a quinone-type 
metabolite by lipid peroxides and active oxygen (Fu et ah, 1996). In contrast, it has been 
recently reported that both CYP2C8 and CYP3A4 are major P450 enzymes involved in 
the oxidation of troglitazone to a quinone-type metabolite in human liver microsomes and 
that the relative roles of these two P450s vary depending on the contents of CYP2C8 and 
CYP3A4 in human livers (Yamazaki et al., 1999).
Pioglitazone is also a novel antidiabetic thiazolidinedione derivative that offers promise 
as an oral insulin-sensitizing agent. Pioglitazone was not found to inhibit the xenobiotic 
oxidations catalyzed by CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, and CYP3A4P450 enzymes (Yamazaki etal., 2000).
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Figure 5.13 Chemical structure of troglitazone and pioglitazone
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A full dose-response curve for troglitazone induction of CYP3 A4 reporter gene construct 
was generated (0.01, 0.05, 0.1, 0.5, 1, 5, 10 and 20jjM), both in the absence and presence 
of co-transfected hGR and hPXR receptors.
As shown in Figure 5.14, troglitazone was observed to cause a concentration-dependent 
increase in CYP3A4-dependent reporter gene expression which was enhanced by co- 
transfection with hGR and hPXR In the basal system (no co-transfected receptors), the 
minimum concentration at which significant induction was observed was lOpM (P<0.05). 
The 20|jM  concentration was also significant (P<0.01).
Co-transfection with hGR and hPXR enhanced CYP3A4 induction by troglitazone with 
the minimum concentration at which significant induction was observed being 0.5pM 
(P<0.05) and the maximum induction was observed at a 20jjM concentration (P<0.01) 
which may signify a role for these receptors in the induction of CYP3A4 gene by 
troglitazone.
Table 5.11 shows the Imax, ECso and intrinsic activation values for troglitazone.
Pioglitazone was not found to induce CYP3A4-dependent reporter gene expression over 
the concentration range examined (data not shown) so it was excluded from further 
analysis.
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Figure 5.14 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by troglitazone
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.11 Imai, ECso and intrinsic activation values for troglitazone
Imax ECso(liM) Intrinsic activation
(Im ax / ECso)
Basal +bGR/bPXR Basal +bGR/bPXR Basal +bGR/bPXR
21.6+3.7 17.1+1.4 4.412.3 0.210.1 4.9 77.5
188
5,3.3 Effect of other compounds on the CYP3A4-dependent reporter gene
expression
Cyproterone acetate (CPA) (Figure 5.15) is a potent androgen antagonist and also 
possesses progestational activity and suppresses the secretion of gonadotropins 
(Neumann and Topert 1986). It competes with dihydrotestosterone for binding to the 
androgen receptor (Brown et al., 1981). Cyproterone acetate has been used for the 
treatment of acne, male-pattem baldness, hirsutism, and virilizing syndromes (Neumann, 
1982).
It has been reported that cyproterone acetate induced hepatic CYP3A in rat and human 
hepatocytes (Kocarek et al., 1995). The drug also induces CYP3A23 through activation 
of PXR (Schuetz et al., 1998). Other effects of cyproterone acetate include liver cell 
proliferation (Menegazzi et al., 1997), rodent liver tumour promotion (Duivenvoorden et 
al., 1995) and increased sensitivity of hepatocytes to undergo apoptosis (Oberhammer et 
al., 1996). Cyproterone acetate has been shown to induce replicative DNA synthesis in 
rat hepatocytes both in vivo (Schulte-Hermann et al., 1980) and in vitro (Parzefall et al., 
1989).
As shown in Figure 5.16, four concentrations of cyproterone acetate were examined for 
their ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In 
the basal system, only the 30 and 50|jM  concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.05 and 0.01, respectively). On co­
transfection with hGR and hPXR, significant induction of CYP3A4-dependent reporter 
gene expression was observed with the 10, 30, and 50pM concentrations (P< 0.01) which 
may signify a role for these receptors in the induction of CYP3 A4 by cyproterone acetate.
Table 5.12 shows the Imax, EC50 and intrinsic activation values for CPA.
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Figure 5.15 Chemical structures of putative CYP3A inducers
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Figure 5.16 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by cyproterone acetate
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.12 Imax» ECso and intrinsic activation values for cyproterone acetate
Im a x E C 5 o ( p M ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
9+0.2 11.2+0.2 17.7+1 1.6+0.1 0.5 6.9
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Clotrimazole (Figure 5.15) is a broad-spectrum imidazole antifimgal and trichomonacidal 
agent that interferes with amino acid transport in the organism by acting at the cell 
membrane (Rang et al., 1999). It is used in the treatment of dermatomycoses, leucorrhoea 
and vaginitis caused by infections with Candida and Trichomonas species (Berg et al., 
1986).
Clotrimazole has been reported to be a potent inducer of CYP3A1 in vivo (Khan et ah, 
1989), acting post-transcriptionally by inhibition of protein degradation (Eliasson et ah, 
1994). It has also been shown to induce CYP3A mRNA levels in primary cultures of 
human hepatocytes and also CYP3A mRNA and protein in rat leukocytes (Mahnke et ah, 
1996) and in primary cultures of rat, but not rabbit, hepatocytes (Kocarek et ah, 1995). 
Marked induction of levels of CYP3A isoforms in rat liver microsomes treated with 
clotrimazole has also been reported (Lake et ah, 1998).
As shown in Figure 5.17, four concentrations of clotrimazole were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In the 
basal system, only the 10, 30 and 50pM concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.05 for lOpM and 0.01 for 30 and 
50pM). On co-transfection with hGR and hPXR, significant induction of CYP3A4- 
dependent reporter gene expression was observed with all the concentrations examined 
(P<0.05 for IpM and 0.01 for 10, 30, and 50pM) which may signify a role for these 
receptors in the induction of CYP3 A4 by clotrimazole.
Table 5.13 shows the Imax, ECso and intrinsic activation values for clotrimazole.
192
Figure 5.17 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by clotrimazole
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.13 Imax» ECso and intrinsic activation values for clotrimazole
Imax E C s o ( i iM ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
8.6+0.4 15.3±0.3 6.1+1.1 l.l+O.l 1.4 14
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Pregnenolone 16a-carbonitrile (PCN) (Figure 5.15) is a synthetic antiglucocorticoid 
widely used experimentally in the study of glucocorticoid-inducible genes (Quattrochi et 
ah, 1995). It is an inducer of CYP3A family in several species including rat and man both 
in vivo and in vitro (Barwick et al., 1996 & Burger et al, 1992 & Gonzalez et al., 1985 & 
Kocarek et al., 1995). It induces CYP3A23 and CYP3A4 at the transcriptional level 
(Barwick et ah, 1996) and the CYP3A4 induction has been shown to be glucocorticoid 
receptor dependent (Ogg et ah, 1999).
PCN has been shown to induce rat CYP3A1 through mRNA stabilisation (Simmons et 
ah, 1987). Immunoblotting procedures confirmed the induction of CYP3A in rat liver 
microsomal preparations treated with PCN (Amacher and Schomaker, 1998). PCN was 
reported not to induce CYP3A7 in HepG2 cells (Guzelian, 1994). It has been also 
reported that testosterone 6p- and 16p-hydroxylase activities were induced by PCN (Lake 
et ah, 199%).
As shown in Figure 5.18, four concentrations of PCN were examined for their ability to 
induce CYP3A4, both in the basal and receptor co-transfected systems. In the basal 
system, only the 30 and 50pM concentrations caused significant induction of CYP3A4- 
dependent reporter gene expression (P<0.05). On co-transfection with hGR and hPXR, 
significant induction of CYP3A4-dependent reporter gene expression was observed with 
10, 30, and 50pM concentrations (P<0.01) which may signify a role for these receptors in 
the induction of CYP3 A4 by PCN.
Table 5.14 shows the Imax, EC50 and intrinsic activation values for PCN
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Figure 5.18 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by PCN
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.14 Imax» ECso and intrinsic activation values for PCN
Imax E C so C liM ) Intrinsic activation
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
13.2+1.1 44.3+2.5 4.5+1.9 2.5+0.9 2.9 17.6
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Terfenadine is an Hi receptor antagonist and is used in the treatment of various
immediate hypersensitivity reactions, suppression of motion sickness and sedation
(Gilman, 1996).
Terfenadine is a substrate for CYP3A4 (Michalets, 1998) and has been reported to be 
metabolized to at least three major metabolites in human liver microsomes and in the 
CYP3A4 fusion protein (Rodrigues et al., 1995). Terfenadine has been reported to inhibit 
testosterone 6 p-hydroxylation in a concentration-dependent manner in human liver 
microsomes (Wang et al., 2000). The drug has been removed from the market because of 
its serious cadiovascular drug interactions; its active carboxy metabolite, fexofenadine 
(Figure 5.19) is now available and devoid of the fatal drug interactions (Michalets, 1998).
As shown in Figure 5.20, four concentrations of fexofenadine were examined for their 
ability to induce CYP3A4, both in the basal and receptor co-transfected systems. In the 
basal system, only the 30 and 50pM concentrations caused significant induction of 
CYP3A4-dependent reporter gene expression (P<0.05). On co-transfection with hGR and 
hPXR, significant induction of CYP3A4-dependent reporter gene expression was 
observed with 10, 30, and 50|nM concentrations (P<0.01) which may signify a role for 
these receptors in the induction of CYP3A4 by fexofenadine.
Table 5.15 shows the Imax, EC50 and intrinsic activation values for fexofenadine.
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Figure 5.19 Chemical structure of fexofenadine
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Figure 5.20 Influence of hGR and hPXR combined co-transfection on
CYP3A4-dependent reporter gene expression by fexofenadine
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Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
Table 5.15 Imax» ECso and intrinsic activation values for fexofenadine
Imax ECsoCliM ) Intrinsic activation 
(Im ax / ECso)
Basal +hGR/hPXR Basal +hGR/hPXR Basal +hGR/hPXR
17.9+2.8 47±0.9 7+4.4 2.4+0.3 2.6 19.8
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CHAPTER 6  - DISCUSSION
6.1 Introduction
The primary aim of my project was to study the mechanism of induction of CYP3A4 
gene by a number of steroids and xenobiotics by transfecting HepG2 cells with the 
CYP3A4-pSPAP reporter gene construct. The role of the antiglucocorticoid RU-486 and 
the human glucocorticoid receptor in the steroid induction of CYP3A4 was also 
examined. Induction of CYP3A4 gene by xenobiotics was examined both in the absence 
and presence of combined co-transfection of human glucocorticoid receptor and human 
pregnane X receptor.
The optimised calcium phosphate transfection protocol was performed over a five day 
period as described in the Materials and Methods chapter (section 2.7.6). Detection of 
reporter gene expression was achieved by a chemiluminescent assay. The SPAP activity 
was measured at day 3 and day 5 of the transfection protocol, pre- and post-dosing with 
the inducer, from the same well. SPAP activity is therefore represented as change from 
the day 3 reading to day 5 for each determination and the data were analysed as described 
in the Materials and Methods chapter (section 2.8).
The secondary aim of my PhD project was to isolate approximately 308 base pairs of the 
5' flanking region of the CYP3A4 gene which was previously shown to have mutation in 
either the HNF-5 or the estrogen response elements (data provided by Dr. Nick Plant, 
University of Surrey). Sequence confirmation of the isolated fragments was followed by 
cloning of the fragments into a secretory placental alkaline phosphatase (SEAP) 
expression vector to study the functional effect of these mutations on the transactivation 
of CYP3A4 gene by steroids and xenobiotics (dexamethasone, hydrocortisone, rifampicin 
and estradiol).
6.2 Reproducibility of the in vitro assay system
In vitro transactivation assays have been used for several years in the investigation of 
how chemicals cause changes in gene expression (Alam and Cook, 1990). Perhaps the
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most common type of experiments is to use transient transfection of a reporter gene 
construct into a suitable cell line (Gaunitz et al., 1996). Other work in our laboratory has 
successfully applied this in vitro approach to regulation of both CYPlAl and CYP4A1 
genes. This system may therefore provide a general methodology applicable to the study 
of a wider range of drug metabolizing enzymes in several species, including man.
6.2.1 Intra-experimental variation
8 replicates were used for determination of each experimental point. These replicates 
represent aliquots taken from a single flask of cultured cells and seeded into individual 
wells of a 96-well plate. SPAP activity was measured on day 3 and day 5 of the 
transfection protocol and the change from day 3 to day 5 for each individual well 
calculated. For example, with the hydrocortisone dose-response curve, for 8 replicates, 
the standard error of the mean (SEM) was typically less than 5% of the mean value. This 
error remained constant throughout the compound concentrations examined (0.05, 0.1, 
0.5, 1, 5, 10, 25, and 50|jM).
6.2.2 Inter-experimental variation
The reproducibility of the system between experiments is best demonstrated using 
dexamethasone as this has been examined multiple times over the same concentration 
range. In two separate experiments, one using eight concentration points (0.1, 0.5, 1, 5, 
10, 30, 50, and lOOjiM) and the second using four concentration points (1, 10, 30, and 50 
pM), Imax, ECso, and intrinsic activation values of 47.4+3.2, 1.9+0.7, and 24.8 and 
48.1+1.7, 1.7+0.4, and 27.5 respectively were obtained for the two experiments. It can be 
seen that the difference between the two sets of values falls within the error given for the 
reiterative fitting of the curve by the software program.
Hence intra- and inter-experimental variations are very low, resulting in a highly 
reproducible system which is very reliable to examine the potential of a compound to 
induce CYP3A4 gene.
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6.3 Induction of CYP3A4 gene by steroids and xenobiotics
Steroid hormones are essential for normal sexual development, ability to withstand stress, 
and regulation of fluid and electrolyte balance (White, 1994). The hormones mediating 
these functions are grouped into sex steroids, glucocorticoids, and mineralocorticoids and 
synthesis of these different classes and their appropriate regulation require precisely 
controlled expression of several different biosynthetic enzymes in various tissues (White, 
1994).
Glucocorticoids mediate transcriptional activation of numerous eukaryotic genes via the 
selective interaction of glucocorticoid receptor (GR) with specific DNA sequences 
(Benore-Parsons et ah, 1991). Comparison of the response regions of different genes 
have identified a consensus 15 base pair (GGTACAnnnTGTTCT) referred to as a 
glucocorticoid response element (GRE) (Buetti and Kuhnel, 1986 & Strahle et ah, 1987).
Previous investigations into the inducibility of CYP3A enzymes in mammalian species 
revealed four classes of structurally unrelated inducers, namely, the steroids (which 
include synthetic glucocorticoids and antiglucocorticoids), phenobarbital-type inducers 
(anticonvulsants, organochlorine and polychlorinated biphenyls), macrolide antibiotics 
(RIF), and antifungal compounds (imidazoles) (Williams et al., 1997). These classes 
were based on the mechanism responsible for the CYP3 A enzyme induction (Williams et 
al, 1997).
In my studies, 9 steroids were examined for their ability to induce the CYP3 A4 gene. The 
effect of hGR and the antiglucocorticoid RU-486 both alone and in combination on the 
steroid induction of CYP3A4 was also examined.
6.3.1 The influence of RU-486 and/or hGR on the CYP3A4 reporter gene expression 
by steroids
Table 6.1 illustrates the concentrations at which significant induction of the CYP3A4 
gene by steroids was observed and the effect of hGR and RU-486.
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Dexamethasone, cholesterol, progesterone, hydrocortisone, cortisone, corticosterone, 
testosterone, estradiol and aldosterone, all induced CYP3A4 reporter gene expression at 
different concentrations. These steroids were expected to induce CYP3A4 because they 
are all metabolized by CYP3A4 (Ueng et ah, 1997) and inducers are often substrates for 
the induced enzyme (Whitlock and Denison, 1995).
Co-transfection with hGR enhanced the induction of CYP3A4 reporter gene expression 
by dexamethasone, cholesterol, progesterone, hydrocortisone, corticosterone, 
testosterone, estradiol and aldosterone. RU-486 caused significant induction of CYP3A4 
reporter gene expression (compared to the solvent control) in the presence of 
dexamethasone, progesterone, hydrocortisone, cortisone, corticosterone, testosterone, 
estradiol and aldosterone.
Hofmann et ah (1998) reported that testosterone propionate and estradiol benzoate had no 
significant affinity for the GR. Testosterone produces its effect through interaction with 
the androgen receptor which is a member of the steroid hormone receptor family (Roche 
et ah, 1992). Although a clear consensus sequence has not been defined for the androgen 
receptor, a glucocorticoid response element (GRE) can mediate induction by androgens 
(Cato et al., 1987 & Ham et ah, 1988). It has been reported that testosterone stimulates 
midazolam hydroxylation, nifedipine oxidation and terfenadine metabolism, all of which 
are CYP3A4 dependent (Wang et ah, 2000).
The estradiol effect is mediated through interaction with estrogen receptor which also 
belongs to the nuclear hormone receptor family (Grandien et ah, 1997). Both GRE and 
ERE are present in the 1 kb of the CYP3A4 5' flanking region (Hashimoto et ah, 1993) 
which was used in these transfection experiments. It has been reported that estradiol 
produced a little increase in the activity of CYP3A1 reporter gene in COS-7 cells 
transfected with PXR expression vector (Masuyama et ah, 2000) and that both estradiol 
and dihydrotestosterone are weak activators of a hPXR expression vector when 
transfected into CV-1 cells (Jones et ah, 2000).
Progesterone forms a ligand with the progesterone receptor which binds to a progesterone 
response element (PRE) in the DNA and triggers transcription (McDonnell et ah, 1993). 
PRE is present in the 1 kb of the CYP3A4 5' flanking region (Hashimoto et ah, 1993)
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which was used in these transfection experiments. The progesterone receptor can also 
recognize the consensus sequence of the GRE (TGTTCT) (McDonnell et al., 1993). 
Progesterone has been shown to activate the in vitro metabolism of carbamazepine (Kerr 
etal., 1994) and estradiol (Kerlan, etal., 1992), both of which are CYP3A4 substrates.
It has been reported that progesterone activated the hPXR and mPXR expression vectors 
transfected into CV-1 cells (Kliewer et al., 1998 & Lahmann et al., 1998), increased 
CYP3A1 reporter gene activity in COS-7 cells transfected with mPXR expression 
plasmid (Masuyama et al., 2000) and induced a CYP3A23 DR-3 reporter plasmid co­
transfected with the PXR expression vector into pig kidney epithelial cells (Schuetz et ah, 
1998) which confirms the original results by Kliewer et al. (1998).
Cortisone is an inert metabolite of cortisol (Fujitaka et al., 1997), and did not induce the 
CYP3A4 reporter gene except at the lOpM concentration when RU-486 was added which 
may be due the effect of RU-486 itself.
There was a significant induction of CYP3A4 by corticosterone (lOpM) which was the 
same in the absence or presence of hGR and RU-486 indicating that corticosterone 
induced CYP3A4 but not tiirough the GR, although corticosterone is a glucocorticoid 
derived from progesterone (Stryer, 1995). One possibility is that corticosterone may 
induce CYP3A4 via the progesterone receptor which then binds to P/GRE. It has been 
reported that corticosterone is an activator of hPXR and hGRa expression vectors 
transfected into CV-1 cells (Jones etal., 2000).
Dexamethasone, progesterone, corticosterone, cortisone and estradiol activated hSXR 
(human steroid and xenobiotic receptor) expression vector, transfected into CV-1 cells, 
which is most closely related to the recently described PXR (95% identical in the DBD 
and 73% identical in the LBD). PXR and SXR may represent a  and P subtypes of the 
same receptor family (Blumberg et ah, 1998).
Aldosterone is a ligand for the mineralocorticoid receptor (Pearce and Yammamoto, 
1993). These receptors have no known corresponding mineralocorticoid response element 
but they are able to bind to P/GRE and activate DNA transcription via this response
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element (Pearce and Yammamoto, 1993). This may be the mechanism of the significant
induction of CYP3 A4 gene which was enhanced by GR.
Addition of RU-486 (IpM) together with each of the steroids examined produced 
significant induction of the CYP3 A4 reporter gene expression. This effect may be either 
due to the steroid itself or the RU-486. RU-486 has been reported to increase testosterone 
2, 6, and 15 P-hydroxylation and immunoreactive CYP3A protein in rat liver microsomes 
(Williams et al., 1997), induce CYP3A mRNA levels in rat, human and rabbit 
hepatocytes (Jones et al., 2000 & Kocarek et al., 1995 & Schuetz et al., 1993a) and 
activate mPXR expression vector co-transfected with CAT reporter plasmid into CV-1 
cells (Kliewer et al., 1998 & Moore et al., 2000).
On the contrary, RU-486 (50pM) has been reported to decrease testosterone 6p- 
hydroxylation activity of CYP3A4 by 81% in the presence of NADPH in a CYP3A4 
reconstituted system (He et al., 1999). The mechanism of inhibition is thought to involve 
the addition of reactive oxygen to the carbon-carbon triple bond of RU-486 yielding a 
highly reactive ketene intermediate through 1,2-methyl rearrangement. This ketene then 
reacts with a nucleophilic residue at the enzyme active site inhibiting it (He et al., 1999). 
The inhibition of CYP3A4 activity by RU-486 was concentration dependent; being 
minimum at IpM and maximum at lOOpM (He et al., 1999). In my project, RU-486 at 
concentrations less than 0.5|jM did not induce CYP3A4 reporter gene expression. Thus, 
RU-486 may induce or inhibit CYP3A according to the concentration examined, at least 
in the in vitro system described herein.
Addition of both RU-486 and hGR to examine the induction of CYP3A4 gene by steroids 
showed only significant induction with testosterone which may be due to the fact that 
androgen receptor (AR) has a relatively low but demonstrable affinity for RU-486 
(Cadepond et al., 1997). Hence, the induction observed may be AR-mediated. RU-486 
inhibited rather the GR-mediated induction of CYP3A4 by other steroids probably by 
competitive inhibition with the steroids for the available GR as it has been reported that 
RU-486 binds to GR at nanomolar concentrations (Cadepond et al., 1997).
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RU-486 has been reported to activate a hPXR expression vector co-transfected into CV-1 
cells with a CYP3A4 ER6 reporter construct with an EC50 value of lOpM (Lehmann et 
ah, 1998 & Moore et ah, 2000). Co-treatment with RU-486 inhibited the dexamethasone- 
mediated RXRa and PXR mRNA accumulation in cultured human hepatocytes (Pascussi 
et ah, 2000).
Williams et ah (1997) reported that there is a "non classical" mechanism for the 
involvement of the GR in the induction of CYP3A gene expression by an intracellular 
species that stereospecifically recognizes glucocorticoids like dexamethasone and 
antiglucocorticoids such as 16a-carbonitrile and that the inducing effect of RU-486 on 
the CYP3A expression fits in with this hypothesis specially in the light of evidence that 
confirms the antagonism by RU-486 of dexamethasone induction of genes regulation by 
glucocorticoids.
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6.3.2 The influence of hGR and hPXR combined co-transfection on the CYP3A4
reporter gene expression by dexamethasone
A fiill dose-response curve for dexamethasone induction of CYP3A4 reporter gene 
expression was carried out both in the basal system and with co-transfection of hGR and 
hPXR (Table 6.2). Dexamethasone produced a concentration dependent increase in the 
CYP3A4 reporter gene expression which was enhanced by hGR and hPXR both alone 
and with combined co-transfection with an EC50 values of 3 and 2|nM and intrinsic 
activation values of 2 and 25 for the basal and receptor co-transfected system, 
respectively. Thus both GR and PXR very likely play a direct role in the CYP3A4 
induction by dexamethasone. Also hGR and hPXR co-transfection did not shift the EC50 
value (as presumably there is endogenous hGR/hPXR to use normally). However, the 
extra receptors allow much higher levels of activation (as evidenced by the increased 
intrinsic activation value). Hence, the hGR/hPXR is a limiting factor in the basal system.
There is some convincing evidence for the direct involvement of both the GR and PXR in 
the dexamethasone-dependent induction of the CYP3 A4 gene. The GR was demonstrated 
to be involved in the CYP3 A4 reporter gene expression by dexamethasone in transfection 
experiment using HepG2 cells (EL-Sankary et a l, 2000 & Ogg et al., 1999). 
Dexamethasone-dependent induction of CYP3A7 and CYP3A5 reporter constructs 
transfected into HuH-7 and HepG2 cells, respectively required co-transfection with GR 
plasmid (Pickwell ah, 1996 & Schuetz et al., 1996). It has also been reported that 
dexamethasone produced a 47-fold activation of a GR expression vector co-transfected 
with MMTV-luciferase reporter construct into COS-7 cells (Calleja et al., 1998).
The possible involvement of GR in the induction of the CYP3A subfamily by 
dexamethasone has also been demonstrated in rat, where 4 day treatment with the drug 
produced a 15- fold increase in testosterone 6P-hydroxylation (Williams et al., 1994). 
RU-486 has been reported to inhibit the dexamethasone-dependent induction of 
CYP3A23 (Burger et al., 1992 & Huss et al., 1996). In man, levels of CYP3A4 mRNA 
and protein were reported to be increased in a dose-dependent manner in patients 
receiving dexamethasone (Molowa et al., 1986).
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Dexamethasone activated hPXR and hGR expression vectors which were separately co­
transfected into CV-1 cells with a CYP3A4 ER6 (the ER6 is the proximal PXRE) 
reporter construct with an EC50 value of lOpM for the hPXR co-transfection (Lehmann et 
ah, 1998). Concomitant administration of dexamethasone enhanced both rifampicin and 
clotrimazole-dependent CYP3A4 mRNA induction in cultured human hepatocytes 
(Pascussi et ah, 2000). The mechanism of this action was through increased expression of 
RXRa immunoreactive protein in response to dexamethasone through enhanced 
transcription (Pascussi et ah, 2000). Hence, the response to compounds acting through 
receptor heterodimerization with RXRa, such as PXR, should be greater in the presence 
of dexamethasone (Pascussi etal., 2000).
Jones et ah (2000) reported the activation of human and rabbit PXR by dexamethasone in 
CV-1 cells transfected with either human or rabbit PXR expression vector. 
Dexamethasone has been reported to increase rat and human PXR mRNA levels in 
Sprague-Dawley rats and cultured human hepatocytes, respectively (Pascussi et ah, 2000 
& Zhang et ah, 1999) and markedly induced the activation of mouse PXR in CV-1 cells 
transfected with a PXR expression vector (Kliewer et ah, 1998 & Moore et ah, 2000). 
Dexamethasone is also an effective inducer of CYP3A mRNA and immunoreactive 
protein in rat, rabbit and human hepatocytes (Kocarek et ah, 1995).
From the above lines of evidence, it can be concluded that dexamethasone activates the 
CYP3A4 gene through interaction with both the GR and PXR. This is supported by the 
work of Pascussi et ah (2000) who reported that the GR positively controls the 
expression of RXRa and PXR which accounts for the synergistic effect of 
dexamethasone and PXR activators on CYP3 A induction.
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Table 6.2 Specific chemical effect of dexamethasone on the CYP3A4
reporter gene expression
Dexamethasone
(pM)
Basal +hGR/
hPXR
0.1 0.14 2.3
0.5 0.49 8.4
1 1.9 19.2*
5 4.0 29.3**
10 4.9 42.4**
30 6.1 47**
50 7.9* 52.1**
100 4.2 38.4**
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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6.3.3 The influence of hGR and hPXR combined co-transfection on the CYP3A4
reporter gene expression by hydrocortisone
A full dose-response curve for hydrocortisone induction of CYP3A4 reporter gene 
expression was carried out both in the basal system and with co-transfection of hGR and 
hPXR (Table 6.3). In the absence of any added receptors (basal system), the inducibility 
of CYP3A4 by different concentrations of hydrocortisone showed a concentration- 
dependent increase in CYP3A4 reporter gene expression which was significant at 10, 25 
and 50pM concentrations indicating the probable presence of constitutively expressed 
receptors in the HepG2 cells.
It was anticipated that hydrocortisone would induce CYP3A4 (as dexamethasone did) 
because dexamethasone is a synthetic hydrocortisone. Hydrocortisone 21-hemisuccinate 
has been previously reported to enhance the level of CYP3A4 induction by metyrapone 
in rat hepatocytes (Wright et ah, 1994).
The induction response was enhanced by both single and combined co-transfection of the 
hGR and hPXR expression plasmids being significant at as low as IpM concentration 
(combined co-transfection) which indicates a role for both receptors in CYP3A4 
induction by hydrocortisone. Probably the hPXR (EC50 value of 0.4pM) plays a more 
predominant role than the hGR (EC50 value of 1.2pM). The EC50 value was 0.3pM when 
both receptors were co-transfected compared to 1.2pM with the basal system. The 
intrinsic activation values were 6, 13, 40, and 63 for the basal, hGR co-transfection, 
hPXR co-transfection and combined co-transfection, respectively, indicating that the 
hPXR plays a more predominant role than hGR in the hydrocortisone induction of 
CYP3A4 gene (EL-Sankary et ah, 2000). The reason may be that the hGR controls 
positively the expression of PXR and RXRa so accounting for the predominant role of 
PXR in the hydrocortisone induction of CYP3A4 gene, as reported for DEX by Pascussi 
et al. (2000)
It has been reported that hydrocortisone induced PXR mRNA level in cultured human 
hepatocytes (Pascussi et ah, 2000). Hydrocortisone was able to activate a GR expression
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vector transfected into mouse hippocampal cells, human neuroblastoma cells or HepG2 
cells (Herr et ah, 2000).
The hPXR binds to a PXR response element (Lehmann et al., 1998 & Waxman, 1999) 
present at - 170 bp to -153 bp in the CYP3A4 5' flanking region. Hence, both the GRE 
and PXRE are present in the 1 kb of CYP3A4 regulatory region used in the transfection 
experiment mediating the effect of hydrocortisone on CYP3A4 induction through hGR 
and hPXR receptors.
6.3.4 The in vivo relevance of the steroid modulation of CYP3A4
The normal blood levels of steroids examined in this project are shown in Table 6.4. 
Hydrocortisone was the only steroid to be examined in concentrations around the 
physiological levels (ranges from 0.2 to 0.75pM with a mean value of 0.5 pM) (Williams 
and Marks, 1996). Combined receptor co-transfection decreased the threshold value for 
CYP3A4 activation by hydrocortisone (from 10 pM to 1 pM) which is of the same order 
of magnitude as the physiological level, thereby inferring a possible physiological role 
for hydrocortisone in regulating the basal level of expression of the CYP3A4 gene. It 
should be noted that I have not determined the constitutive levels of neither 
hydrocortisone nor of the GR and the PXR in HepG2 cells.
The fact that CYP3A4 was transactivated in the absence of co-transfected hGR and 
hPXR receptors (albeit at a lower level) suggested that native HepG2 cells express 
sufficient amounts of these receptors to contribute to the overall response (EL-Sankary et 
al, 2000).
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Table 6.3 Specific chemical effect of hydrocortisone on the CYP3A4
reporter gene expression
Hydrocortisone
(pM)
Basal +hGR +hPXR +hGR/
hPXR
0.05 0.4 1.3 3.3 4.5
0.1 1.2 2.7 4.8 7.5
0.5 1.9 4.2 8 9.5
1 3.8 7.5 11.6 14.7*
5 5.1 11.3 15.6 15.6*
10 6.7* 14.3* 15.9* 18.6**
25 7* 14.9* 16* 20**
50 7.4** 15.5* 15.2* 20.8**
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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Table 6.4 Normal blood levels of steroids in the human body
Steroid Mean level (pM)
Cholesterol 0.000002
Progesterone 0.02
Hydrocortisone 0.5
Corticosterone 0.03
Cortisone 0.0001
Testosterone 0.002
Estradiol 0.0007
Aldosterone 0.0002
Adapted from Stryer, 1995 & Williams and Marks, 1996
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6.3.5 The influence of hGR and hPXR combined co-transfection on the CYP3A4
reporter gene expression by rifampicin
A full dose-response curve for rifampicin induction of CYP3 A4 reporter gene expression 
was carried out both in the basal system and with co-transfection of hGR and hPXR 
(Table 6.5). Rifampicin produced a concentration dependent increase in the CYP3A4 
reporter gene expression which was enhanced by hGR and hPXR both as single and 
combined co-transfection with an EC50 values of 3 and IpM and intrinsic activation 
values of 3 and 40 for the basal and receptor co-transfected system, respectively. These 
data are not inconsistent with the view that both GR and PXR have a direct role in the 
CYP3 A4 induction by rifampicin.
There is some convincing evidence for the direct involvement of both the GR and PXR in 
the rifampicin-dependent induction of CYP3A4 gene. It has been reported that rifampicin 
was capable of binding to and transactivating the GR in COS-7 cells (Calleja et ah,
1998), a mechanism by which rifampicin produces its immunosuppressive properties 
(Blanchard, 1998 & Calleja a/., 1998).
Rifampicin was still able to induce CYP3A4 reporter gene expression in HepG2 cells in 
which dexamethasone induction was lost because of reduced GR (Ogg et ah, 1999). So, 
although rifampicin requires GR to induce CYP3 A4, it is not exclusively dependent upon 
it (Ogg et al., 1999). In contrast, rifampicin was not found to activate hGR in human 
neuroblastoma, mouse hippocampal, and HepG2 cells (Herr et at., 2000) or COS-7 cells 
(Ray et ah, 1998) transfected with hGR expression vector.
It has been previously reported that rifampicin was the most potent inducer of an hPXR 
expression plasmid co-transfected with a CYP3A4 ER6 reporter plasmid into CV-1 cells 
with an EC50 of 800nM (Lehmann et ah, 1998 & Moore et ah, 2000). The same workers 
failed to show activation of GR by rifampicin in this cell line which may be due to 
different metabolism of rifampicin in different cell lines. There was substantially more 
induction of CYP3A activity (measured by the rate of testosterone 6p-hydroxylation), 
mRNA and protein levels by rifampicin in human and rabbit hepatocytes than in rat 
hepatocytes (Jones et ah, 2000 & Kocarek et ah, 1995 & Ramachandran et ah, 1999).
214
The hSXR expression vector transfected into CV-1 cells was found to be activated by 
rifampicin (Blumberg e /ûf/., 1998).
A distal enhancer module (XREM) located ~ 7800 bp upstream of the CYP3A4 
transcription initiation site has been identified and comprises of at least two elements 
(designated dNRl and dNR2) that are capable of binding hPXR-RXRa heterodimers. 
This element is essential for rifampicin induction of the CYP3A4 gene together with the 
proximal PXRE (-170 to -153 bp of the upstream transcription site of CYP3A4) in 
HepG2 cells (Goodwin et ah, 1999). The EC50 value for rifampicin induction of a 
CYP3A4 construct containing both the XREM and the proximal PXRE which was 
transfected into HepG2 cells was 1 - 2pM.
It has to be noted that in the in vitro system used in this project, this XREM is not needed 
as the system contains CMV which mimic the enhancer.
Rifampicin has been reported to induce the metabolism of co-administered drugs at 
therapeutic concentrations in humans by increasing the amount of CYP3A4 in the 
microsomes (Albengres et al., 1998). Treatment of humans with rifampicin resulted in 
the induction of the erythromycin breath test activity or in the excretion of 6P- 
hydroxycortisol, both of which are non-invasive measures of CYP3A4 activity (Watkins 
et ah, 1989).
From the above lines of evidence it can be concluded that rifampicin activates the 
CYP3 A4 gene through interaction with both the GR and PXR.
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Table 6.5 Specific chemical effect of rifampicin on the CYP3A4
reporter gene expression
Rifampicin
(pM)
Basal +hGR/
hPXR
0.1 0.24 4.9
0.5 0.4 12.9
1 1.91 22.1**
5 4.6 37.2**
10 7.3 44.8**
30 8.4* 52.6**
50 10.2* 54.3**
100 4.5 35.1**
Data shown as SCE (specific chemical effect), where n = 8 replicate data 
points derived from one experiment. Statistical significance is indicated by 
stars, where * = P<0.05, ** = P<0.01, both relevant to the solvent control
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6.3.6 hGR/hPXR combined co-transfection, why?
A functional cross talk has been reported to exist between GR- and PXR-signalling 
pathways (Pascussi et al., 2000) which may explain some controversial aspects of the 
role of the GR in CYP3A4 induction. These latter workers have reported that DEX 
increased both RXRa and PXR mRNA expression in cultured human hepatocytes which 
seemed to be due to a direct action on the GR Hence, there is a synergistic effect 
between DEX and PXR activators on CYP3 A4 induction.
Hence, the possible mechanisms of induction of CYP3 A4 gene by DEX may be: 1) hGR 
and/or hPXR acting directly on the 5'-flanking region or 2) hGR stimulation of hPXR and 
hRXRa, which subsequently act on the 5'-flanking region or 3) a combination of 1 and 2.
To maximise the possibility of identifying CYP3A4 inducers, I decided to use a double 
receptor transfection system (i.e., hGR+hPXR). However, the disadvantage of the 
combined receptor co-transfection is that one can not predict which receptor has the 
predominant role in the induction of CYP3A4 gene by different compounds. Had time 
permitted, I would have repeated many of my studies with single receptor co-transfection 
system.
6.3.7 The influence of hGR and hPXR combined co-transfection on the CYP3A4 
reporter gene expression by other classical CYP3A4 inducers
Sulfinpyrazone, phénobarbital, spironolactone, phenytoin, carbamazepine and 
metyrapone significantly induced CYP3A4 reporter gene expression in the basal system 
at concentrations of 30 and 50pM (10, 30, and 50|jM  for carbamazepine). Combined co­
transfection with hGR and hPXR enhanced the level of significant induction for 
phénobarbital, spironolactone, carbamazepine and metyrapone suggesting a role for these 
receptors in the CYP3A4 induction by these compounds. For sulfinpyrazone, and 
phenytoin, there was no change in the level of significant induction of CYP3A4.
Although the EC50 value for sulfinpyrazone in the combined co-transfection with 
receptors was half that for the basal system (8 and 16pM, respectively), the intrinsic
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activation value was almost the same (1.8 and 1.3, respectively) indicating that these 
receptors have no role in the sulfinpyrazone induction of CYP3A4 gene. This is in 
agreement with Ogg et al. (1999) who showed that GR alone did not enhance the 
CYP3A4 reporter gene construct induction by sulfinpyrazone.
The ECso value for phénobarbital was lower for the combined receptor co-transfection 
than for the basal system (9.5 and 17pM, respectively) and the intrinsic activation value 
was 4 fold with receptor co-transfection (1 and 4, respectively) indicating that GR and 
PXR have a role in the induction of CYP3 A4 gene by phénobarbital. It has been reported 
that phénobarbital activated hPXR expression vector co-transfected with a CYP3A4 ER6 
reporter construct into CV-1 cells more than mPXR expression vector (Jones et al., 2000 
& Lehmann et al., 1998 & Moore et al., 2000) and slightly increased rPXR mRNA levels 
in Sprague-Dawley rats (Zhang et ah, 1999).
Barbiturates have been reported to induce the metabolism of co-administered drugs at 
therapeutic concentrations in humans by increasing the amount of CYP3A4 in the 
microsomes (Albengres et al., 1998). Immunoblotting procedures clearly confirmed the 
induction of CYP3A in microsomes prepared from livers of rats treated with 
phénobarbital (Amacher and Schomaker, 1998). Kocarek et al. (1995) reported that 
phénobarbital induced CYP3A mRNA in rat, rabbit and human hepatocyte cultures. GR 
was previously found to enhance the CYP3A4 induction by phénobarbital in HepG2 cells 
(Ogg et al., 1999).
Both the ECso (9 and IpM) and the intrinsic activation values (1 and 12) for 
spironolactone in the basal system and the receptor co-transfection system respectively, 
are indicative of a role for the GR and/or PXR in the induction of CYP3A4. It has been 
reported that spironolactone activates an hPXR expression vector co-transfected with a 
CYP3A4 ER6 reporter construct into CV-1 cells (Lehmann et ah, 1998) and an hGR 
expression vector co-transfected with a CYP3A4 construct into HepG2 cells (Ogg, 1998). 
Spironolactone was a much more effective inducer of CYP3A expression in rat but not in 
rabbit hepatocytes but rabbit PXR was much more sensitive than its human orthologue to 
activation by spironolactone (Jones et ah, 2000).
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Northern blot analysis, using a cDNA probe that recognizes CYP3A mRNA, revealed 
that cultured rat and human hepatocytes treated with spironolactone had abundant 
amounts of CYP3A1/2 and CYP3A4 mRNA, respectively (Kocarek et ah, 1995). 
Spironolactone activated the CYP3A23 DR3 in LLC-PKl pig kidney epithelial cells co­
transfected with a PXR expression vector although the observed induction was less than 
the effect produced by dexamethasone (Schuetz et al., 1998) which was in agreement 
with this study.
The EC50 value for phenytoin in the combined receptor co-transfection system was 
slightly greater than that for the basal system (25 and 17|xM, respectively), although the 
intrinsic activation value was the same (1 for both). This would indicate that combined 
co-transfection of these receptors did not produce any effect on the phenytoin induction 
of the CYP3A4 reporter gene construct, although GR alone was previously shown to 
enhance the induction of CYP3A4 by phenytoin in HepG2 cells by 1.5-fold (Ogg et al.,
1999). The reason why combined co-transfection with both receptors did not enhance the 
CYP3A4 induction by phenytoin may be due to the fact that the receptors competed for 
the available phenytoin.
Phenytoin has been reported to induce the metabolism of co-administered drugs at 
therapeutic concentrations in humans by increasing the amount of CYP3A4 in the 
microsomes (Albengres etal., 1998).
Although the EC50 value for carbamazepine was approximately the same for the basal 
and combined receptor co-transfection (1.5 and IpM, respectively), the intrinsic 
activation value increased approximately 3 fold with receptor co-transfection (5 and 16, 
respectively) indicating that the GR and PXR have a role in the induction of CYP3A4 
gene by carbamazepine. GR was found to enhance the CYP3A4 induction by 
carbamazepine in HepG2 cells (Ogg et ah, 1999).
Carbamazepine has been reported to induce the metabolism of co-administered drugs at 
therapeutic concentrations in humans by increasing the amount of CYP3A4 in the 
microsomes (Albengres et ah, 1998).
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Although the EC50 value for metyrapone was the same for the basal and combined 
receptor co-transfections (6.5pM), the intrinsic activation value increased approximately 
1.5 fold with receptor co-transfection (2 and 3, respectively) and the level of significance 
increased with the 50pM concentration from the basal to the receptor co-transfected 
system indicating that GR and PXR have a role in the induction of CYP3A4 gene by 
metyrapone. However, this may be due to the small changes observed in this, more 
sensitive analysis. Such small changes would appear to indicate that while hGR/hPXR 
play a role in metyrapone-mediated induction of CYP3A4, it may not be a major role, as 
that metyrapone is a poor CYP3 A4 inducer. GR was previously not found to enhance the 
CYP3A4 induction by metyrapone in HepG2 cells (Ogg et ah, 1999).
Metyrapone has been reported to be a potent transcriptional inducer of the 
CYP3A1/CYP3A23 in rat and it also induced the de novo synthesis of CYP3A4 in 
cultured human hepatocytes (although weaker than rifampicin) (Wright et al., 1996 & 
Wright, 1999). The hPXR expression vector co-transfected with a CYP3A4 ER6-CAT 
reporter construct into CV-1 cells was found to be activated by metyrapone in 
concentrations similar to that required to induce de novo CYP3A4 synthesis in cultured 
human hepatocytes (Wright, 1999). Hence, the small increase in the intrinsic activation 
from the basal to the receptor co-transfection system may be due to the interaction of 
metyrapone with PXR and not GR
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6.3.8 The influence of hGR and hPXR combined co-transfection on the CYP3A4
reporter gene expression by putative CYP3A4 inducers
A full dose-response curve for lovastatin and troglitazone induction of CYP3A4 reporter 
gene expression was carried out both in the absence and presence of co-transfected hGR 
and hPXR. Both compounds produced a concentration dependent increase in the 
CYP3A4 reporter gene expression which was enhanced by combined co-transfection of 
hGR and hPXR with EC50 values of 2.3 and 0.5pM for lovastatin and 4.4 and 0.2 )jM for 
troglitazone and intrinsic activation of 11 and 223 for lovastatin and 5 and 77.5 for 
troglitazone for the basal and receptor co-transfected system, respectively. Thus both GR 
and PXR have a direct role in the CYP3 A4 induction by lovastatin and troglitazone.
Simvastatin, CPA, clotrimazole, PCN and fexofenadine significantly induced CYP3A4 
reporter gene expression in the basal system at concentrations 30 and 50pM (10, 30, and 
50|iM for cyproterone acetate and clotrimazole). The induction of CYP3A4 reporter gene 
was enhanced by combined co-transfection with hGR and hPXR suggesting a role for 
these receptors in the CYP3A4 induction by these compounds.
Although lovastatin, simvastatin and pravastatin are structurally related since they have a 
hydronaphthalene ring in common and differ only at few sites in the molecule, only 
lovastatin and simvastatin significantly induced CYP3A4 reporter gene expression. This 
may be due to the fact that lovastatin and simvastatin are lipophilic (diffuse easily across 
the cell membrane) and dissolve about 40 000 to 50 000 times more readily in octanol 
than in water but pravastatin dissolves twice as readily in water (Serajuddin etal., 1991). 
A parallel can be drawn with the rat where both lovastatin and simvastatin, but not 
pravastatin, increased CYP3A1/2 mRNA in primary cultures of rat hepatocytes (Kocarek 
and Reddy, 1996). It has also been reported that pravastatin is not taken up via a carrier- 
mediated system (hepatocellular sulfobromophthalein transporting protein) into HepG2 
cells (Ziegler et al., 1994), a mechanism which was not reported for both lovastatin and 
simvastatin.
On the contrary, pravastatin has been reported to increase urinary level of 6p- 
hydroxycortisol and urinary free cortisol and 6p-hydroxycortisol/free cortisol ratio in
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normal volunteers and in patients with heterozygous familial hypercholesterolaemia 
(Karayalcin et ah, 1991). It can therefore be hypothesized that this increase in CYP3A 
activity is due to post-transcriptional induction of CYP3A4, or possibly due to the action 
of pravastatin on another CYP3A.
Another explanation for why not all the statins examined induced CYP3A4 may be 
because hepatic CYP3A4 metabolizes both lovastatin (Cheng et al., 1992 & Wang et al., 
1991) and simvastatin (Cheng et al., 1992 & Vyas et al., 1990) and as previously stated 
inducers are often substrates for the induced enzyme (Whitlock and Denison, 1995). 
Pravastatin is not dependent on enzyme(s) to become pharmacologically active 
(Lennemas and Pager, 1997), although it has been reported that CYP3A4 and CYP3A5 
are involved in the biotransformation of pravastatin to its hydroxy and 3'a, 5'P, 6'P - 
trihydroxy metabolites (Jacobsen et al., 1999). However, compared with lovastatin, the 
binding constant of pravastatin to CYP enzymes and the Michaelis-Menten constants for 
metabolite formation are 1000-fold higher (Jacobsen etal.,  1999).
It has been reported that lovastatin activated an hPXR expression vector co-transfected 
with a CYP3A4 ER6 reporter construct into CV-1 cells more than mPXR expression 
vector with an E C 5 0  value of 1 to 5|oM (Lehmann et al., 1998). This E C 5 0  is in excellent 
agreement with the E C 5 0  obtained for lovastatin in this project ( 2  and 0.5pM for the basal 
and receptor co-transfected system, respectively). Lovastatin induces CYP3A gene 
expression in rat (Kocarek et al., 1993 & Schuetz et al., 1993a), rabbit and human 
hepatocytes (as effective as rifampicin induction in human hepatocytes) (Kocarek et al., 
1995 & Schuetz et al., 1993a) and potentiates phénobarbital- and clotrimazole- (but not 
dexamethasone-) mediated CYP3A1 induction in rat hepatocytes (Kocarek et al., 1993).
Simvastatin has been reported to increase the urinary excretion of 6P-hydroxy-cortisol 
and the ratio of 6P-hydroxycortisol/cortisol in man, an in vivo marker of CYP3A 
activation (Horsmans etal., 1993 & Mckenney, 1988).
It has to be noted that another hypocholesterolaemic drug, SR-12813 increased 
testosterone 6P-, 15p- and 2P-hydroxylations (a marker of CYP3A activity) in female rat 
(Williams e ta l,  1997).
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From the above evidence it is apparent that lovastatin and simvastatin are capable of 
inducing the expression of CYP3A4 and this induction is mediated through hGR and/or 
hPXR. In contrast, pravastatin does not transcriptionally activate CYP3A4 gene 
expression although vyork by others suggest possible post-transcriptional effects.
Troglitazone was described by Kaplan et al. (1998) as an inducer of CYP3A and 
increased CYP3A activity in a concentration dependent manner (measured by 
testosterone 6p-hydroxylation), mRNA and protein level in both primary rat and human 
hepatocytes with an EC50 of 5 to lOpM (Ramachandran et al., 1999 & Sahi et al., 2000). 
The increased CYP3A4 expression is most probably mediated through the PXR 
(Lehmann et al., 1998) and troglitazone has been reported to activate both human and 
rabbit PXRs with an EC50 value of 3pM (Jones et al., 2000). The increased CYP3A 
activity caused by troglitazone was found to be less potent that that caused by rifampicin 
but more potent that that caused by dexamethasone and phénobarbital (Sahi et al., 2000). 
In our experiments, the iutrinsic activation values suggest that troglitazone is a more 
potent inducer than rifampicin, both in the basal and receptor enhanced systems. This 
discrepancy may be due to post-transcriptional effects, or experimental variations.
Urinary excretion of 6p-hydroxycortisol and the ratio of 6P-hydroxycortisol/cortisol, an 
in vivo marker of CYP3A activation, was found to be increased in healthy human 
subjects after troglitazone administration (Koup et al., 1998). Drug-drug interactions in 
man also indicate that troglitazone is a CYP3A4 inducer. For example, troglitazone has 
been reported to induce CYP3A4 in vivo at dosage administered in clinical practice, 
thereby lowering plasma concentrations of terfenadine and its active metabolites and oral 
contraceptives containing ethinyl estradiol and norethindrone (Sparano and Seaton,
1998). It should however be noted that another report contradicts these previous findings 
and shows that troglitazone suppressed CYP3A4-dependent testosterone 6P- 
hydroxylation in human liver microsomes (Yamazaki et al., 2000). The reasons for this 
apparent contradiction are unclear at present.
From the above evidence, it is apparent that troglitazone is capable of inducing the 
expression of CYP3A4 and it is one of the best transcriptional inducers found in this 
study. This induction may be mediated via hGR/or hPXR.
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It is also of interest to note that pioglitazone which is structurally related to troglitazone 
was not found to induce CYP3A4 reporter gene expression over the concentration range 
examined for some reasons which are not clear for the time being.
Both the EC50 (18 and 1.5pM) and the intrinsic activation values (0.5 and 7) for CPA in 
the basal system and the receptor co-transfection are indicative of roles for the GR and/or 
PXR in the induction of CYP3 A4. CPA activated a CYP3A23 DR-3 reporter construct in 
pig kidney epithelial cells co-transfected with a PXR expression plasmid which was 
comparable to that produced by dexamethasone ^-butyl acetate (Schuetz et ah, 1998).
CPA induced CYP3A mRNA and protein in rat and human hepatocytes but was less 
effective in rabbit hepatocytes (Kocarek et al., 1995). It has been reported that 
cyproterone acetate activates an hPXR expression vector co-transfected with a CYP3A4 
ER6 reporter construct into CV-1 cells (Lehmann et al., 1998). CPA was a much more 
effective inducer of CYP3A expression in rat but not in rabbit hepatocytes but rabbit 
PXR was much more sensitive than its human orthologue to activation by CPA (Jones et 
a l, 2000).
It has been reported that CPA binds to androgen, progesterone and glucocorticoid 
receptors (Moguilewsky et a l, 1986). Compared with a binding affinity of 100 for 
endogenous androgen agonists, cyproterone acetate had a relative binding affinity for 
androgen receptors of 20, for progesterone receptors of 60 and for glucocorticoid 
receptors of 5 in animal tissues in vitro (Moguilewsky et a l, 1986).
From the above evidence, it is apparent that CPA is capable of inducing the expression of 
CYP3 A4 which also may be hGR/or hPXR receptor mediated.
Both the EC50 (6 and IpM) and the intrinsic activation values (1 and 14) for clotrimazole 
in the basal and the receptor co-transfected system, respectively are indicative of a role 
for a receptor(s) in the induction of CYP3A4. Clotrimazole has been reported to exert a 
post-transcriptional regulatory effect on CYP3A4 reporter gene expression by increasing 
mRNA in cultured human hepatocytes (Ogg et a l, 1999 & Pascussi et a l, 2000). 
However, it has been reported that clotrimazole activated an hPXR expression vector co­
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transfected with a CYP3A4 ER6 reporter construct into CV-1 cells more than mPXR 
expression vector with an EC50 value of 1 to 5pM (Jones et al., 2000 & Lehmann et al., 
1998 & Moore et al., 2000). This EC50 is in excellent agreement with the EC50 obtained 
for clotrimazole in this project (6 and IpM in the basal and receptor co-transfected 
system, respectively).
Clotrimazole induced CYP3A mRNA and increased protein levels in cultured rat and 
human hepatocytes but was less effective in rabbit hepatocytes (Kocarek et al., 1995). 
Clotrimazole also markedly induced the levels of CYP3A isoforms in rat liver 
microsomes (Lék&etal., 1998).
From the above evidence, it can be concluded that clotrimazole is capable of 
transcriptionally inducing the expression of CYP3A4 which also may be receptor 
mediated.
Both the EC50 (4.5 and 2.5pM) and the intrinsic activation values (3 and 18) for PCN in 
the basal and the receptor co-transfected system, respectively are indicative of the role of 
GR and/or PXR in the compound induction of CYP3A4. It has been reported that PCN 
was 3 times more potent in the activation of mPXR than hPXR expression vectors 
transfected into CV-1 cells (Kliewer et al., 1998 & Lehmann et al., 1998 & Moore et al.,
2000). The hSXR expression vector transfected into CV-1 cells was found to be activated 
by PCN (Blumberg a/., 1998).
PCN was a much more effective inducer of CYP3A expression and increased 
immunoreactive protein level in rat hepatocytes and rat liver microsomes but not in rabbit 
hepatocytes. Rabbit PXR was however much more sensitive than its human orthologue to 
activation by PCN (Burger et al., 1992 & Jones et al., 2000 & Kocarek et al., 1995 & 
Lake et al., 1998). The rat PXR mRNA level in Sprague-Dawley rats has been reported to 
be increased following administration of PCN (Zhang et al., 1999).
Barwick et al. (1996) reported that PCN is a good inducer of rat CYP3A2 and CYP3A23, 
but a weak inducer of human CYP3A4 and rabbit CYP3A6, An hGR expression vector
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co-transfected with a CYP3A4 construct into HepG2 cells enhanced the induction of the 
CYP3A4 gene by PCN (Ogg et ah, 1999).
From the above evidence, it may be concluded that PCN is capable of inducing the 
expression of CYP3A4 which also may be receptor mediated.
Both the EC50 (7 and 2pM) and the intrinsic activation values (2.5 and 20) for 
fexofenadine in the basal and the receptor co-transfected system, respectively are 
indicative of the role of GR and/or PXR in the induction of CYP3A4. Fexofenadine is an 
active metabolite of terfenadine by CYP3A4 (Jurima-Romet et al., 1995 & Yun et al., 
1993). Terfenadine has been reported to inhibit testosterone 6|3- and midazolam 1- 
hydroxylation and nifedipine oxidation in a concentration-dependent manner in human 
liver microsomes (Wang et al., 2000). Although fexofenadine has not been examined for 
the induction of CYP3A4, our data demonstrate that fexofenadine is a relatively strong 
CYP3A4 inducer, and that hGR/or hPXR play a role in this induction.
6.3.9 In vivo relevance of the in vitro xenobiotic induction studies
In patients treated with the standard 600mg oral dose of rifampicin, the peak blood level 
is lOpM and can reach levels as high as 40pM (Physicians Desk Reference, 1992) which 
is well above the concentration required to activate CYP3A4 gene in vitro (EC50 value of 
3pM in the basal system). The peak blood level of lovastatin was 15 pM after an oral 
dose of 20mg (Azie et al., 1998) which is well above the concentration required to 
activate CYP3A4 gene in vitro (EC50 value of 2pM in the basal system). The EC50 value 
for DEX and clotrimazole in the basal system ranged from 3-6pM. Although blood 
concentrations of DEX and clotrimazole do not normally reach micromolar 
concentrations in patients (Physicians Desk Reference, 1992), these drugs are subjected 
to extensive first-pass metabolism in the liver and gut and therefore the actual liver 
concentrations are very likely to be higher than the blood levels and possibly in the range 
of the EC50 values (Lehmann et al., 1998).
There was also a good correlation between the in vitro EC50 value for phénobarbital and 
phenytoin in the basal system (~17pM) and the in vivo peak blood level (29 and 36.5 pM,
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respectively) (Gilman, 1996). The peak blood level of clotrimazole is 38pM which is 
well above the EC50 value for carbamazepine in the basal system (-1.5pM) (Gilman, 
1996).
6.3.10 Rank order potencies of compounds examined
Based on the intrinsic activation values (Imax divided by the EC50) of the compounds 
examined for their ability to induce CYP3A4 reporter gene expression both in the basal 
system and with combined co-transfection of hGR and hPXR, the compounds are ranked 
as follow
In the basal system:
Lovastatin > carbamazepine > troglitazone > pregnenolone 16a-carbonitrile > rifampicin 
> fexofenadine > dexamethasone > metyrapone > simvastatin > clotrimazole > 
sulfinpyrazone > phénobarbital = spironolactone = phenytoin > cyproterone acetate
Combined co-transfection with hGR / hPXR:
Lovastatin > simvastatin > troglitazone > rifampicin > dexamethasone > fexofenadine > 
pregnenolone 16a-carbonitrile > carbamazepine > clotrimazole > spironolactone > 
cvproterone acetate > phénobarbital > metyrapone > sulfinpvrazone > phenvtoin
Underlined compounds signify a shift in the rank order from the basal to the receptor 
augmented system, which is very likely a result of the different levels of receptor 
expression (and ratios) in the basal versus the double-transfected system. Had time 
permitted, the levels of receptor mRNA expression would have been analyzed by PGR
The induction of CYP3A4 by these compounds and the steroids could therefore result in 
a significant alteration in the metabolism of any co-administered drugs or endogenous 
steroids and may lead to potential drug-drug interaction, unless taken into account. The 
nature of any drug-steroid and drug-drug metabolic interactions is dependent on the
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relative potency of the substrate to induce CYP3 A4 enzyme and its affinity to the specific 
receptor.
These results show that both endobiotics and xenobiotics appear to activate CYP3A4 
gene expression via both the hGR and/or the hPXR Hence, the likelihood exists that 
there is mutual competition for these two receptors between endobiotics and xenobiotics 
which may decrease the therapeutic effects of many administered xenobiotics.
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6.4 Isolation of mutant fragments from the CYP3A4 gene upstream regulatory 
region
For the cytochrome P4502D6, poor or slow metabolizers possess the homozygous 
autosomal recessive allele (usually mutant alleles), whereas the extensive or rapid 
metabolizers have the heterozygous or homozygous dominant allele (Chang and Kam,
1999). The reason for the differences has recently been suggested to be aberrant splicing 
of the CYP2D6 gene controlling formation of cytochrome P4502D6 (Daly, 1995).
Several cytochrome P450 isoenzymes are associated with genetic polymorphism 
(Murray, 1992) with the best known example being the CYP2D6 or debrisoquine 
hydroxylase enzyme (Kroemer and Eichelbaum, 1995 & Wrighton and Stevens, 1992). 
CYP2C19 is also associated with a genetic polymorphism which was first recognized 
with the hydroxylation of S-mephenytoin (Nemeroff et ah, 1996). The enzyme CYP2E1 
also demonstrates genetic polymorphism affecting the 5 '-flanking region (the non-coding 
region of the gene containing DNA that interacts with proteins to facilitate or inhibit 
transcription) of the human CYP2E1 gene (Lieber, 1997).
In my study, two mutations within the CYP3A4 5' flanking region have been identified 
in human liver samples with low CYP3A activity (measured by midazolam 
hydroxylation) and CYP3A4 protein levels (measured by western blot using an anti­
peptide antibody specific for the CYP3A4 isoenzyme). In order to assess the possible role 
of such mutations in the regulation of CYP3A4 gene expression, the appropriate mutant 
promoter-reporter genes were constructed and compared to the wild type.
I demonstrated that both mutations (in the HNF-5 RE and ERE) decreased the ability of 
the CYP3A4 reporter gene construct to respond to xenobiotics and/or steroids. The 
choice of compounds for this study was based upon their putative intracellular receptors, 
namely the pregnane X receptor (PXR; rifampicin (Lehmann et al., 1998)), the estrogen 
receptor (ER; estradiol (Grandien et al., 1997)) and the glucocorticoid receptor (GR; 
dexamethasone and hydrocortisone (EL-Sankary et al., 2000 & Ogg et al., 1999).
The response of the reporter gene constructs to these ligands additionally sheds light 
upon the possible mechanisms of CYP3A4 induction in vivo. Firstly, neither of the
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mutations was associated with the PXR response element (PXRE (TGAACT-n6- 
AGGTCA) (Waxman, 1999); - 170 bp to -153 bp of the CYP3A4 5' flanking region) and 
induction with rifampicin, a PXR ligand (Goodwin et al., 1999 & Lehmann et al., 1998), 
was unaffected in either mutant construct. This is not inconsistent with the fact that the 
inductive effect of rifampicin is mediated via the PXR and not the GR, as the HNF-5 
mutation, which effects the classic GR-ligand-mediated induction 
(dexamethasone/hydrocortisone) (Rigaud et al., 1991) did not affect rifampicin-mediated 
induction of CYP3A4 (Jones et al., 2000). The intrinsic activation values for rifampicin 
were 1.1, 1.1, and 1.3 for the wild type, HNF-5 mutant and ERE mutant constructs, 
respectively.
Mutation within the putative ERE (-201 bp to -198 bp of the CYP3A4 5' flanking region) 
predictably caused a decrease in the response to the ER ligand estradiol. The common 
consensus sequence for the ERE has been confirmed to be a 13 bp inverted repeat 
(GGTCAnnnTGACC), was essential for estrogen responsiveness (Driscoll et al., 1998) 
and the symmetry of the sequence has been reported to facilitate the binding of ER as a 
homodimer.
Of interest is that whereas the Imax value for estradiol induction of CYP3 A4 decreased 
(from 18.5 and 16.5 for the wild type and the HNF-5 mutant constructs to 11.6 for the 
ERE -mutant construct), the EC50 value did not change (1, 1.5 and 0.9pM for the wild 
type, HNF-5 mutant and ERE mutant constructs, respectively), suggesting that the 
affinity of the receptor-ligand complex for the ERE did not change from the wild type to 
the mutant construct, yet there may be some delay in the binding of the receptor-ligand 
complex to the mutant ERE leading to this decrease in the CYP3 A4 activation.
Perhaps the most interesting observation was with the HNF-5 binding site mutation. This 
mutation clearly effected the response to glucocorticoids, which may be interpreted in 
one of two ways. Firstly, dexamethasone and hydrocortisone could directly, or indirectly, 
affect HNF-5 activation without mediation via the GR, although co-transfection 
experiments with a GR expression plasmid suggest this is not the case (EL-Sankary et al., 
2000 & Ogg era/., 1999).
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Secondly, a more plausible explanation involves the interaction of ligand activated GR 
and HNF-5 binding to the 5' flanking region, a previously proposed mechanism for the 
transcriptional activation of glucocorticoid dependent genes (Rigaud et ah, 1991). These 
latter workers proposed a "hit and run" mechanism for GR mediated activation of the rat 
tyrosine aminotransferase gene wherein transient binding of the activated GR-ligand 
complex caused a stable binding of HNF-which then initiates transcription (Rigaud et ah, 
1991). My data fit with such a hypothesis, with binding of activated GR (complexed with 
either dexamethasone or hydrocortisone) to the putative GRE (-177 bp to -171 bp of the 
CYP3A4 5' flanking region) causing HNF-5 binding at neighbouring sites (-194 bp to - 
187 bp of the CYP3A4 5' flanking region). This is also consistent with recent evidence 
that the GR complexes with histone acetyltransferases, which are directly involved in 
removing histones from DNA, thus freeing binding sites for other factors (Lemon and 
Freedman, 1999 & Wallberg etal., 1999), possibly HNF-5.
Hence, in the HNF-5 mutant construct, it is possible that binding at the mutated -191 bp 
site is ablated, but binding still occurs at a second site on the other side of the GR (-143 
bp to -136 bp of the CYP3A4 5' flanking region). Whereas the ECso value did not 
change, only half the number of sites for HNF-5 exist, leading to an approximate halving 
of the maximal effect ( I m a x )  (from 29.6 to 13 for the wild type and HNF-5 mutant 
constructs for hydrocortisone induction of CYP3A4). Such an hypothesis presumes that 
activation of gene expression is directly related to the number of auxiliary factors (i.e. 
HNF-5) binding to a promoter. The Imax value for dexamethasone also decreased from 18 
for the wild type and ERE mutant constructs to 13 for the HNF-5 mutant construct 
suggesting that this is a general glucocorticoid effect and not compound specific for 
hydrocortisone.
It should noted that whereas this evidence clearly demonstrates that the identified 
mutations suppress activation within the studied fragment, this may not hold true for the 
CYP3A4 gene in vivo. It is possible that loss of binding at one response element is 
compensated by activation of other response elements within the promoter region, but 
outside the fragment studied inhere. However, the fact that these functional mutations are 
in samples with poor CYP3A activity / CYP3A4 protein levels is not inconsistent with 
them being functional in the in vivo situation.
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6.5 Conclusions
Of the CYP3A4 inducers examined in this project, all the compounds previously reported 
to transcriptionally induce the CYP3A family were found to activate CYP3A4 reporter 
gene expression in the in vitro system used in this project. Hence, this in vitro system 
represents an advance in the assessment and detection of steroids and xenobiotic 
induction of CYP3 A4 gene. Induction in this system shows a strong correlation with the 
induction of CYP3A4 in human liver. Therefore, this system provides a useful 
complement to animal studies in the assessment of the endobiotic and xenobiotic 
induction of the CYP3 A family.
The evidence presented in this project and in the literature cited suggests that the 
regulation of CYP3A4 gene is a complex process and that hGR and hPXR are both 
involved in the transcriptional regulation of CYP3A4 gene by steroids and xenobiotics. 
These two receptors interact in an, as yet undefined, manner to control this regulation.
The functional mutations identified within the CYP3 A4 promoter provide an insight into 
the possible interindividual variation in CYP3A activity seen in the human population 
and their mixed response to xenobiotic treatment. They also provide useful tools for 
experiments to increase our understanding of the molecular mechanism of CYP3A4 
transcriptional gene activation.
Figure 6.1 shows the proposed role of hGR and hPXR in the transcriptional activation of 
CYP3A4 gene
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Figure 6.1 Proposed role of hGR and hPXR in the transcriptional
activation of the CYP3A4 gene
GR
Nucleus
Direct
CYP3A4
activation
HSP9^ GR GR
HSP7^
GRE
Indirect
fPX R  and 
RXRa
CYP3A4
activationER6
GR: glucocorticoid receptor, GRE: glucocorticoid response element, HSP: heat 
shock protein, I: inducer, PXR: pregnane X receptor, RXRa: retinoid X receptor a. 
Adapted from my work herein & Huss and Kasper, 2000 & Pascussi et ah, 2000.
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6,6 Further work
1. In the current transfection system, it would be interesting to examine the effects of 
other plasmids encoding receptors, such as members of the estrogen receptor (ER) family 
or the constitutive androstane receptor (CAR), on the induction of CYP3 A4 reporter gene 
expression by steroids and xenobiotics. To further delineate the individual effects of hGR 
and hPXR and their interaction it would be interesting to transfect them separately and to 
obtain and transfect plasmids encoding mutated GR or PXR with the xenobiotics 
examined herein and others.
2. Also it would be of interest to study the effect of RU-486 in a concentration which did 
not induce CYP3A4 gene (<0.5pM) on the steroid induction of the CYP3A4 gene. It 
would be of interest also to examine the steroid induction of CYP3A4 gene in parallel 
with a construct encoding a gene classically induced by glucocorticoids, such as the 
mouse mammary tumour virus (MMTV) or tyrosine aminotransferase (TAT).
3. It would be also interesting to evaluate direct ligand-receptor binding and their 
relationship to transcriptional activation.
4. Inducer-receptor specificity and the relative ability of inducers to produce 
transcriptional activation through interaction with more than one receptor is also worthy 
of study.
5. The relative expression and roles of hPXR-1 and hPXR-2 (splice variant) in binding 
and activation of CYP3A4 gene may contribute to interindividual sensitivity to induction 
and hence to interindividual variation in expression. Related to this latter aspect, is an 
examination of the GR/PXR ratios in human populations and in HepG2 cells.
6. Generation of an HepG2 stable cell line expressing the alkaline phosphatase reporter 
gene under the direct control of the CYP3A4 regulatory region would constitute a 
valuable experimental tool.
234
7. The cell system used in this project (HepG2 cells) are liver-derived cell line. It has 
been reported that human hepatic and enteric CYP3A4 content appear to be 
independently regulated (Dresser et al., 2000). Thus high liver CYP3A4 expression does 
not mean high intestinal expression in the same individual and vice-versa, suggesting 
tissue-specific regulation of the human CYP3A. It would therefore be of interest to 
examine the induction of CYP3A4 using this system in an intestinal cell line, such as 
CaC02 cells, as the inducibility of the intestinal CYP3A may be an important 
determinant in the bioavailability of orally administered CYP3A substrates.
8. The comparative study of animal and human CYP3A reporter gene constructs would 
enable the identification of the potentially most suitable animal species for any in vivo 
induction studies and drug-drug interaction that have to be carried out to satisfy 
regulatory authorities.
9. Computer sequence analyses of response elements need to be backed up by conclusive 
studies involving foot-printing assays and electrophoretic mobility shift assays of the 
CYP3 A4 promoter region.
10. The results of the HNF-5 mutant study suggested an interaction between GRE and 
HNF-5 response element in the glucocorticoid-mediated transcriptional activation. This 
interaction needs further studies probably by deletion of the HNF-5 response elements in 
the CYP3A4 promoter to be studied and examine the effect of this deletion on the GR- 
mediated induction of CYP3A4 gene. Further studies are required to examine the role of 
these mutations within the entire promoter and to determine the frequency of these 
mutations in the different ethnic groups.
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APPENDIX
Solutions, Media and Buffers
Ammonium persulfate stock solution (10% w/v) (for SSCP)
O.lg ammonium persulfate
1ml distilled water
Mix well. Prepare fresh
Ampicillin stock solution
lOOmg/ml ampicillin is dissolved in distilled water.
The solution is fiter sterilised.
Store at -20°C.
Use at lOOpg /ml in growth media for selection of ampicillin resistant bacteria. 
Aurora chemiluminescent alkaline phosphatase assay solutions 
Assay buffer
Contains a mixture of differential alkaline phosphatase inhibitors 
Dilution buffer 
Reaction buffer
Contains StarLight chemiluminescent substrate and luminescence enhancer. 
Calcium chloride stock solution (2M) for transfection experiments 
Dissolve 10.8g of CaC^.bHiO in 20ml distilled water.
Sterilise by filtration; store in 1ml aliquots at -20°C.
Calf intestinal alkaline phosphatase (CIAP) reaction buffer (lOx)
500mMTris-HCl,pH9.3
lOmMMgCli
ImM ZnCh
lOmM spermidine
Calf intestinal alkaline phosphatase (CIAP) stop buffer
10mMTris-HCl,pH7.5 
ImM EDTA, pH 7.5 
200mMNaCl 
0.5% SDS
Developer solution (for development of SSCP films)
262
391.45gm D19 developer powder 
Dissolve in 2.5L distilled water 
Shake to mix
Leave overnight at 56°C in water bath.
Store at room temperature.
EDTA stock solution (0.5M)
186.1gEDTA 
20g NaOH pellets
Add 800ml distilled water, adjust the pH to 8.0 
Make up to IL with distilled water.
Ethidium Bromide
Stock solution of lOmg/ml in TAE buffer.
BBS (2x) (HEPES-buffered saline) for transfection experiments
1.6gNaCl(280mM)
0.074gKCl(10mM)
0.027gNa2HP04.2H20 (1.5mM)
0.2g dextrose (12mM)
IgHEPES (50mM)
Distilled water to 90ml.
pH to 7.05 with N NaOH; make up to 100ml with distilled water.
Sterilise by filtration; store in 5ml aliquots at -20°C.
LB (Luria-Bertani) Medium 
lOg tryptone 
5g yeast extract 
lOgNaCl
Add distilled water to IL.
Sterilise by autoclaving.
LB (Luria-Bertani) Agar 
15g agar/L of LB medium.
Sterilise by autoclaving.
Cool to 50°C before addition of ampicillin (if required).
Pour into petri dishes.
Ligase buffer (Ix) (Promega)
30mMTris-HCl,pH7.8
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10mMMgCl2
lOmMDTT
ImMATP
PCR purification buffer (Promega)
SOmMKCl
lOmM Tris-HCl, pH 8.8 at 25°C
1.5mMMgCl2
0.1% Triton X-100
Phosphate Buffered Saline (PBS), pH 7.5
1 tablet (Oxoid) dissolved in 100ml distilled water. 
Sterilise by autoclaving.
Qiagen Endofree maxiprep solutions (Qiagen) 
Buffer PI (resuspension buffer)
50mMTris-Cl,pH8.0 
lOmMEDTA 
lOOpg/ml Rnase 
Store at 4°C.
Buffer P2 (lysis buffer)
200mMNaOH 
1% SDS
Buffer P3 (neutralization buffer)
3M potassium acetate. pH 5.5 
Store at 4°C
Buffer QBT (column equilibration buffer)
750mMNaCl 
50mMMOPS,pH7.0 
15% isopropanol 
0.15% Triton X-100 
Buffer QC (wash buffer)
1.6MNaCl
50mM Tris-Cl, pH 8.5 
15% isopropanol
Buffer ER (endotoxin removal buffer)
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The content of this solution was unavailable.
Buffer QN (elution buffer)
1.6MNaCl
50mMMOPS,pH7.0 
15% isopropanol 
RecoverEase DNA solutions (Stratagene)
Digestion buffer (pH 8.0)
1.75gNa2H P04
g.OgNaCl
0.2gKCl
0 .2 g K H 2 P O 4
20ml 0.5M EDTA, pH 8.0
800ml distilled water
Adjust the pH to 8.0 and add distilled water to a final volume of IL 
Autoclave for 30 minutes 
Lysis buffer (per liter)
8.20gNaCl
0.22gKCl
120g sucrose
0.3gEDTA
10ml Triton X-100
1.58g Tris-HCl, pH 8.3
800ml distilled water
Adjust the pH to 8.3 and add distilled water to a final volume of IL 
Filter sterile and store at 4°C 
Proteinase K solution (per 50ml)
1 OOmg proteinase K 
30ml distilled water 
10ml 10%(w/v) SDS 
10ml 0.5MEDTA,pH7.5 
Restriction enzyme reaction buffers (Ix) (Promega)
Buffer B
6mM Tris-HCl, pH 7.5 
50mMNaCl
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6 mM MgCl2 
lmMDTTat37°C 
Buffer C
lOmM Tris-HCl, pH 7.9 
50mM NaCl 
1 0 mMMgCl2 
lmMDTTat37°C 
Buffer D
6 mM Tris-HCl, pH 7.9 
ISOmMNaCl 
6 mM MgCl2 
lmMDTTat37°C 
Buffer E
6 mM Tris-HCl, pH 7.5 
lOOmMNaCl 
6 mMMgCl2 
lmMDTTat37°C 
Buffer K
lOmM Tris-HCl, pH 7.4 
150mMNaCl 
1 OmM MgCl2 at 3 7°C 
TAE electrophoresis buffer (lOx)
48.4g Tris base 
40ml 0.5MEDTApH8.0
11.42ml glacial acetic acid 
Add distilled water to IL 
Dilute to Ix prior to use
TBE (lOx) for running acrylamide gel for SSCP
108g Tris-Cl
55g boric acid
20ml IM EDTA
Make up to IL by distilled water
TE buffer (Tris-EDTA)
10mMTris-HCL,pH7.5
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ImMEDTA
Dilute lOx for use in transfection
Sterilise by filtration
X-Gal (for cloning purposes)
40mg/ml in dimethylformamide
Prepare fresh and add to IL of agar (58°C) to give a final concentration of 40pg/ml.
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